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General introduc on
Gastrointes nal cancer represents a  signi cant disease burden, and is one of the  leading 
causes  of  cancer-related  mortality  worldwide  ( gure  1)     .  The  gastrointes nal  tract 
comprises  of  all  organs  responsible  for  diges on,  including  the  accessory  organs  liver, 
gallbladder,  biliary  tract  and  pancreas.  The most  common  gastrointes nal malignancy  is 
colorectal cancer, which ranks globally third in incidence rate, and even second in mortality 
rate, as  it  solely accounts  for  approximately 1  in  10  cancer-related deaths . Other highly 
incident gastrointes nal  cancers  include  liver, gastric and  esophageal  cancer,  all  listed  in 
the top 10 of  incidence and mortality rates worldwide . However, malignancies of several 
other gastrointes nal sites are scarce with crude incidence rates less than 6 per 100.000, 
including the gallbladder and extrahepa c bile duct, small bowel, appendix and anal canal . 
An overview of the distribu on of the incidence of several gastrointes nal cancers in the 
Netherlands is shown in  gure 2 .
&         Incidence and mortality of the most frequent solid cancers worldwide in 2018.
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&         Incidence of several gastrointes nal cancers in the Netherlands by year of diagnosis.
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Most  recent  research  has  focused  on  the most  frequently  encountered  gastrointes nal 
malignancies. As small bowel and appendiceal cancers are rare, these malignancies have not 
been well studied. In daily clinical prac ce, pa ents with small bowel or appendiceal cancer 
are consequently mostly treated in a similar fashion as frequently studied gastrointes nal 
                                                      .  However,  it  is  largely  unknown  if  the 
treatment op ons for colorectal and gastric cancer can be extrapolated for the treatment of 
small bowel and appendiceal cancer.
                  
Despite  the  length  of  the  small  bowel  within  the  gastrointes nal  tract,  small  bowel 
cancer  is  only  encountered  in  2-3%  of  all  gastrointes nal  cancers. Mul ple  theories  are 
suggested to clarify the rarity of small bowel cancer, including the rapid transit  me of the 
nutri onal elements in  the small bowel, more alkaline environment,  lower bacterial  load 
and the  rapid  turnover of the mucosal area    . Small bowel adenocarcinoma  (SBA)  is the 
most common histologic subtype, accoun ng for almost 40% of the tumours . E ology  is 
largely  unexplained,  although an adenoma-carcinoma driven  sequence  analogous  to  the 
development of colorectal  cancer has been suggested. However, molecular altera ons  in 
SBA and colorectal cancer di er greatly, with especially dis nct di erences in the muta onal 
status of the adenomatous polyposis coli (APC) gene        .
Mul ple  risk  factors  for SBA  are  iden  ed,  including  celiac  disease,  Crohn’s  disease  and 
hereditary  syndromes,  such  as  hereditary  non-polyposis  colon  cancer  (HNPCC;  Lynch 
 
  
         
syndrome),  familial  adenomatosis  polyposis  (FAP)  and  Peutz-Jeghers  syndrome7-9. 
Celiac  disease  and  Crohn’s  disease  both  cause  an  immunological  response  with  chronic 
in amma on in either the proximal or distal small bowel, respec vely, which results in an 
80-fold increased rela ve risk for dysplasia and SBA compared to the general popula on   
         . Other lifestyle associated risk factors include the high consump on of sugar, re ned 
carbohydrate, alcohol, smoking and red meat     .
Symptomatology in pa ents with SBA is generally nonspeci c, like abdominal pain, weight 
loss,  gastrointes nal  bleeding  or  anemia  or  an  acute  clinical  presenta on  with  bowel 
obstruc on     .  Diagnosis  can  also  be  challenging,  as  the  small  bowel  beyond  the  distal 
duodenum or above the terminal ileum is di cult to access for endoscopic examina on with 
either gastroscopy or colonoscopy, causing an average delay un l diagnosis of approximately 
6-8 months . Moreover, it has been hypothesized that due to the combina on of nonspeci c 
symptoms  and  the  lack  of  simple  diagnos c  tools,  metasta c  disease  is  common,  with 
approximately 40% of the pa ents presen ng with metasta c SBA        . Though, guidelines 
on the e ec veness of systemic therapy and the preferred treatment op ons for pa ents 
with metasta c disease are absent.
                  
The  incidence  of  appendiceal  cancer  is  also  very  rare,  accoun ng  for  less  than  0.5%  of 
all  gastrointes nal  cancers  and  occurring  in  less  than  2%  of  all  appendectomies       . 
Appendiceal cancer is o en rarely considered or diagnosed preopera vely, as typical and 
speci c symptoms are lacking. General symptoms include vague acute or chronic abdominal 
pain or  symptoms  resembling acute  appendici s            . Also  the  incidence of  diagnosing 
appendiceal  cancer  coincidentally  during  surgical  interven on  for  another  indica on  is 
      .
The most frequently encountered malignant subtype is the adenocarcinoma, accoun ng for 
50-70% of the cases17, 19-21. Appendiceal adenocarcinomas are subdivided into the mucinous, 
non-mucinous and signet ring cell histologic subtype      . Histologic subtype is thought to be 
of clinical relevance, as historic research showed that pa ents with a mucinous appendiceal 
adenocarcinoma have a be er or comparable clinical outcome, compared to non-mucinous 
adenocarcinomas              .
Mucinous  and  signet  ring  cell  adenocarcinomas  belong  to  the  subgroup  of  mucinous 
appendiceal  neoplasms,  which  have  been  of  great  interest,  as  these  tumours  are  the 
leading cause of pseudomyxoma peritonei      . Pseudomyxoma peritonei is a rare peritoneal 
disease,  characterized  by  progressive  accumula on  of  mucinous  ascites  and  mucinous 
  
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tumour deposi on23-26. In recent years, new insights were gathered with regard to mucinous 
appendiceal  neoplasms  and  its  rela on  to  pseudomyxoma  peritonei23,  27-34.  In  2017,  an 
interna onal expert panel on behalf of the Peritoneal Surface Oncology Group Interna onal 
published an innova ve and overarching consensus-based histopathological classi ca on for 
mucinous appendiceal neoplasms and pseudomyxoma peritonei  . With this classi ca on, 
clear and universal de ni ons for mucinous appendiceal neoplasms were speci ed, which 
could be dis nguished  into true premalignant lesions or adenomas, tumours of uncertain 
malignant poten al, known as low-grade mucinous appendiceal neoplasms and high-grade 
mucinous  appendiceal neoplasms,  and malignant  lesions,  including mucinous  and signet 
ring cell adenocarcinomas  .
                                                                                               
classi ca on,  it  is  possible  that  tumours  of  uncertain  malignant  poten al  with  a  more 
favourable  prognosis  in  both  locoregional  and metasta c  disease, were  falsely  classi ed 
as mucinous  appendiceal  adenocarcinomas and consequently,  incorrectly  in uenced  the 
results of treatment.
                                                                   
Due to  the rarity of  small bowel and appendiceal  tumours, prospec ve cohort studies or 
randomized  controlled  trials  are  nearly  impossible  to  conduct. Most  research  regarding 
small bowel and appendiceal tumours derive from small phase II-studies or retrospec ve 
databases of specialised or referral centres, which causes inevitable selec on bias. Moreover, 
due to the lack of studies, no guideline exist how to treat these pa ents. However, clinicians 
are s ll confronted with these pa ents in daily prac ce, which challenges them to decide 
which treatment suits best.
The need for popula on-based studies
In  the  area of  rare diseases as  in small bowel  and appendiceal cancer, popula on-based 
research is highly valuable in providing important clinical insights into basic epidemiology, 
prognos c factors and the use and e ects of treatment, as more pa ents over  me could 
be  enrolled,  compared  to  other  observa onal  studies  or  randomized  controlled  trials  . 
Due to the higher number of pa ents with a rare cancer in an unselected popula on, the 
obtained results are both a re ec on of the clinical disease course and the delivered care to 
these pa ents in daily prac ce. Consequently, these results could be useful for a poten al 
guideline for trea ng physicians in daily clinical prac ce.
            
The data sources for the studies included in this thesis were the Netherlands Cancer Registry 
 
  
         
and the Dutch Pathology Registry.
Netherlands Cancer Registry
The Netherlands  Cancer  Registry  (NCR)  is  a na onwide popula on-based  registry, which 
collects  data  on  all  newly  diagnosed  malignancies  in  the  Netherlands  since  1989.  It  is 
managed by  the Netherlands Comprehensive Cancer Organisa on  (IKNL),  consis ng  of 9 
regions  throughout  the Netherlands, which covers  the en re Dutch popula on of nearly 
17 million inhabitants. Primary source of no  ca on is the Dutch na onwide network and 
registry  of  histo-  and  cytopathology  (PALGA),  accompanied with  data  from  the Na onal 
Registry  of  Hospital  Discharge  Diagnoses  and  radiotherapy  ins tu ons.  Informa on  on 
pa ent  and  tumour  characteris cs,  diagnosis  and  ini al  treatment  is  rou nely  collected 
by  registry  clerks  from  the medical  records.  In  the NCR,  all  primary  tumours  are  staged 
and  registered  according  to  the  Tumour  Node  Metastasis  (TNM)  classi ca on  .  The 
topographical site of the primary tumour and systemic metastases are registered according 
to  the  third  version  of  the  Interna onal  Classi ca on of Disease  for Oncology  (ICD-O)  . 
Informa on of the vital status of pa ents is annually obtained through linkage of the NCR 
with  civil municipal  registries  and  the  central  bureau  for  genealogy,  in which  data  of  all 
deceased and emigrated inhabitants of the Netherlands are collected.
Addi onal data collec on
In  the NCR, extensive data on  the  type and dura on of systemic  therapy of  small bowel 
cancer  is  not  rou nely  collected.  Fortunately,  with   nancial  support  of  the  Catharina 
Research Fund, addi onal data on systemic treatment regimens for pa ents treated with 
pallia ve  systemic  therapy  for  synchronous metastases  of  SBA diagnosed between  2007 
and 2016 was retrospec vely collected by registry clerks of the NCR in March of 2018. The 
addi onal data comprised informa on on  rst-, second- and third-line systemic treatment 
regimens, including details and dura on of the chemotherapeu cal and targeted agents.
Dutch Pathology Registry (PALGA)
In appendiceal cancer, mul ple tumour classi ca ons for appendiceal mucinous neoplasms 
and various  interpreta ons  of  the  invasive  aspect of  these  lesions  existed  over   me.  As 
cancer registries only collect data on invasive malignancies, data on previously assumed non-
malignant lesions as tumours of uncertain malignant poten al, are not rou nely registered 
in locoregional disease. Moreover, due the various histopathological changes in classi ca on 
and stra  ca on of mucinous lesions, including mucinous appendiceal adenocarcinomas, it 
is possible that the group of pa ents which is registered as having mucinous appendiceal 
adenocarcinomas in the NCR could be contaminated. Therefore, the pathological reports, 
including  macroscopy  and  microscopy  reports,  of  pa ents  with  appendiceal  mucinous 
  
General introduc on
adenocarcinomas with morphology codes 8470 and 8480, in which cystadenomas (8470/0), 
tumours of uncertain malignant poten al (8480/1) and pseudomyxoma peritonei (8480/6) 
could be included, were retrospec vely revised through a repeated linkage with PALGA. The 
histologic subtype was retrospec vely changed for the pa ents concerned, according to the 
most recent histopathological classi ca on for mucinous appendiceal neoplasms  .
                             
This thesis aims to provide insight into clinical and pathological aspects of small bowel and 
appendiceal  cancer,  by  examining  the  epidemiology,  clinical  disease  course,  treatment 
and prognos c  factors of  these  rare  gastrointes nal  cancers.  The main  objec ves  of  the 
described studies in this thesis were:
   To  obtain  insight  into  the  epidemiology  of  locoregional  and metasta c  small  bowel 
cancer by studying the incidence, trends in treatment and overall survival (part I).
   To evaluate the use and e ects of pallia ve systemic therapy in pa ents with metasta c 
small bowel cancer (part II).
   To assess the prognos c value of histologic subtype and its impact on treatment op ons 
and survival in pa ents with appendiceal cancer (part III).
Part I: Epidemiology of small bowel cancer
In chapter 2, the incidence, treatment and overall survival over  me of pa ents with SBA is 
established, with emphasis on the loca on of the primary tumour and its rela on to pa ent 
outcomes. In chapter 3, the incidence, risk factors and treatment-related survival is studied, 
in the subgroup of pa ents with peritoneal metastases of SBA, one of the most frequently 
encountered metastases in SBA.
Part II: Pallia ve systemic therapy in metasta c small bowel cancer
Part  II  of  this  thesis  focuses  on  the  use  and  e ec veness  of  pallia ve  systemic  therapy, 
de ned as the administra on of cytotoxic and/or targeted agents, in pa ents with metasta c 
SBA. The use and e ects of pallia ve chemotherapy are evaluated in chapter 4, whereas 
the use and e ec veness of the addi on of targeted therapy to pallia ve chemotherapy in 
pa ents with metasta c SBA is described in chapter 5.
Part III: Histologic subtype in appendiceal cancer
In part  III of this  thesis,  the prognos c value of histologic  subtype  in appendiceal cancer 
is  studied,  with  special  a en on  to mucinous  appendiceal  neoplasms,  using  the  recent 
interna onal histopathological classi ca on.  In chapter 6, an overview of the di erences 
in  mucinous  appendiceal  neoplasms  in  terms  of  histologic  subtype  and  its  impact  on 
 
  
         
management  of  these  tumours  is  provided.  In  chapter  7,  the  prognos c  relevance  of 
histologic  subtype  in  a  subset  of  pa ents with mucinous,  non-mucinous  and  signet  ring 
cell adenocarcinomas in both locoregional disease and metasta c disease of appendiceal 
adenocarcinoma  is  determined.  Chapter  8  evaluated  the  di erences  in  clinical  course of 
disease  in  pa ents  with  metasta c  mucinous  appendiceal  neoplasms  and  showed  the 
importance to subdivide pa ents with mucinous appendiceal lesions according to the latest 
proposed consensus-based histopathological classi ca on.
In chapter 9 of this thesis, a summary of the main  ndings, methodological considera ons 
and implica ons for clinical prac ce and future research are outlined.
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            We conducted a popula on-based study to establish the incidence, treatment 
and overall survival over  me of pa ents with small bowel adenocarcinoma.
                         All  pa ents  diagnosed  with  small  bowel  adenocarcinoma  in 
the  Netherlands  between  1999  and  2013  were  included  (n  =  1775).  Age-standardized 
incidence rates were calculated per 100.000 person-years using the European standardized 
popula on rate. The in uence of pa ent and tumour characteris cs on the administra on 
of chemotherapy was analysed by means of a mul variable logis c regression analysis. The 
Cochran-Armitage trend test was conducted to evaluate trends  in  treatment and survival 
and the cox propor onal hazards model was used to iden fy prognos c factors of overall 
survival.
         The incidence of small bowel adenocarcinomas increased, mainly due to an almost 
twofold  increase  of  duodenal  adenocarcinomas.  Pa ents  with  locoregional  duodenal 
tumours were less likely to undergo surgery (58%), towards 95% of the locoregional jejunal 
and ileal tumours (p < 0.0001). The use of chemotherapy doubled for adjuvant (7 to 15%) 
and  pallia ve  chemotherapy  (19  to  37%).  Overall  survival  of  pa ents  with  locoregional 
disease increased from 19 to 34 months (p = 0.0006), whereas overall survival of pa ents 
with metasta c disease remained 4-5 months. Favourable prognos c factors for prolonged 
survival in locoregional disease, iden  ed by mul variable survival analysis, included age <60 
years, tumour stage I or II, diagnosis in 2009-2013, surgical treatment and chemotherapy. 
Favourable  prognos c  factors  for  prolonged  survival  in metasta c  disease were  age  <50 
years, jejunal tumours, surgical treatment and chemotherapy.
            Small bowel adenocarcinomas are rare tumours with an increasing incidence. 
The administra on of adjuvant and pallia ve chemotherapy doubled, but overall survival 
only increased for pa ents with locoregional disease. Given the rarity and dismal prognosis, 
it  is  important  to  develop  interna onal  studies  to  determine  the  op mal  treatment  for 
these pa ents.
  
Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013
Introduc on
Small bowel tumours are rare malignant tumours, accoun ng for less than 5% of all gastro-
intes nal  tumours,  but  the  incidence  is  rising .  Small  bowel  tumours  have  an  unequal 
distribu on in the small bowel. The preferred loca on depends on the histological subtype. 
The  four major  subtypes of  small bowel  tumours  are  adenocarcinomas,  neuroendocrine 
tumours (including carcinoids), gastro-intes nal stromal tumours (GIST) and lymphomas . 
Adenocarcinomas  and  neuroendocrine  tumours  are  the  most  common  subtypes  in  the 
small bowel, both accoun ng for approximately 40% of small bowel tumours3-5.
Pa ents with small bowel adenocarcinomas merely present with non-speci c symptoms, 
such  as  vague  abdominal  pain,  weight  loss,  nausea  and  vomi ng,  bowel  obstruc on, 
gastrointes nal bleeding or anaemia, which challenges the diagnosis. Known predisposing 
risk factors for these tumours are autoimmune disorders  including celiac disease, Crohn’s 
disease and several hereditary cancer syndromes, including familial adenomatous polyposis 
(FAP), hereditary nonpolyposis colorectal cancer (HNPCC) and the Peutz-Jeghers syndrome. 
These predisposing gene c disorders also play a role in the pathogenesis of colon cancer. 
Although  the  precise  pathogenesis  of  small  bowel  adenocarcinomas  is  unknown,  most 
available data suggest a carcinoma sequence driven mul step process of speci c gene c 
changes similar to colorectal cancers5-9.
Due  to  the  rarity  of  the  disease,  data  about  small  bowel  adenocarcinomas  are  scarce, 
diverse and contradictory. Therefore we conducted a popula on-based study to establish 
the  incidence,  treatment  and  overall  survival  over   me  of  pa ents  with  a  small  bowel 
adenocarcinoma in the Netherlands between 1999 and 2013.
 
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Data collec on
For  this study, data were  retrieved  from the Netherlands Cancer Registry (NCR), which  is 
managed  by  the  Comprehensive  Cancer  Organisa on  the  Netherlands.  The  na onwide 
NCR  covers  nearly  17  million  inhabitants  and  comprises  popula on-based  data  on  all 
newly diagnosed malignancies. Primary source of no  ca on of the NCR is the automated 
na onwide  pathological  archive  (PALGA),  supplemented  with  data  from  the  Na onal 
Registry  of Hospital  Discharge Diagnoses.  Required  informa on on  diagnosis,  treatment, 
pa ent- and tumour characteris cs are rou nely extracted from hospital medical records by 
specially trained registrars opera ng on behalf of the NCR.
Pa ents  were  included  if  they  were  diagnosed  between  1999  and  2013  with  an 
adenocarcinoma  of  the  small  bowel,  according  to  the  third  version  of  the  Interna onal 
Classi ca on of Disease for Oncology (ICD-O) (topography code C17). Tumours were classi ed 
as adenocarcinomas with the following morphology codes: 8140, 8144, 8145, 8210, 8255, 
8260,  8261,  8263,  8480,  8481,  8490,  8560,  8570,  8574.  Pa ents with  adenocarcinomas 
arising  from  a Meckel’s  diver culum,  as well  as  pa ents  with  neuroendocrine  tumours, 
gastrointes nal  stromal  tumours,  lymphomas  or  undi eren ated  tumours  in  the  small 
bowel were excluded from analysis.
All  adenocarcinomas  were  classi ed  according  to  the  Tumour  Lymph  Node  Metastasis 
(TNM) classi ca on and were staged following the recommenda ons of the Interna onal 
Union Against Cancer in the respec ve period. The tumours were categorized in two groups, 
either as locoregional (T
1-4
 
0-2
D
 
) or metasta c cancer (T
1-4
 
0-2
D
 
).
Vital status of pa ents at 1 January 2014 was assessed through linkage with civil municipal 
registries and the central bureau for genealogy, which collects data on all deceased Dutch 
inhabitants. Survival was computed based on all-cause mortality.
Sta s cal analysis
Descrip ve  sta s cs  were  used  to  describe  the  pa ent  and  tumour  characteris cs. 
Di erences  in  certain  tumour  characteris cs  and  treatment  between  the  locoregional 
and metasta c group were compared and analysed using a two-sided χ -test. To evaluate 
trends in treatment and survival, pa ents were  rst categorized in three groups by period of 
diagnosis (1999-2003, 2004-2008 and 2009-2013), and subsequently, trends between the 
subgroups were analysed by means of a Cochran-Armitage trend test.
Age-standardized  incidence  rates  were  calculated  per  100.000  person-years  using  the 
  
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European  standardized  popula on  rate  (ESR)  for  the  respec ve  study  period.  Es mated 
annual  percentage  changes  (EAPCs)  in  incidence  were  es mated  by  Poisson  regression 
models. The independent in uence of relevant pa ent and tumour characteris cs on the 
administra on of chemotherapy for pa ents with locoregional and metasta c disease was 
analysed by means of a mul variable logis c regression analysis.
Survival  me was de ned as the  me from date of diagnosis to death. Pa ents who were 
lost  to  follow-up or  s ll alive at  1  January  2014 were censored.  Evalua on of  signi cant 
di erences  of  survival  between  the  subgroups  occurred  by  means  of  a  log-rank  test. 
Mul variable survival analyses, using the cox propor onal hazards model, were carried out 
to  iden fy  independent prognos c  factors of  overall  survival.  In  order  to  inves gate  the 
e ect of therapy on the hazard ra os (HR) of dying, two separate mul variable models were 
run with and without treatment variables (surgery yes vs. no and chemotherapy yes vs. no).
The sta s cal package SAS Sta s cal so ware (version 9.4, SAS ins tute, Cary, NC, USA) was 
used to analyse the data. For all sta s cal tests, a two-sided p-value p < 0.05 was considered 
as sta s cally signi cant.
 
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A  total of  3930 pa ents were  diagnosed with  a  small  bowel  tumour between  1  January 
1999 and 31 December 2013. The most common histological subtype was adenocarcinoma, 
accoun ng for 1775 cases (45%), followed by neuroendocrine tumours (1429 pa ents, 36%) 
and  gastro-intes nal  stromal  tumours  (529 pa ents,  13%).  The  1775 pa ents  diagnosed 
with an adenocarcinoma were enrolled in this study.
The  pa ents’  characteris cs  are  summarized  in  table  1.  We  found  an  equal  gender 
distribu on, the median age at  me of diagnosis was 69 (range 17-97). The tumours were 
mainly located in the duodenum (58%), and respec vely 19% and 14% in the jejunum and 
the ileum.
The age-standardized  incidence of  small bowel adenocarcinomas  increased  from 0.5  per 
100,000 inhabitants in 1999 to 0.7 per 100,000 inhabitants in 2013 with an es mated annual 
percentage  change  (EAPC)  of  3.7%  (p  <  0.001).  The  increased  incidence  of  small  bowel 
adenocarcinomas  is mainly  caused  by  a  twofold  increase  of  duodenal  adenocarcinomas 
from 233 in 1999-2003 to 478 cases in 2009-2013 (p = 0.013) ( gure 1).
Thirty-three percent of the pa ents had metasta c disease. Over  me the propor on of 
pa ents presen ng with metasta c  disease  increased  from 27%  in  1999-2003  to 38%  in 
2009-2013 (p < 0.0001). Moreover, the percentage of pa ents presen ng with metastases 
in mul ple organs increased as well from 8% in 1999-2003 to 28% in 2009-2013 (p = 0.0003). 
The most  common metasta c  site was  the  liver  (46%),  followed by  the peritoneal cavity 
(29%) and extra regional lymph nodes (12%). Pa ents with metasta c disease arising from 
duodenal origin showed a di erent metasta c pa ern compared to pa ents with primary 
tumours  located  elsewhere  in  the  small bowel. The majority of  pa ents with metasta c 
duodenal adenocarcinomas had metastases located in the liver (54%), whereas in pa ents 
with metastases from non-duodenal adenocarcinomas the peritoneal cavity was the most 
frequently a ected site (44%).
In the group of pa ents with  locoregional disease, 73% underwent a surgical resec on of 
the primary tumour in contrast to 30% of the pa ents with metasta c disease (p < 0.0001). 
The  percentage  of  pa ents  with  locoregional  disease  undergoing  a  resec on  slightly 
increased from 71% in 1999-2003 to 77% in 2009-2013, while the percentage of pa ents 
with metasta c disease undergoing a surgical resec on of the primary tumour decreased 
from 38% to 25% (p = 0.0031). 
  
Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013
d        Characteris cs of pa ents diagnosed with a small bowel adenocarcinoma, by primary tumour 
localiza on (n = 1775).
d    
N (%)
Duodenum
N (%)
Non-Duodenum
N (%)
       
   
 D   
 Female
909 (51.2)
866 (48.8)
541 (52.7)
485 (47.3)
368 (49.1)
381 (50.9)
0.1343
Age (years)
 < 50
 50-59
 60-69
 70-79
 ≥ 80
178 (10.0)
281 (15.8)
458 (25.8)
509 (28.7)
349 (19.7)
84 (8.2)
155 (15.1)
257 (25.1)
307 (29.9)
223 (21.7)
94 (12.6)
126 (16.8)
201 (26.8)
202 (27.0)
126 (16.8)
0.0028
Loca on primary tumour
 Duodenum
 Jejunum
 Ileum
 Overlapping
 Unknown/NOS
1026 (57.8)
336 (18.9)
257 (14.5)
42 (2.4)
114 (6.4)
1026 (100.0)
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
336 (44.9)
257 (34.3)
42 (5.6)
114 (15.2)
n.a.
dE             
  
   
    
 IV
 X
115 (6.5)
501 (28.2)
419 (23.6)
581 (32.7)
159 (9.0)
66 (6.4)
219 (21.4)
257 (25.1)
352 (34.3)
132 (12.9)
49 (6.5)
282 (37.7)
162 (21.6)
229 (30.6)
27 (3.6)
< 0.0001
Number of metasta c sites
  
  
 ≥ 3
447 (76.9)
97 (16.7)
37 (6.4)
286 (81.3)
48 (13.6)
18 (5.1)
161 (70.3)
49 (21.4)
19 (8.3)
0.0092
                   
 1999-2003
 2004-2008
 2009-2013
436 (24.6)
559 (31.5)
780 (43.9)
233 (22.7)
315 (30.7)
478 (46.6)
203 (27.1)
244 (32.6)
302 (40.3)
0.0207
       
 Yes
   
1045 (58.9)
730 (41.1)
418 (40.7)
608 (59.3)
627 (83.7)
122 (16.3)
< 0.0001
            
 Yes
   
321 (18.1)
1454 (81.9)
165 (16.1)
861 (83.9)
156 (20.8)
593 (79.2)
0.0103
d                  
NOS = not otherwise speci ed
 
  
         
&         Primary tumour loca on within the small bowel for pa ents diagnosed with a small bowel 
adenocarcinoma between 1999 and 2013 in the Netherlands according to period of diagnosis (n = 1775).
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Tumour loca on was an important predic ve factor for surgery. In locoregional disease, 58% 
of the pa ents with duodenal carcinomas underwent a surgical interven on with cura ve 
intent as compared to 95% of the pa ents with jejunal and ileal carcinomas (p < 0.0001). 
The percentage of pa ents with duodenal adenocarcinomas undergoing surgery increased 
from 54% to 64% throughout the study period (p = 0.0179). In metasta c disease, only 7% 
of  the  pa ents  with  duodenal  adenocarcinomas  underwent  surgery,  in  contrast  to 
respec vely 63% and 81% of the pa ents with jejunal and ileal tumours (p < 0.0001). Other 
pallia ve  interven ons,  such  as  a  bilio-diges ve  or  intes nal  bypass,  endoscopic  stent 
placement or celiac plexus block, were performed in 24% of the pa ents with metasta c 
duodenal adenocarcinomas, and respec vely in 5% and 6% of the pa ents with metasta c 
jejunal  and  ileal  tumours.  In  addi on,  14%  of  the  pa ents  with  locoregional  duodenal 
adenocarcinomas received a pallia ve interven on.
Eleven  percent  of  the  pa ents  with  locoregional  disease  received  chemotherapy,  while 
33%  of  the  pa ents  with  metasta c  disease  did.  The  use  of  chemotherapy  increased 
over  me  for pa ents with  locoregional  disease  from 7%  in  1999-2003  to  15%  in  2009-
2013 (p = 0.0001). Of the 91 pa ents with locoregional disease, undergoing both surgical 
resec on  and  chemotherapy,  the  majority  received  the  chemotherapy  in  the  adjuvant 
se ng. Mul variable  logis c  regression analyses  showed  that  chemotherapy  in  pa ents 
with  locoregional disease was more o en o ered to younger pa ents, pa ents with ileal 
or stage III tumours or pa ents who were diagnosed in the period 2009-2013 (table 2). In 
pa ents with metasta c disease  the prescrip on of pallia ve chemotherapy signi cantly 
  
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increased from 19% in 1999-2003 to 37% in 2009-2013 (p = 0.001). In metasta c disease, 
younger  pa ents  and  pa ents  who  were  diagnosed  a er  2003  received  chemotherapy 
more frequently (table 2).
 
 
d        Crude percentages and adjusted odds for receiving chemotherapy among pa ents diagnosed with 
small bowel adenocarcinomas between 1999 and 2013 in the Netherlands (n = 1775).
Locoregional disease (n = 1194)  Metasta c disease (n = 581)
      
percentage (%)
Odds ra os 
(95% CI)
      
percentage (%)
Odds ra os 
(95% CI)
   
 D   
 Female
12.1
9.9
1.00 (reference)
0.85 (0.57-1.27)
31.0
34.0
1.00 (reference)
1.18 (0.80-1.73)
Age (years)
 < 50
 50-59
 60-69
 70-79
 ≥ 80
25.9
18.9
16.0
5.6
0.0
2.16 (1.22-3.81)
1.54 (0.92-2.59)
1.00 (reference)
0.34 (0.19-0.61)
Not applicable
56.5
51.1
39.4
23.7
3.2
1.99 (1.08-3.67)
1.63 (0.95-2.78)
1.00 (reference)
0.48 (0.29-0.78)
0.05 (0.02-0.16)
Loca on primary tumour
 Duodenum
 Jejunum
 Ileum
 Overlapping
 Unknown/NOS
9.5
13.0
15.1
8.3
9.7
1.00 (reference)
1.61 (0.97-2.68)
2.00 (1.16-3.47)
1.03 (0.21-5.02)
1.28 (0.52-3.16)
28.7
43.3
34.7
38.9
33.3
1.00 (reference)
1.49 (0.90-2.48)
1.16 (0.64-2.12)
1.11 (0.40-3.06)
1.33 (0.61-2.86)
dE             
  
   
    
 X
0.0
7.6
20.8
4.4
Not applicable
1.00 (reference)
3.45 (2.22-5.35)
1.89 (0.77-4.66)
                
            
                   
 1999-2003
 2004-2008
 2009-2013
6.6
9.8
15.0
1.00 (reference)
1.74 (0.96-3.16)
3.10 (1.79-5.38)
18.6
34.7
36.9
1.00 (reference)
2.31 (1.27-4.19)
3.00 (1.72-5.26)
NOS = not otherwise speci ed
 
The  median  overall  survival  of  pa ents  diagnosed  with  a  small  bowel  adenocarcinoma 
remained stable around 13-14 months, with one and  ve year survival  rates of 53% and 
25%  respec vely.  Pa ents with  locoregional  disease  had a median  overall  survival  of  25 
months  (one and  ve year survival  rates 65% and 36% respec vely). The median overall 
survival of pa ents with locoregional disease increased from 19 months in the  rst period 
to  34 months  in  the  last  period  (p  =  0.0006).  In  pa ents with  locoregional  disease who 
underwent a surgical resec on, an overall survival of 48 months was observed. Whereas 
pa ents  receiving  (neo-)adjuvant chemotherapy  in combina on with surgery exhibited a 
 
  
         
signi cantly be er overall survival of 66 months (p = 0.0338).
The median overall survival of pa ents with metasta c disease remained stable around 4-5 
months (one and  ve year survival rates 26% and 3% respec vely). A median overall survival 
of 10 months was seen in pa ents with metasta c disease who were treated with pallia ve 
chemotherapy,  in contrast  to a  3 month median overall  survival  in pa ents who  did not 
receive pallia ve chemotherapy.
Favourable  prognos c  factors,  iden  ed  by  a  separate  mul variable  survival  analysis, 
including pa ents with locoregional disease, were age < 60 years, low tumour stage (stage 
I,  II)  and diagnosis  in  the  period  2009-2013  (table  3).  Factors  that were  associated with 
poor survival included age ≥70 years, tumour localiza on in the duodenum and an unknown 
tumour stage (stage X). Surgical treatment and chemotherapy, were added separately to the 
model to inves gate its e ect on the hazard ra o of death according to period of diagnosis 
and  di erent  pa ent  and  tumour  characteris cs.  Surgical  treatment  and  chemotherapy 
were both favourable prognos c factors. Remarkably, a er adjustment for surgery only, a 
tumour located in the duodenum was no longer a nega ve prognos c factor and diagnosis in 
the period 2004-2008 became a posi ve prognos c factor. Chemotherapy did not in uence 
the e ect of the other characteris cs on the hazard ra o of death.
In a mul variable survival analysis without adjustment for treatment including pa ents with 
metasta c disease, age <50 years and primary tumour located in the jejunum or ileum were 
posi ve prognos c factors (table 4). Age ≥80 years was the only nega ve prognos c factor. 
No bene cial in uence of  me was seen. A er adjustment for chemotherapy and surgery, 
both posi ve prognos c factors, a primary tumour located in the ileum became a nega ve 
prognos c factor.
  
Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013
d        Crude median overall  survival, crude 1-year survival, adjusted hazard ra os with and without 
adjustment for treatment for pa ents diagnosed with locoregional small bowel adenocarcinoma between 
1999 and 2013 in the Netherlands (n = 1194).
             
                
(months)
             
        
(%)
Mul variate HR
 (95% CI)  
Mul variate HR
(95% CI)
             
           
   
 D   
 Female
26.1
24.5
65.8
64.7
1.00 (reference)
0.87 (0.75-1.00)
1.00 (reference)
0.82 (0.71-0.95)
Age (years)
 < 50
 50-59
 60-69
 70-79
 ≥ 80
73.0
66.4
32.4
21.9
7.9
84.9
79.8
72.1
62.8
40.9
0.61 (0.44-0.83)
0.66 (0.51-0.86)
1.00 (reference)
1.34 (1.09-1.64)
2.18 (1.76-2.71)
0.66 (0.48-0.91)
0.68 (0.53-0.89)
1.00 (reference)
1.21 (0.98-1.48)
1.52 (1.21-1.90)
Loca on primary tumour
 Duodenum
 Jejunum
 Ileum
 Overlapping
 Unknown/NOS
16.3
62.6
40.2
41.3
22.6
57.8
81.9
73.3
79.1
55.5
1.00 (reference)
0.62 (0.51-0.77)
0.79 (0.63-0.98)
0.76 (0.45-1.29)
0.75 (0.55-1.02)
1.00 (reference)
0.93 (0.74-1.16)
1.22 (0.97-1.54)
0.97 (0.58-1.65)
1.12 (0.82-1.54)
dE             
  
   
    
 X
77.2
42.7
20.5
4.7
84.8
73.4
65.0
26.4
0.39 (0.29-0.53)
0.65 (0.55-0.77)
1.00 (reference)
1.73 (1.39-2.17)
0.42 (0.31-0.56)
0.63 (0.53-0.75)
1.00 (reference)
0.85 (0.67-1.07)
                   
 1999-2003
 2004-2008
 2009-2013
18.5
23.1
34.1
61.3
63.7
69.4
1.00 (reference)
0.87 (0.73-1.03)
0.68 (0.56-0.81)
1.00 (reference)
0.84 (0.70-0.99)
0.74 (0.61-0.89)
       
 Yes
   
50.3
5.6
79.8
73.6
             
               
0.23 (0.18-0.28)
1.00 (reference)
            
 Yes
   
35.5
23.5
84.3
63.0
             
               
0.55 (0.41-0.73)
1.00 (reference)
NOS = not otherwise speci ed;   adjusted for all variables listed
 
  
         
d        Crude median overall  survival,  crude 1-year survival, adjusted hazard ra os with and without 
adjustment for treatment for pa ents diagnosed with metasta c small bowel adenocarcinoma between 
1999 and 2013 in the Netherlands (n = 581).
             
                
(months)
             
        
(%)
Mul variate HR 
(95% CI)  
Mul variate HR
(95% CI)
             
           
   
 D   
 Female
4.5
5.1
21.2
30.5
1.00 (reference)
0.89 (0.75-1.06)
1.00 (reference)
0.90 (0.75-1.07)
Age (years)
 < 50
 50-59
 60-69
 70-79
 ≥ 80
8.3
5.7
5.2
4.7
2.4
38.7
31.0
28.9
23.1
12.2
0.69 (0.50-0.95)
0.97 (0.73-1.27)
1.00 (reference)
1.16 (0.93-1.46)
1.64 (1.26-2.15)
0.79 (0.57-1.08)
1.00 (0.76-1.32)
1.00 (reference)
1.02 (0.81-1.29)
1.21 (0.91-1.60)
Loca on primary tumour
 Duodenum
 Jejunum
 Ileum
 Overlapping
 Unknown/NOS
4.0
9.7
5.0
4.9
5.7
19.2
40.5
29.9
29.6
39.1
1.00 (reference)
0.54 (0.42-0.70)
0.74 (0.56-0.97)
0.83 (0.51-1.36)
0.79 (0.56-1.12)
1.00 (reference)
0.90 (0.68-1.18)
1.57 (1.13-2.17)
1.19 (0.72-1.97)
1.48 (1.03-2.15)
                   
 1999-2003
 2004-2008
 2009-2013
4.5
4.8
5.2
27.1
27.7
23.9
1.00 (reference)
0.92 (0.72-1.17)
0.95 (0.76-1.20)
1.00 (reference)
1.10 (0.86-1.41)
1.12 (0.89-1.42)
       
 Yes
   
10.6
3.9
47.2
16.6
             
               
0.38 (0.30-0.50)
1.00 (reference)
            
 Yes
   
10.5
3.2
43.4
17.5
             
               
0.50 (0.40-0.61)
1.00 (reference)
NOS = not otherwise speci ed,   adjusted for all variables listed
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Discussion
This  popula on-based  study  examined  the  incidence,  treatment  and  overall  survival 
over  me  in pa ents  diagnosed with  a  small  bowel  adenocarcinoma  in  the Netherlands 
between 1999 and 2013 and is one of the  largest conducted  studies  in the  eld of  small 
bowel  adenocarcinomas  so  far.  Our  study  showed  that  the  incidence  of  small  bowel 
adenocarcinomas is rising. Furthermore, we found that the resec on rates in non-metasta c 
small bowel cancer increased and the overall survival in pa ents with locoregional disease 
improved  over   me.  The  overall  survival  of  pa ents  with  metasta c  disease  remained 
stable, despite the increased treatment with pallia ve chemotherapy.
The  distribu on  pa ern  of  small  bowel  adenocarcinomas  throughout  the  bowel  was 
comparable with previous studies3-5, 7. It has been hypothesized that the duodenum might 
be more suscep ble for carcinogenesis than the jejunum and ileum due to the metabolism 
or dilu on of ingested carcinogens in transit through the small bowel or interac ons of the 
carcinogens with the pancrea cobiliary secre ons            .
Based  on  our  comparison  between  pa ents  diagnosed  with  tumours  located  in  the 
duodenum versus pa ents diagnosed with tumours located elsewhere in the small bowel, 
it could be ques oned whether these tumours should be considered as one en ty. Pa ents 
with tumours located in the duodenum are o en slightly older, have more advanced disease 
and have a di erent metasta c pa ern.
A slight increase in the incidence of small bowel adenocarcinomas was seen between 1999 
and 2013, which is mainly caused by the twofold  increase of duodenal adenocarcinomas. 
The exact cause for the speci c increase in duodenal adenocarcinomas is unknown. Par ally 
it  can be  explained  by  improved diagnos cs,  resul ng  in  a  reduc on of misclassi ca on 
of  duodenal  adenocarcinomas  as  pancrea c  tumours  and  adenocarcinoma  of  unknown 
primary  (ACUP)       . The modi ed  food  consump on might  have  a ributed  to  increased 
incidence rates as well. Previous studies found sugar, re ned carbohydrates, red meat and 
smoked food to be associated with the development of small bowel adenocarcinomas     .
The percentage of pa ents diagnosed with metasta c disease increased over  me, which 
can  be  explained  by  stage migra on  caused  by  new  and  improved  diagnos cs,  such  as 
mul detector  row  computed  tomography  scans  (MDCT)  and  magne c  resonance  (MR) 
              .
Surgical resec on  is  the only  therapy for poten al cure in  small bowel adenocarcinoma . 
In line with previous studies, 73% of the pa ents with locoregional disease underwent an 
 
  
         
inten onally cura ve  resec on    . Resec on rates were higher  in  jejunal  and  ileal  tumours 
compared to resec on rates in duodenal tumours, since surgical resec on of upper duodenal 
tumours  requires  a  pancrea coduodenectomy,  which  is  specialized  major  surgery  in 
comparison to the more simple segmental resec ons with removal of surrounding  ssue for 
jejunal and ileal tumours    .
Over  me the resec on rates increased, especially due to an increased number of resec ons 
in pa ents with duodenal tumours. We hypothesize that may be due to the centraliza on of 
pancrea coduodenectomies in the Netherlands      . The amount of surgical interven ons in 
pa ents with metasta c disease decreased dras cally, which is probably the result of improved 
pallia ve  interven ons, such as endoscopically placed  (bilio-)duodenal endoprotheses, and 
the increased use of chemotherapy  . Pallia ve interven ons in pa ents with non-metasta c 
small  bowel  cancer  were  mostly  performed  in  pa ents  with  duodenal  adenocarcinomas, 
which are more o en irresectable compared to jejunal and ileal tumours .
The propor on of pa ents  receiving chemotherapy doubled during  the study period, both 
for pa ents with locoregional and metasta c disease. Especially in pa ents with locoregional 
disease  the twofold  increase  is  remarkable,  since non-observa onal  studies addressing  the 
bene cial e ect of chemotherapy are  lacking. Overman et al found adjuvant chemotherapy 
to be associated with an  improvement of disease  free survival, but not with  improvement 
                      . Recently, a popula on-based study conducted by Ecker et al showed a 
survival bene t of 16 months (42 vs 26 months) for pa ents with stage III tumours treated 
with adjuvant chemotherapy  . We demonstrate  that  in pa ents with  locoregional disease 
chemotherapy was more  o en  o ered  to younger pa ents,  pa ents with  ileal  or  stage  III 
tumours and pa ents who were diagnosed in the period 2009-2013.  In metasta c disease 
however, the doubling of pallia ve chemotherapy is not surprising, since a survival bene t of 
several months has already been observed in mul ple retrospec ve studies5, 19-21. In pa ents 
with metasta c disease, only a younger age and diagnosis a er 2003 were posi ve predic ve 
factors for receiving pallia ve chemotherapy.
The overall survival rate of all pa ents with an adenocarcinoma of the small bowel did not 
improve over  me and  remained dismal with an overall median survival of 13-14 months. 
Our results are inferior to the reported overall survival of approximately 20 months in other 
popula on-based studies, but these studies were merely conducted before the millennium 
and might have included neuroendocrine tumours with a more indolent behaviour            .
The median overall survival of pa ents with locoregional disease improved from 19 months in 
1999-2003 to 34 months in 2009-2013, which might be explained by stage migra on, increased 
  
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use of chemotherapy and the centraliza on of pancrea c cancer surgery. Moreover, we found 
that  pa ents  treated  with  adjuvant  chemotherapy  a er  surgical  resec on  had  signi cant 
higher  survival  rates,  66  months  compared  to  48  months  for  pa ents  not  treated  with 
adjuvant chemotherapy. However,  it should be noted that the amount of pa ents receiving 
both treatments were limited in our study. Other favourable prognos c factors for prolonged 
survival in pa ents with locoregional disease,  iden  ed by mul variable analysis, were age 
<60 years,  tumour stage  I and  II,  surgical  treatment and chemotherapy. These  ndings are 
comparable  to previously determined prognos c  factors                   .  In addi on,  in pa ents 
with  locoregional  disease, duodenal  tumours appeared  to be an adverse prognos c  factor 
in mul variable  analysis without adjustment  for  treatment. However,  a er adjustment  for 
surgery only, a duodenal tumour was not a nega ve prognos c factor anymore, which implies 
that the poor prognosis of these tumours is the result of the rela ve lack of possibili es for 
surgical interven on.
In metasta c disease the overall survival remained stable around 4-5 months despite doubling 
of the prescrip on of pallia ve chemotherapy from 19% to 37% in the recent years. In pa ents 
with metasta c  disease,  favourable  prognos c  factors  iden  ed  by mul variable  analysis 
included  age  <50  years,  primary  tumour  located  in  the  jejunum,  surgical  treatment  and 
chemotherapy. These prognos c factors are also consistent to previously published data        .
A  limita on  of  our  study  is  that  detailed  informa on  on  performance  status,  nutri onal 
status,  disease  related  symptoms,  the  speci c  tumour  localiza on  within  the  duodenum, 
type of chemotherapy and type of surgical and pallia ve interven on are lacking, due to the 
popula on based nature of our data. However, our results did not di er from other studies3-5, 7.
In conclusion, small bowel adenocarcinomas are rare tumours with an increasing incidence, 
mainly  caused  by  the  rise  of  duodenal  adenocarcinomas.  The  median  overall  survival  of 
pa ents with  locoregional disease  improved signi cantly over  me, which might be due  to 
the increasing use of chemotherapy and the implementa on of centralizing pancrea c cancer 
surgery. However,  the overall  survival of pa ents with metasta c disease  remained stable, 
despite doubling the administra on of pallia ve chemotherapy. Due to the rarity and dismal 
prognosis of this disease,  it  is of importance  to develop  interna onal  studies  to determine 
the op mal treatment for these pa ents. The di erences found in characteris cs and median 
overall  survival  between  pa ents  diagnosed  with  tumours  located  in  the  duodenum  and 
tumours  located elsewhere  in  the small  bowel might  suggest  that  in  future  research both 
should be considered as di erent en  es.
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             The  aim  of  this  popula on-based  study  was  to  provide  insight  into  the 
incidence, risk factors and treatment-related survival of pa ents with peritoneal metastases 
(PM) of small bowel adenocarcinoma (SBA).
          Data  from  the Netherlands  Cancer  Registry were  used.  All  pa ents  diagnosed 
with  SBA  between  2005  and  2014 were  included.  The  in uence  of  pa ent  and  tumour 
characteris cs on  the odds of developing PM was analysed. Subsequently,  for all  further 
analyses, pa ents without  synchronous PM of SBA were excluded. The  log-rank  test and 
Kaplan-Meier  analyses  were  conducted  to  es mate  survival,  and  the  Cox  propor onal 
hazards model was used to evaluate the risk of death.
         Of  the  1428  included  pa ents  diagnosed  with  SBA,  181  (13%)  presented  with 
synchronous  PM.  Synchronous  PM  was  found  in  9%  of  the  duodenal  tumours  and  in 
17% of  the more distal  tumours. Median overall survival of all pa ents with PM was 5.9 
months, whereas survival of both 11 months was observed in pa ents treated with primary 
tumour  resec on or  pallia ve chemotherapy and  32 months  a er  cytoreduc ve surgery 
with hyperthermic intraperitoneal chemotherapy (CRS+HIPEC). Poor prognos c factors for 
survival were age  ≥70 years  (hazard  ra o  [HR] 1.6, 95% con dence  interval  [CI] 1.1-2.2), 
systemic metastases other than PM (HR 2.0, 95% CI 1.4-2.9) and an advanced (HR 1.9, 95% 
CI 1.3-3.0) or unknown T-stage (HR 2.1, 95% CI 1.2-3.5).
              Synchronous  PM  was  frequently  encountered  in  SBA.  Without  treatment, 
prognosis was extremely poor. Survival was higher a er primary tumour resec on, pallia ve 
chemotherapy and CRS+HIPEC, but selec on bias probably played a signi cant role calling 
for further clinical research.
  
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Introduc on
One  of  the  most  frequently  a ected  metasta c  sites  in  pa ents  with  small  bowel 
adenocarcinoma (SBA) is the peritoneal cavity, especially in tumours arising from the jejunum 
and  ileum1-3. Other  common metasta c  sites  of  SBA  include  the  liver  and  extra-regional 
lymph nodes. The prognosis of metasta c SBA is poor with a median overall survival of 4-5 
months and 5-year survival rates of 3-5%          . Data on survival according to metasta c site 
in pa ents with a primary SBA are absent, and as a result, speci c informa on on survival of 
pa ents with peritoneal metastases (PM) is unknown.
In gastro-intes nal malignancies, PM is usually regarded as a virtually untreatable condi on, 
mainly because of  the poor  response  to  conven onal  types of  therapy,  such as systemic 
therapy, surgical resec on or radia on3, 6-10. Since the introduc on of cytoreduc ve surgery 
and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) more than two decades ago, 
major improvements in overall survival have been achieved in pa ents with pseudomyxoma 
peritonei and PM of colorectal cancer  (CRC)6, 11-13. Owing to similari es between SBA and 
CRC,  it  is  thought  that  CRS+HIPEC might  also  bene t  pa ents with  PM of  SBA      .  Some 
small studies already showed the poten al bene cial e ect of CRS+HIPEC in small groups of 
selected pa ents with PM of SBA, but prospec ve studies are lacking    .
Currently, data about PM of SBA are virtually absent. Since these data are of  importance 
to  pa ents  su ering  from  this  condi on  and  physicians  trea ng  it,  we  performed  a 
popula on-based study to establish incidence, risk factors and overall survival of pa ents 
with synchronous PM of SBA in the Netherlands between 2005-2014.
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Data collec on
Data were retrieved from the Netherlands Cancer Registry (NCR). The NCR covers nearly 17 
million inhabitants of the Netherlands and comprises popula on-based data on all newly 
diagnosed malignancies of all Dutch ci zens. Primary source of no  ca on of the NCR  is 
the  automated  na onwide  pathological  archive  (PALGA),  supplemented  with  data  from 
the  na onal  registry of hospital  discharge diagnoses.  The NCR comprises  informa on on 
pa ent and tumour characteris cs, diagnosis and treatment, which is  rou nely extracted 
from medical records by specially trained registrars opera ng on behalf of the NCR. In the 
databases  of  the NCR,  the  stage  of  the  primary  tumour  is  established  according  to  the 
tumour-node-metastasis  (TNM)  classi ca on.  In  case  of  missing  pathological  data,  the 
clinical TNM stage is used. The anatomical site of the tumour and metastases are registered 
according  to  the  third  version  of  the  Interna onal Classi ca on  of Disease  for Oncology 
(ICD-O).
Pa ents diagnosed with SBA (ICD-O code C17) between 2005 and 2014 were  included  in 
this study and analysed for synchronous PM (C48). Synchronous metastases were de ned 
as metastases  diagnosed  within  3 months  a er  the  ini al  SBA  diagnosis.  Tumours were 
classi ed  as  adenocarcinomas  with  the  following morphology  codes:  8140,  8144,  8145, 
8210,  8255,  8260,  8261,  8263,  8480,  8481,  8490,  8560,  8570  and  8574.  Pa ents  were 
excluded if they were diagnosed with neuro-endocrine tumours, including carcinoids, gastro-
intes nal  stromal  tumours  or  undi eren ated  tumours  or  if  they were newly  diagnosed 
during autopsy.
The  following  treatment modali es were  included  in  the study: pallia ve chemotherapy, 
pallia ve primary tumour  resec on and CRS+HIPEC. Pallia ve chemotherapy was de ned 
as  the  administra on  of  cytotoxic  drugs  or  targeted  agents.  CRS+HIPEC  was  performed 
according to a na onwide Dutch protocol.
Vital status of pa ents was assessed on 1 February 2016 through linkage of the NCR with 
civil municipal  registries and  the central bureau for genealogy, which collects data on all 
deceased inhabitants of the Netherlands. Survival was computed on all-cause mortality.
Sta s cal analysis
Age-standardized  incidence  rates  were  calculated  per  100,000  person-years  using  the 
European  standardized  popula on  rate  for  the  respec ve  study  period.  Di erences  in 
pa ent  and  tumour  characteris cs  were  analysed  with  a  two-sided  chi-square  test  or 
Fisher’s exact  test  in case of small samples. Trends between the two periods (2005-2009 
  
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and 2010-2014) were evaluated by means of a Cochran-Armitage trend test. The in uence 
of  independent  pa ent  and  tumour  characteris cs  on  the  odds  of  developing  PM was 
analysed in a mul variable logis c regression analysis, and the 95% con dence interval (CI) 
was assessed.
Survival  me was de ned as the  me from the date of diagnosis un l death or un l the last 
follow-up date for pa ents who were lost to follow-up or who were s ll alive on 1 February 
2016.  Survival  was  es mated  with  the  log-rank  test  and  Kaplan-Meier  analyses.  For  all 
possible prognos c factors of overall survival, univariable survival analyses were performed, 
using the Cox propor onal hazards model. If univariable analyses tended towards sta s cal 
signi cance  (p <  0.10),  the  risk of  death  corrected  for  these poten al prognos c  factors 
was subsequently evaluated with mul variable survival analyses. Hazard ra os (HRs) were 
presented with 95% CIs.
Data  were  analysed  with  the  sta s cal  package  SAS  Sta s cal  So ware,  version  9.4 
(SAS Ins tute, Cary, NC, USA). For all sta s cal tests, a two-sided p-value of p < 0.05 was 
considered as sta s cally signi cant.
 
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The present study included 1428 pa ents diagnosed with an SBA between 2005 and 2014, 
181 of whom presented with synchronous PM (13%). According to topographical subtype, 
most pa ents with PM had a primary  tumour  in  the duodenum (44%). Synchronous PM 
was found in 9% of the pa ents with a primary duodenal tumour, compared with 17% of 
the pa ents with a more distal  tumour. Throughout  the study period,  the percentage of 
pa ents presen ng with synchronous PM increased from 10% to 15% ( gure 1). In duodenal 
tumours, this percentage increased from 8% to 10% (p = 0.22), and in non-duodenal tumours, 
it increased from 13% to 22% (p < 0.01). The age-standardized  incidence of PM from SBA 
could not be calculated, as the incidence rate was below 0.1 per 100,000 inhabitants.
&         The percentage of pa ents presen ng with synchronous peritoneal metastases (PM) in small 
bowel adenocarcinoma (SBA) in the Netherlands between 2005 and 2014, plo ed against the total number 
of pa ents with a primary SBA per year.
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In 62% of  the PM of SBA pa ents, the peritoneal cavity was the only a ected metasta c 
site.  The  most  commonly  a ected  metasta c  sites  besides  the  peritoneal  cavity  were 
the  liver  (59%),  extra-regional  lymph  nodes  (24%)  and  lungs  (16%).  Sex  was  distributed 
equally, and a median age of 66 years was found.  Further details on pa ent and  tumour 
characteris cs are listed in table 1. In comparison to all pa ents with an SBA, pa ents with 
PM of SBA were younger, more o en had a primary non-duodenal tumour, more o en had 
an advanced T- and N-stage and were more o en diagnosed  in  the period  from 2010 to 
2014. Primary tumour surgery was performed less o en, whereas pallia ve chemotherapy 
was administered more frequently in the group of PM pa ents than in the overall group of 
SBA pa ents. All details on the di erences between these groups are shown in table 2.
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d        General characteris cs of pa ents diagnosed with PM of SBA in the Netherlands between 2005 
and 2014, stra  ed for primary tumour loca on (n = 181)
d    
(n = 181)
Duodenum
(n = 80)
E           
(n = 101)
       
  (%)   (%)   (%)
   
 D   
 Female
  
  
(47)
(53)
  
  
(51)
(49)
  
  
(44)
(56)
0.37
Age (years)
 < 70
 ≥ 70
   
  
(60)
(40)
  
  
(56)
(44)
  
  
(63)
(37)
0.36
Loca on of primary tumour
 Duodenum
 Jejunum
 Ileum
 NOS
  
  
  
  
(44)
(22)
(23)
(11)
  
 
 
 
(100)
(0)
(0)
(0)
 
  
  
  
(0.0)
(40)
(41)
(20)
n.a.
d      
 T1-3
 T4
 Tx
  
  
  
(25)
(48)
(28)
  
  
  
(14)
(43)
(44)
  
  
  
(34)
(51)
(15)
< 0.0001
E      
   
 N+
   
  
  
  
(24)
(45)
(31)
  
  
  
(25)
(38)
(38)
  
  
  
(23)
(51)
(27)
0.18
          
  D     
 PM + other metastases
   
  
(62)
(38)
  
  
(65)
(35)
  
  
(60)
(40)
0.53
      
 2005-2009
 2010-2014
  
   
(36)
(64)
  
  
(36)
(64)
  
  
(36)
(64)
0.93
                      
 Yes
   
  
   
(43)
(57)
 
  
(10)
(90)
  
  
(68)
(32)
< 0.0001
Pallia ve chemotherapy
 Yes
   
  
   
(31)
(69)
  
  
(20)
(80)
  
  
(41)
(59)
< 0.01
    ,    
 Yes
   
  
   
(8)
(92)
 
  
(3)
(98)
  
  
(13)
(87)
0.01
NOS = not otherwise speci ed; PM = peritoneal metastases; CRS+HIPEC = cytoreduc ve surgery with 
hyperthermic intraperitoneal chemotherapy; SBA = small bowel adenocarcinoma. 
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d        Comparison of general characteris cs of pa ents with PM of SBA and of all pa ents with an SBA 
in the Netherlands between 2005 and 2014.
                 
  (%)   (%)
   
 D   
 Female
  
  
(47)
(53)
   
   
(51)
(49)
Age (years)
 < 70
 ≥ 70
   
  
(60)
(40)
   
   
(52)
(48)
Loca on of primary tumour
 Duodenum
 Jejunum
 Ileum
 NOS
  
  
  
  
(44)
(22)
(23)
(11)
   
   
   
   
(60)
(18)
(14)
(7)
d      
 T1-3
 T4
 Tx
  
  
  
(25)
(48)
(28)
   
   
   
(38)
(37)
(25)
E      
   
 N+
   
  
  
  
(24)
(45)
(31)
   
   
   
(39)
(41)
(19)
      
 2005-2009
 2010-2014
  
   
(36)
(64)
   
   
(45)
(55)
                      
 Yes
   
  
   
(43)
(57)
   
   
(57)
(43)
Pallia ve chemotherapy
 Yes
   
  
   
(31)
(69)
   
    
(22)
(78)
    ,    
 Yes
   
  
   
(8)
(92)
  
    
(1)
(99)
d         (100)      (100)
NOS = not otherwise speci ed; PM = peritoneal metastases; CRS+HIPEC = cytoreduc ve surgery and 
hyperthermic intraperitoneal chemotherapy; SBA = small bowel adenocarcinoma.
 
Resec on  of  the  primary  tumour  was  performed  in  43%  of  the  PM  pa ents.  This  was 
signi cantly more o en the case in pa ents with non-duodenal  tumours than  in pa ents 
with duodenal tumours, 69% versus 10% (p < 0.0001). Over  me, no signi cant di erences 
were seen in primary tumour resec on.
In  this  10-year  period,  15  pa ents  underwent  CRS+HIPEC  (8%).  Of  these  pa ents,  two 
had with PM of duodenal origin, whereas 13 pa ents had PM of non-duodenal tumours 
  
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(p = 0.01). In comparison to all SBA pa ents with PM, pa ents who underwent CRS+HIPEC 
were signi cantly younger with a median age of 53 years (p < 0.01) and more o en had a 
primary tumour with a low T- and N-stage. Almost half of all procedures were performed in 
one hospital. Of the 15 pa ents receiving CRS+HIPEC,  ve underwent CRS+HIPEC in 2014, 
but no signi cant di erences over  me could be noted in the administra on of CRS+HIPEC.
Pallia ve  chemotherapy was  administered  in 31% of  the  pa ents with  PM.  It was  twice 
more commonly prescribed to pa ents with a primary non-duodenal  tumour (41%)  than 
to  pa ents  with  a  primary  duodenal  tumour  (20%)  (p  <  0.01).  Pallia ve  chemotherapy 
was given more frequently to pa ents younger than 70 years than to pa ents older than 
70 years (p = 0.02). No signi cant di erences between the two periods were found in the 
prescrip on of systemic therapy. 
Mul variable  logis c  regression  showed  that  higher  odds  ra os  of  developing  PM were 
associated with  a  primary  tumour  distal  to  the  duodenum,  an  advanced  or  unknown  T- 
and N-stage and diagnosis  in  the last period 2010-2014, whereas  lower odds  ra os were 
associated with age ≥70 years (table 3).
 
d        Mul variable logis c regression modelling the risk of PM among all pa ents with SBA diagnosed 
between 2005 and 2014 in the Netherlands (n = 1428).
Odds ra o (OR) 95% CI
   
 D   
 Female
1.0
1.2
(reference)
(0.8-1.6)
Age (years)
 < 70
 ≥ 70
1.0
0.6
(reference)
(0.5-0.9)
Loca on of primary tumour
 Duodenum
 Jejunum
 Ileum
 NOS
1.0
2.5
3.2
2.6
(reference)
(1.6-3.9)
(2.0-5.1)
(1.5-4.6)
d      
 T1-3
 T4
 Tx
1.0
2.1
2.0
(reference)
(1.4-3.2)
(1.2-3.4)
E      
   
 N+
   
1.0
1.8
3.8
(reference)
(1.2-2.7)
(2.4-6.2)
      
 2005-2009
 2010-2014
1.0
2.0
(reference)
(1.4-2.8)
NOS = not otherwise speci ed; CI = con dence interval; SBA = small bowel adenocarcinoma.
 
  
         
The median overall survival for all pa ents with PM was 5.9 months, with a 1-year survival 
rate of 25%. With suppor ve care only, median overall survival was 2.5 months. Median 
overall  survival  increased  to  11  months  in  pa ents  who  were  treated  with  pallia ve 
chemotherapy, also to 11 months a er surgery of the primary tumour, to 20 months a er 
combined tumour resec on and pallia ve chemotherapy and to 32 months a er CRS+HIPEC 
( gure  2). Over  me,  survival  rates  remained  stable  and  did  not  improve.  Survival  rates 
di ered between the primary tumour loca ons. Pa ents with a primary duodenal tumour 
had a median overall  survival of 3.0 months  (1-year survival  rate 15%),  compared  to 8.6 
months  (1-year  survival  rate 34%)  in pa ents with  a  primary  non-duodenal  tumour  (p < 
0.0001).
&         Median overall survival of pa ents with PM of SBA in the Netherlands between 2005 and 2014 
per treatment regimen.
Months a er diagnosis
Su
rv
iv
al
(%
)
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Pallia ve surgery
Pallia ve chemotherapy
CRS+HIPEC
Best suppor ve care
Log rank p<0.001
Pallia ve surgery + chemo
Time to event (months)
Pa ents at risk (n)                         
Best suppor ve care                    
Pallia ve surgery                      
Pallia ve chemotherapy                    
Pallia ve surgery + 
chemotherapy
                    
CRS+HIPEC                      
Chemo = chemotherapy; CRS+HIPEC = cytoreduc ve surgery and hyperthermic intraperitoneal chemotherapy; 
PM = peritoneal metastases; SBA = small bowel adenocarcinoma.
Univariable and mul variable propor onal hazards regression analyses modelling the risk 
of death for pa ents with PM of SBA are shown in table 4. In univariable survival analysis 
of pa ents with PM, almost all pa ent,  tumour and  treatment characteris cs seemed to 
  
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be of prognos c signi cance. In mul variable survival analysis, age ≥70 years, an advanced 
or unknown T-stage and other metastases besides PM were associated with lower survival, 
whereas  surgery  of  the  primary  tumour,  pallia ve  chemotherapy  and  CRS+HIPEC  were 
associated with higher survival.
 
d        Crude median overall survival, univariable and mul variable propor onal hazards regression 
analysis modelling risk of death for pa ents with PM of SBA in the Netherlands between 2005 and 2014 
(n = 181).
             
                 
(months)
h              
              
       
 Mul variate HR (95% CI)
   
 D   
 Female
4.8
6.9
0.09
1.0
0.8
(reference)
(0.6-1.1)
Age (years)
 < 70
 ≥ 70
7.2
4.6
< 0.01
1.0
1.6
(reference)
(1.1-2.2)
Loca on of primary 
      
 Duodenum
 Jejunum
 Ileum
 NOS
3.0
11.1
5.1
9.5
< 0.001
1.0
0.7
1.3
0.8
(reference)
(0.4-1.2)
(0.8-2.1)
(0.5-1.5)
d      
 T1-3
 T4
 Tx
11.8
5.9
3.0
< 0.0001
1.0
1.9
2.1
(reference)
(1.3-3.0)
(1.2-3.5)
E      
   
 N+
   
5.6
7.4
4.7
0.03
1.0
0.8
0.9
(reference)
(0.5-1.1)
(0.6-1.4)
          
  D     
 PM + other
7.2
3.1
0.03
1.0
2.0
(reference)
(1.4-2.9)
      
 2005-2009
 2010-2014
5.9
5.8
0.98
               
       
 Yes
   
11.4
3.1
< 0.0001
0.5
1.0
(0.3-0.9)
(reference)
Pallia ve 
            
    
   
11.1
3.0
< 0.0001
0.6
1.0
(0.4-0.8)
(reference)
    ,    
    
   
32.0
5.0
< 0.0001
0.3
1.0
(0.1-0.7)
(reference)
NOS = not otherwise speci ed; PM = peritoneal metastases; CRS+HIPEC = cytoreduc ve surgery and hyperthermic 
intraperitoneal chemotherapy; HR = hazard ra o; CI = con dence interval; SBA = small bowel adenocarcinoma.
 
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Discussion
This is the  rst popula on-based study repor ng on the incidence, risk factors and overall 
survival of pa ents with synchronous PM from SBA. Our study revealed that 1 in 8 Dutch 
pa ents  with  SBA  presented  with  synchronous  PM.  PM was most  likely  to  occur  in  the 
small bowel distal to the duodenum (17%). Furthermore, the risk of being diagnosed with 
synchronous PM was higher in pa ents with an advanced or unknown T- and N-stage and 
diagnosis  in  the  period  2010-2014.  Although  median  overall  survival  was  poor,  higher 
survival rates were achieved in the selected group of treated pa ents.
Almost  half  of  all  synchronous  PM  of  SBA  originated  from  duodenal  tumours.  As  the 
duodenal site accounts for approximately 60% of all tumours in primary SBA, the absolute 
number of synchronous PM of duodenal origin is higher than men oned in some previous 
              . Synchronous PM according to primary tumour loca on was found in 9% of the 
pa ents with a primary duodenal  tumour, compared to 17% of the pa ents with a more 
distal tumour. This di erence might be explained by the earlier symptoms in pa ents with 
primary  duodenal  tumours and by  the  retroperitoneal  loca on  of  the duodenum, which 
makes  direct  con guous  tumour  spread  less  likely  than  for  tumours  in  intraperitoneally 
located organs, such as the jejunum and the ileum     .
Pa ents  with  PM  of  SBA were  slightly  younger  and  predominantly  female.  Also,  in  this 
group, an advanced or unknown T- and N-stage was more common than in the overall group 
of SBA pa ents. These  ndings are in line with the di erences between pa ent and tumour 
characteris cs of pa ents with PM of CRC and those of all CRC pa ents. Risk factors for PM 
of SBA and PM of CRC, as  iden  ed  in mul variable  logis c  regression, match to a great 
       . However, the percentage of pa ents presen ng with synchronous PM of SBA (13%) 
was almost three  mes higher than the incidence of PM in pa ents with CRC (4-5%)         .
Surgery  with  primary  tumour  resec on was  performed  almost  seven   mes more  o en 
in  pa ents  with  PM  of  non-duodenal  origin  than  in  pa ents  with  a  primary  duodenal 
tumour. The explana on for this di erence is that in case of duodenal tumours, the pa ent 
burden of major and complex surgery with substan al risk of mortality and postopera ve 
complica ons is not propor onal to the poten al bene ts, considering the pallia ve nature 
of these interven ons     .
The propor on of pa ents with PM of SBA who received pallia ve chemotherapy is in line 
with previous studies repor ng on  the usage of pallia ve chemotherapy in pa ents with 
metasta c SBA               . Of note, we found that systemic therapy was administered twice as 
frequently in pa ents with PM of a primary jejunal or ileal tumour than in pa ents with PM 
  
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of duodenal origin.
In  the  present study, pallia ve chemotherapy resulted  in a median  overall  survival  of  11 
months, which  is broadly  equivalent  to  the  results  of  earlier  retrospec ve observa onal 
       1, 20-23.  Since  it  is  thought  that  SBA and  CRC  are  similar  in  terms of  carcinogenesis 
and, to some extent, in terms of tumour behaviour, treatment regimens for SBA, especially 
chemotherapeu cal treatment, are extrapolated from CRC      . Various studies have already 
demonstrated  that  the most  bene cial  e ect  on survival  in metasta c  SBA  seems  to  be 
achieved with combina on chemotherapy regimens as used in CRC, consis ng of  uorouracil 
and pla num compounds20, 23, 25-27.
The highest survival was observed in pa ents who received CRS+HIPEC. However, it should 
be men oned  that  only  a  small  group  of  highly  selected  pa ents with  probably  limited 
peritoneal  tumour  spread  and  a  good  general  condi on,  as  partly  re ected  in  these 
pa ents’ younger age, have undergone CRS+HIPEC. We found survival rates of more than 
30 months, which were also achieved a er CRS+HIPEC in pa ents with PM of CRC, where 
CRS+HIPEC is regarded as the standard of care for selected pa ents  . Indeed, other small 
series reported that CRS+HIPEC seemed to contribute signi cantly to prolonged survival in 
a substan al number of pa ents with PM of SBA               . Despite these promising results, it 
was remarkable that almost half of all CRS+HIPEC procedures were performed in the same 
centre, while  there  are  eight  ter ary  referral  centres  for  CRS+HIPEC  in  the Netherlands, 
sugges ng that not all centres o er all their suitable pa ents CRS+HIPEC, probably because 
the poten al bene cial e ect of CRS+HIPEC on survival has not been proven by a randomised 
controlled trial (RCT) in pa ents with PM of SBA. However, all these results together seem to 
suggest that CRS+HIPEC could be a reasonable treatment op on for selected pa ents with 
 D               .
Of  course,  due  to  the  popula on-based  nature  of  our  study,  these  results  should  be 
interpreted with cau on. Unfortunately, the database of the NCR does not provide detailed 
informa on  on  performance  status,  the  extent  of  peritoneal  burden  of  the  disease,  the 
regimen  of  the  systemic  therapy  or  other  prognos c  factors.  Ideally,  an  RCT  should  be 
performed to demonstrate the value of the various available therapies. However, it is di cult 
to conduct large and successful prospec ve clinical studies, given the rarity of small bowel 
cancer, as also demonstrated by the RARECARE group, which showed the incidence of small 
bowel  cancer  to  be  the  lowest  among  all  rare  epithelial  diges ve  cancers  . Meanwhile, 
the present study might provide helpful  insight into PM of SBA, as it showed that certain 
subgroups of  selected pa ents might bene t  from treatment. Nevertheless,  it  should be 
reiterated that  this  is an observa onal study, and therefore, no statements can be made 
 
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about the precise e ect of a therapy, because pa ents for all treatment arms were highly 
selected by their clinicians.
In conclusion, although SBA is a rare disease, synchronous PM was frequently encountered, 
a ec ng more than 1 in 6 pa ents with a primary non-duodenal tumour and approximately 
1 in 10 pa ents with a primary duodenal adenocarcinoma. This study observed a signi cant 
higher median  overall  survival  for  the  selected  group  of  treated  pa ents.  Analogous  to 
PM of CRC,  it  could be  that a mul disciplinary approach might  result  in a be er pa ent 
selec on for speci c pa ent tailored treatment op ons including aggressive therapy such 
as CRS+HIPEC.
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Pallia  ve systemic therapy in metasta  c small bowel cancer
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            As small bowel adenocarcinoma (SBA) is scarce, no standard systemic regimen 
in metasta c disease has been de ned.
Objec ve: To obtain insights into the use and e ects of pallia ve chemotherapy in pa ents 
with metasta c SBA in a popula on-based se ng.
          Data  from  the  Netherlands  Cancer  Registry  of  pa ents  with  metasta c 
SBA  between  2007  and  2016  were  used  (n  =  522).  For  pa ents  treated  with  pallia ve 
chemotherapy, di erences in treatment regimens and survival were evaluated.
         Pallia ve chemotherapy was received by 38% of the pa ents (n = 199). First-line 
combina on chemotherapy was administered to 80% of the pa ents, mainly CAPOX/FOLFOX. 
Single-agent chemotherapy mostly consisted of capecitabine. Second-line  treatment was 
prescribed  to  27% of  the  pa ents, mostly  irinotecan-based  (58%). Age 70 years of  older 
was  an  adverse  predic ve  factor  for  receiving   rst-line  combina on  chemotherapy  (OR 
0.2, 95%CI 0.08-0.62) and second-line therapy  (OR 0.3, 95%CI 0.10-0.72). Median overall 
survival with pallia ve chemotherapy was 9.3 months, compared with 3.0 months without. 
In sub analyses, pa ents who only received  rst-line treatment had a median overall survival 
of 5.6 and 7.0 months a er single-agent and combina on chemotherapy, respec vely.
             A minority  of  pa ents  were  treated  with  pallia ve  chemotherapy.  First-line 
treatment  consisted  predominantly  of  oxalipla n-based  combina on  chemotherapy, 
whereas  second-line  treatment  was  mainly  irinotecan-based.  Popula on-based  median 
overall survival for selected pa ents treated with chemotherapy amounted to 9 months.
  
Pallia ve chemotherapy in synchronous metastases of small bowel adenocarcinoma
Introduc on
Small  bowel  adenocarcinoma  (SBA)  is  a  rare  gastro-intes nal  tumour,  accoun ng  for 
only  2-3%  of  all  malignant  diges ve  tumours.  In  SBA  pa ents,  metasta c  disease  is  a 
common phenomenon, as approximately 30 to 40% of pa ents presents with synchronous 
metastases1-4. It has been hypothesised that these high metasta c rates are caused by the 
nonspeci c and atypical symptoms in pa ents and the lack of simple and reliable diagnos c 
tools to reach the small bowel. The prognosis of pa ents with metasta c SBA is poor with a 
reported overall survival of 4-11 months    .
Due to the rarity of the disease, most data on pallia ve chemotherapy in SBA are derived from 
phase II trials and retrospec ve series of mainly high-volume or ter ary medical centres5-7. 
These studies have demonstrated that chemotherapy prolongs overall survival  in pa ents 
with metasta c SBA4-15. However, in the absence of randomised controlled trials, a standard 
chemotherapeu cal  regimen  has  not  been  de ned.  Pa ents  are  usually  treated  with 
chemotherapeu cal  regimens which  have  been  extrapolated  from  other  gastrointes nal 
cancers. Several studies have demonstrated that combina on chemotherapy consis ng of 
a  uoropyrimidine and pla num compound seems to have  the most bene cial e ect on 
survival, with median overall  survival  rates  ranging between 14 and 18 months                . 
As  a  result,  a  frontline  regimen  of pla num-based  combina on  chemotherapy  has been 
              .
Popula on-based  data, which  re ect daily prac ce and could  be of help  for clinicians  to 
guide  treatment  decisions,  are  currently  lacking.  As  large  prospec ve  clinical  studies 
and  randomised controlled  trials  are virtually  impossible  to conduct  due  to  the  rarity of 
SBA,  this  popula on-based  study was  performed  to  provide  insight  into  the  daily-based 
chemotherapeu cal treatment and its results in pa ents with synchronous metasta c SBA.
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Data collec on
Data  were  obtained  from  the  popula on-based  Netherlands  Cancer  Registry  (NCR).  The 
na onwide NCR  covers  all  nearly  17 million  inhabitants  of  the Netherlands  and  collects 
data on all newly diagnosed malignancies. Primary source of no  ca on is the automated 
na onwide pathological archive (PALGA), accompanied with data from the Na onal Registry 
of  Hospital  Discharge  Diagnoses.  Informa on  on  pa ent  and  tumour  characteris cs, 
diagnosis and treatment were rou nely collected from medical records by specially trained 
administrators. In the NCR, the primary tumour stage was determined based on the tumour-
node-metastasis (TNM) classi ca on. In case the pathological TNM stage was missing, the 
clinical TNM stage was used. The anatomical site of the primary tumour and its metastases 
were recorded according to the third version of the Interna onal Classi ca on of Disease 
for Oncology (ICD-O).
For  the present study, addi onal data were  retrospec vely collected by  registry clerks of 
the NCR on systemic treatment regimens for pa ents treated with pallia ve chemotherapy 
for  synchronous metastases of small bowel adenocarcinoma (ICD-O code C17) diagnosed 
between 2007 and 2016. Synchronous metastases were de ned as metastases diagnosed 
within 3 months a er the ini al SBA diagnosis. The addi onal data comprised informa on 
on  rst-, second- and third-line systemic treatment regimens, including details and dura on 
of the chemotherapeu cal and targeted agents. First-line systemic treatment was de ned 
as the ini al therapy with chemotherapeu cal and/or targeted agents. If one of the agents 
of  the  ini al  therapy  was  discon nued,  while  other  drug(s)  were  con nued,  it  was  s ll 
regarded as  rst-line treatment. Second- and third-line systemic treatment was de ned as 
the adop on of a di erent treatment regimen, mostly because of failure of  rst-line therapy 
or unacceptable toxici es. In case of a rechallenge of a chemotherapeu cal and/or targeted 
agent within 3 months or a er maintenance therapy, we de ned the therapy to be a next 
line treatment. If the rechallenge occurred a er 3 months, without maintenance therapy, 
the therapy was classi ed as the same-line treatment.
Sta s cal analysis
Descrip ve sta s cs were used  to describe the pa ent and tumour characteris cs of the 
study popula on. Di erences in pa ent- and tumour characteris cs between the  treated 
and  nontreated  pa ents were  analysed with  a  two-sided  chi-square  test.  In  all  analyses 
concerning pallia ve chemotherapy, only the pa ents receiving pallia ve chemotherapy with 
a known treatment regimen were included. First-, second- and third-line systemic treatment 
regimens were categorised according to the administrated number of chemotherapeu cal 
agents  into  single-agent  chemotherapy  and  combina on  chemotherapy,  apart  from  the 
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addi onal  administra on of  targeted  agents.  Time  to progression  from  the start of  rst- 
to start of  second-line  treatment and second-  to  third-line  treatment was calculated and 
presented in months. Di erences in  me to progression from  rst- to second-line treatment 
between the pa ents receiving single-agent chemotherapy and combina on chemotherapy 
was evaluated with  the Wilcoxon  rank-rum test. Univariable  logis c regression,  including 
the  95%  con dence  interval  (CI),  was  used  to  assess  the  independent  in uence  of  all 
pa ents and clinical characteris cs on  the probability of receiving second-line  treatment. 
If  univariable  analyses  tended  towards  sta s cal  signi cance  (p  <  0.20),  the  probability 
of  receiving  second-line  treatment  corrected  for  these  poten al  prognos c  factors  was 
a erwards calculated with mul variable regression analyses. For the odds of receiving  rst-
line combina on chemotherapy, only mul variable logis c regression analyses were run.
Overall survival was calculated on mortality of any cause. Overall survival  me was de ned 
as the  me from date of diagnosis to death or last follow-up date. Pa ents who were lost 
to  follow-up,  emigrated or  s ll  alive  at 1  February  2018 were  censored. Overall  survival 
was es mated with  the  log-rank  test and Kaplan-Meier analyses. Median overall survival 
was presented  in months, with  its  corresponding 95% CIs. The median overall survival of 
the  treated  pa ents  was  compared  to  the  pa ents  only  receiving  best  suppor ve  care. 
Mul variable  cox  propor onal  hazards  regression  analyses  were  performed  to  iden fy 
prognos c  factors  for  overall  survival  in  pa ents  treated  with  pallia ve  chemotherapy. 
Hazard ra os (HRs) were presented with its corresponding 95% CIs.
The sta s cal package SAS Sta s cal So ware  (version 9.4,  SAS  Ins tute, Cary, NC, USA) 
was used to analyse the data. A two-sided p-value of p < 0.05 was considered as sta s cally 
signi cant for all sta s cal tests.
 
  
         
       
Pa ents
A  total  of  522  pa ents  were  diagnosed  with  synchronous  metastases  of  small  bowel 
adenocarcinoma between 2007 and 2016, of whom 199 pa ents (38%) received pallia ve 
systemic  treatment.  Mul ple  pa ent-  and  tumour  characteris cs  di ered  between  the 
treated pa ents and  the nontreated  pa ents, as  shown  in  table 1. Pa ents  treated with 
chemotherapy  were  signi cantly  younger,  with  a  median  age  of  63  years,  compared 
with  72  years  in  non-treated pa ents  (p  < 0.0001).  A nonsigni cant  trend was  observed 
with  respect to the primary tumour site, as rela vely more pa ents with a distal tumour 
received  systemic  treatment  than  pa ents  with  a  primary  duodenal  tumour  (p  =  0.10). 
Pa ents with a higher metasta c tumour load were treated more frequently than pa ents 
with solitary metastases (p < 0.001), which was not a ected by the poten al in uence of 
surgical resec on of metasta c sites among the di erent subgroups (p = 0.53). Over  me, 
the percentage of treated with chemotherapy remained stable at 35 to 40%. Among treated 
pa ents, the exact treatment regimen was known in 187 pa ents (94%). Only these pa ents 
were included for all further analyses concerning pallia ve chemotherapy.
In  pa ents  receiving pallia ve chemotherapy,  the primary  tumour was mainly  located  in 
the duodenum (60%), followed by the jejunum (20%) and ileum (12%). Pa ents presented 
with liver and peritoneal metastases  in 63% and 36% of the cases, respec vely. In 40% of 
the pa ents mul ple metasta c sites were diagnosed. Only 2 pa ents were diagnosed with 
Lynch syndrome.  In 66 pa ents  (35%)  pallia ve  interven ons were performed,  including 
surgical bypass and sten ng, mostly in pa ents with a primary duodenal tumour (79%).
                     
The  rst-line chemotherapy regimens were mainly based on  uoropyrimidines (5- uorouracil 
and capecitabine) and oxalipla n ( gure 1). Combina on chemotherapy was prescribed to 
80% of the pa ents, of whom 97% received an oxalipla n-based doublet or triplet regimen, 
including capecitabine (CAPOX, n = 91), 5- uorouracil (FOLFOX, n = 29) or epirubicin with 
capecitabine  (EOX,  n  =  2).  Single-agent  chemotherapy  was  administered  to  20%  of  the 
pa ents, consis ng of  uoropyrimidines in 92% of the cases, mainly capecitabine (n = 32). 
The  targeted  agent  bevacizumab  was  prescribed  to  13%  of  the  pa ents  (n  =  25),  most 
frequently  in addi on  to combina on chemotherapy. Other nonfrequently used  rst-line 
treatment regimens included epirubicin, cispla n and capecitabine (ECC, n = 2), carbopla n 
with paclitaxel (n = 2), capecitabine with irinotecan (CAPIRI, n = 1) and oxalipla n (n = 2) or 
irinotecan monotherapy (n = 1).
  
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 
d        General  characteris cs of  the  total pa ent popula on according  to pallia ve chemotherapy 
treatment  (n  =  522)  and  of  patients  treated  with  palliative  chemotherapy  according  to  first-line 
chemotherapy regimen (n = 187).
Pallia ve chemotherapy   &                   
    
(n = 199)
E 
(n = 323)
             
              
(n = 37)
Combina on 
              
(n = 150)
  (%)   (%) p-        (%)   (%)  -value
      
 D   
 Female
   
  
(51.3)
(48.7)
   
   
(50.5)
(49.5)
0.86
  
  
(56.8)
(43.2)
  
  
(51.3)
(48.7)
0.55
Age (years)
 <60
 60-69
 ≥70 
  
  
  
(35.7)
(35.7)
(28.6)
  
  
   
(16.7)
(27.5)
(55.7)
< 0.0001
 
  
  
(24.3)
(27.0)
(48.7)
  
  
  
(39.3)
(38.0)
(22.7)
< 0.01
      
 2007-2010
 2011-2013
 2014-2016
  
  
  
(32.2)
(32.2)
(42.8)
   
   
  
(35.0)
(35.6)
(29.4)
0.21
  
  
 
(56.8)
(27.0)
(16.2)
  
  
  
(24.7)
(35.3)
(40.0)
< 0.001
Loca on primary 
      
 Duodenum
 Jejunum
 Ileum
 NOS
    
  
  
  
(59.8)
(19.6)
(12.1)
(8.5)
   
  
  
  
(70.0)
(13.0)
(9.9)
(7.1)
0.10
  
 
 
 
(64.9)
(18.9)
(8.1)
(8.1)
  
  
  
  
(58.7)
(20.7)
(13.3)
(7.3)
0.86
Number of a ected 
metasta c sites
  
  
 ≥ 3
   
  
  
(61.3)
(23.1)
(15.6)
   
  
  
(74.6)
(18.9)
(6.5)
< 0.001
  
  
 
(56.8)
(35.1)
(8.1)
  
  
  
(60.7)
(21.3)
(18.0)
0.12
NOS = not otherwise speci ed. 
 
Logis c regression showed signi cant di erences between the prescrip on of single-agent 
chemotherapy and combina on chemotherapy in  rst-line treatment (table 2). Combina on 
chemotherapy was less frequently administered to elderly pa ents (≥70 years) and in the 
 rst  me period (2007-2010).
Second-line  systemic  therapy was  received by  only 27% of  the  pa ents  (n  =  50), mostly 
consis ng  of  single-agent  chemotherapy  (58%)  ( gure  1).  Irinotecan  was  administered 
as  a  single-agent  in  69%  of  the  pa ents  (n  =  20).  Pa ents  treated  with  combina on 
chemotherapy, received an oxalipla n-based (n = 12) or an irinotecan-based (n = 9) regimen 
with either capecitabine (CAPOX/CAPIRI) or 5- uorouracil (FOLFOX/FOLFIRI).  In 7 pa ents 
who received a second-line oxalipla n-based regimen, a rechallenge a er use of oxalipla n-
based combina on chemotherapy in  rst-line occurred. Epidermal growth factor receptor 
 
  
         
(EGFR)  monotherapy  was  administered  to  2  pa ents.  In  8  pa ents,  bevacizumab  was 
prescribed in addi on to second-line chemotherapy.
&         The prescribed chemotherapeu c regimens according to combina on chemotherapy and sin-
gle-agent chemotherapy in  rst-, second- and third-line treatment  in metasta c small bowel adenocar-
cinoma.
First-line Second-line Third-line
0
10
20
30
40
50
60
70
80
90
100
P
ro
p
o
r 
o
n
o
f
p
a
 
e
n
ts
(%
)
CAPOX/FOLFOX
CAPIRI/FOLFIRI
Fluoropyrimidine monotherapy
Irinotecan monotherapy
Other
Logis c regression analysis iden  ed advanced age (≥70 years) to be inversely associated 
with the receipt of second-line treatment (OR 0.26, 95% CI 0.10-0.72) (table 2).
Third-line  systemic  therapy  was  received  by  11  pa ents  (6%). Most  third-line  regimens 
were irinotecan-based (n = 8), consis ng of irinotecan monotherapy (n = 3), or combina on 
therapy of a  uoropyrimidine with irinotecan (CAPIRI/FOLFIRI, n = 3) ( gure 1). The targeted 
agent  panitumumab  was  used  in  4  pa ents  (36%),  either  as monotherapy  (n  =  2)  or  in 
combina on with irinotecan (n = 2).
        
The median overall survival for pa ents treated with pallia ve chemotherapy and a known 
systemic  treatment regimen was 9.3 months, with a 1-year survival rate of 39%. Pa ents 
only  receiving  best  suppor ve  care  had  a median overall  survival  of  3.0 months, with  a 
1-year  survival  rate  of  17%.  In  pa ents  only  receiving   rst-line  treatment,  the  median 
overall survival of pa ents receiving single-agent chemotherapy was 5.6 months, compared 
with  7.0 months with  combina on  chemotherapy, with  1-year survival  rates of 22% and 
29%, respec vely. The median  me to progression from  rst- to second-line therapy was 
7.7 months, which did not signi cantly di er between the single-agent chemotherapy and 
combina on chemotherapy group (p = 0.82).
  
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d        General characteris cs and mul variable logis c regression modelling the odds of pa ents receiving 
combina on therapy in  rst-line treatment (le ) and general characteris cs, univariable logis c regression 
and mul variable logis c regression modelling the odds of receiving second-line treatment compared to 
pa ents receiving  rst-line treatment (right).
(n = 187) Combina on 
             
in  rst-line
Mul variable 
logis c regression
            
         
h           
logis c 
          
Mul variable 
logis c regression
E (%) K  (95% CI) E (%)         K  (95% CI)
      
 D   
 Female
  
  
(78.6)
(82.0)
1.00
1.28
         
(0.57-2.88)
  
  
(30.6)
(22.5)
0.21
Age (years)
 <60
 60-69
 ≥70
  
  
  
(86.8)
(85.0)
(65.4)
1.00
0.87
0.22
         
(0.31-2.49)
(0.08-0.62)
  
  
 
(36.8)
(28.4)
(11.5)
0.01
1.00
0.77
0.26
         
(0.36-1.62)
(0.10-0.72)
      
 2007-2010
 2011-2013
 2014-2016
  
  
  
(63.8)
(84.1)
(90.9)
1.00
2.72
7.28
         
(1.08-6.86)
(2.47-21.45)
  
  
  
(31.0)
(31.7)
(18.2)
0.15
1.00
0.94
0.49
         
(0.42-2.11)
(0.20-1.17)
Loca on primary 
      
 Duodenum
 Jejunum
 Ileum
 NOS
  
  
  
  
(78.6)
(81.6)
(87.0)
(78.6)
1.00
1.31
2.17
1.00
         
(0.44-3.89)
(0.55-8.58)
(0.21-4.77)
  
  
 
 
(25.0)
(34.2)
(26.1)
(21.4)
0.69
E         
a ected 
metasta c sites
  
  
 ≥ 3
  
  
  
(81.3)
(71.1)
(90.0)
1.00
0.47
1.49
         
(0.18-1.20)
(0.36-6.17)
  
  
  
(22.3)
(31.1)
(40.0)
0.10
1.00
1.57
2.25
         
(0.70-3.52)
(0.91-5.57)
&          
            
 Single-agent
 Combina on
  
  
(27.0)
(26.7)
0.96
NOS = not otherwise speci ed, OR = Odds ra o, CI = con dence interval
 
Pa ents  receiving  second-line  systemic  therapy  had  a  signi cant  higher  median  overall 
survival, compared with those who only received  rst-line therapy, with observed median 
overall survival  mes of 15.2 and 6.8 months respec vely (p < 0.0001). In the 11 pa ents 
receiving third-line treatment, a median overall survival of 28.4 months was noted. Among 
this  subgroup  of  pa ents,  5  out  of  11  had  a  rechallenge  of  CAPOX/FOLFOX  (n  =  4)  or 
capecitabine monotherapy (n = 1) in second-line treatment. The median  me to progression 
from second- to third-line systemic therapy was 9.8 months.
 
  
         
Mul variable survival analyses showed, a er adjustment for di erent pa ent- and clinical 
characteris cs, including use of second-line and third-line therapy, that pa ents with jejunal 
tumours (HR 0.51, 95% CI 0.33-0.79) and those who received second-line systemic therapy 
(HR 0.42, 95% 0.29-0.63) had a higher overall survival (table 3).
 
d        Mul variable survival analyses for pa ents treated with pallia ve chemotherapy in synchronous 
metasta c small bowel adenocarcinoma (n = 187).
                     
survival (months)
,  (95% CI)
      
 D   
 Female
9.3
9.3
1.00
0.88
(reference)
(0.63-1.21)
Age (years)
 <60
 60-69
 ≥70
8.6
10.7
8.3
1.00
1.03
0.87
(reference)
(0.70-1.51)
(0.57-1.33)
      
 2007-2010
 2011-2013
 2014-2016
10.5
10.7
6.5
1.00
1.00
1.06
(reference)
(0.68-1.46)
(0.72-1.57)
Loca on primary tumour
 Duodenum
 Jejunum
 Ileum
 NOS
8.2
13.2
11.5
5.8
1.00
0.51
0.65
1.41
(reference)
(0.33-0.78)
(0.40-1.05)
(0.78-2.57)
Number of a ected metasta c sites
  
  
 ≥ 3
8.8
10.0
7.8
1.00
0.98
1.31
(reference)
(0.67-1.45)
(0.82-2.10)
                     
 First-line
 Second-line
 Third-line
6.8
15.2
28.4
1.00
0.42
0.67
(reference)
(0.29-0.63)
(0.33-1.36)
NOS = not otherwise speci ed, HR = hazard ra o, CI = con dence interval
  
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Discussion
This  popula on-based  study  aimed  to  provide  insight  into  the  community-based  use 
of  pallia ve  chemotherapy  in  pa ents  with  synchronous  metastases  of  SBA.  Pallia ve 
chemotherapy was administered to 38% of the pa ents with metasta c disease. The vast 
majority of treated pa ents received an oxalipla n-based combina on regimen in  rst-line 
treatment with CAPOX/FOLFOX. Second-line therapy was administered to only 27% of the 
pa ents, with mainly irinotecan monotherapy.
In   rst-line  treatment,  combina on  chemotherapy  with mainly  an  oxalipla n-containing 
regimen  was  most  o en  prescribed,  analogous  to  gastric  cancer  and  colorectal  cancer 
(CRC), for which  uoropyrimidines and pla num deriva ves are the backbone of pallia ve 
chemotherapy      .  In  the present study, only a  small minority of pa ents with a primary 
duodenal  tumour were classically  treated as gastric cancer with  triplet chemotherapy as 
ECC or EOX, probably as it was historically thought that duodenal tumours more behave like 
gastric cancer, whereas distal tumours share more similari es with CRC .  In recent years, 
several  studies  conducted  on  the  e cacy  of  chemotherapy  in  advanced  gastric  cancer 
have  favoured  the  use  of  oxalipla n  over  cispla n  in  terms  of  its  toxicity  pro le  and  its 
noninferiority in overall survival, and have ques oned a bene cial e ect on survival from the 
contribu on of anthracyclines as epirubin to an oxalipla n-based combina on regimen18-20. 
As a result, both CAPOX/FOLFOX are a well-studied and e ec ve  rst-line pallia ve treatment 
regimen  in a variety of gastro-intes nal cancers,  including gastric cancer and CRC. These 
obtained results suggested a poten al role for this regimen in metasta c SBA, because of 
the  embryological  deriva on  of  the  small  bowel  and  the  presence of  some overlapping 
genomic altera ons both with gastric cancer and CRC  . Other small retrospec ve and phase 
II studies conducted on the e cacy of CAPOX/FOLFOX in metasta c SBA showed improved 
survival rates in treated pa ents with tolerable toxicity                .
Combina on chemotherapy in  rst-line treatment was increasingly administered over  me, 
although all used cytotoxic agents were registered and available during the total study period in 
               22-24. Hypothe cally, the obtained experience of clinicians with these cytotoxic 
drugs in more frequently encountered gastrointes nal cancers, and the obtained evidence of 
the bene cial e ect of oxalipla n-based regimens in phase II studies for metasta c SBA, could 
account for the increased use of combina on chemotherapy over  me        .
Second-line  therapy was  administered  to  only  about  a  quarter  of  the  pa ents,  which  is 
limited,  even  on  a  popula on-based  level,  as  compared with  pa ents  receiving  second-
line  treatment  in metasta c  disease  of  gastric  cancer  and  CRC25-27.  Possibly,  the  lack  of 
data  for  second-line  chemotherapy  in  SBA  could  be  accountable  for  these  lower  rates. 
 
  
         
Second-line  treatment  was  mainly  irinotecan-based,  and  40%  of  the  pa ents  received 
irinotecan monotherapy, which  could  have  been  in uenced  by  the  favourable  results  of 
second-line FOLFIRI in establishing disease control a er failure of  rst-line pla num-based 
chemotherapy as reported in a French study  . The prescrip on of irinotecan-based second-
line  chemotherapy  is  in  accordance  to  the  Dutch  guidelines  for  second-line  treatment 
for metasta c CRC, but not  for gastric cancer  . Of note,  the median  me to progression 
between  rst- and second-line treatment is comparable for SBA and CRC30-32.
The median overall survival of 6 to 9 months as found in the current study is lower than 
survival rates that are reported in other retrospec ve studies, although equivalent treatment 
regimens were used           .  In  the  present  study,  the median  age was  slightly  higher  and 
more pa ents had liver metastases compared with other retrospec ve studies. Moreover, 
no pa ents with locally advanced disease were included in the current study, whereas one 
study  did  include  pa ents both with  locally advanced and metasta c disease of  SBA .  In 
comparison to pa ents  in popula on-based studies  treated with pallia ve chemotherapy 
for  other  gastro-intes nal  cancers,  pa ents  with  metasta c  SBA  have  a  worse  median 
overall  survival  than  pa ents with metasta c CRC, whereas  the  survival  of pa ents with 
metasta c SBA and gastric cancer is comparable      .
Pa ents who received  rst-line chemotherapy only had a higher overall survival of 3 to 4 
months  compared  with  pa ents  receiving  best  suppor ve  care. However,  selec on  bias 
should be taken into account as pa ents treated with pallia ve chemotherapy were already 
selected  by  their  trea ng  physician, as  for  instance  re ected  in a  lower median  age. On 
a popula on-based level, a doubling of median overall  survival was observed  in pa ents 
receiving  rst-line combina on chemotherapy.
The  highly  selected  group  of  pa ents  who  were  prescribed  second-line  or  even  third-
line  treatment  had  a median  overall  survival  of  almost  15  and  28 months,  respec vely. 
However, immortal  me bias could have in uenced these results and should be taken into 
account,  since  pa ents  should  be  alive  to  receive  further  line  chemotherapy. Moreover, 
considering nearly half of the pa ents treated with third-line therapy had a rechallenge of 
oxalipla n doublet chemotherapy or capecitabine monotherapy in second-line treatment, 
it could suggest that these pa ents had a more indolent tumour behaviour or their tumours 
had  a  prolonged  or  increased  chemosensi vity  to  oxalipla n-containing  combina on 
chemotherapy. The impact of irinotecan on median overall survival in second- and third-line 
treatment needs to be studied in a larger subset of pa ents.
As already stated, selec on bias is a poten al drawback of the current study with regards 
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to overall survival. Furthermore, detailed informa on on for instance performance status, 
nutri onal status, comorbidi es, disease-related symptoms and the extent of disease were 
lacking, since these data were not provided in the databases of the NCR or were o en not 
noted in the pa ent records.
In conclusion, a minority of pa ents with synchronous metastases of SBA were treated with 
pallia ve chemotherapy in daily prac ce. First-line  treatment consisted predominantly of 
oxalipla n-based combina on chemotherapy, whereas second-line treatment was mainly 
irinotecan-based.  Popula on-based median  overall  survival  for  selected  pa ents  treated 
with chemotherapy amounted to 9 months.
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             Data  about  the  use  and  e ec veness  of  targeted  therapy  in  metasta c 
small  bowel  adenocarcinoma  (SBA)  are  scarce.  The  aim  of  this  popula on-based  study 
was to obtain  insights  into the use and e ec veness of targeted therapy in pa ents with 
synchronous metastases of SBA.
                      Data were retrieved from the Netherlands Cancer Registry. Pa ents 
treated with pallia ve chemotherapy and/or targeted therapy for synchronous metasta c 
SBA between 2007 and 2016 were included (n = 187). Di erences  in treatment with and 
without targeted therapy and the subsequent e ects on overall survival (OS) were evaluated.
          In   rst-line  treatment,  25  pa ents  (13%)  received  addi onal  targeted  therapy, 
exclusively bevacizumab, and mostly in combina on with CAPOX/FOLFOX (n = 24). A primary 
ileal  tumour  was  the  only  posi ve  predic ve  factor  for  receiving  bevacizumab  in   rst-
line treatment (OR 3.2, 95% CI 1.06-9.93). Median OS for pa ents in whom bevacizumab 
was  added  to   rst-line  chemotherapy  was  9.3  months,  compared  to  9.1  months  with 
chemotherapy only  (p = 0.85). Median OS for pa ents  receiving  rst-line treatment only, 
was  8.5 months with  and  6.4 months without  the addi on  of  bevacizumab  respec vely 
(p=0.54). In mul variable survival analyses, the addi on of bevacizumab was no prognos c 
factor (HR 1.01, 95% CI 0.65-1.59).
            Bevacizumab was the only prescribed targeted therapy in  rst-line treatment. 
Considering the limited numbers of pa ents receiving  rst-line bevacizumab and the unkown 
reasons to prescribe addi onal targeted therapy, the corresponding survival rates of pa ents 
treated with and without addi onal bevacizumab in  rst-line  treatment, might suggest a 
limited clinical e ect  of  bevacizumab  in  addi on  to   rst-line pallia ve  chemotherapy on 
OS. Future research should focus on iden fying the subgroup of pa ents who might bene t 
from an -VEGF therapy in metasta c SBA.
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Introduc on
Small  bowel  adenocarcinoma  (SBA)  is  rarely  encountered,  despite  the  substan al 
mucosal  surface of  the  small  bowel within  the gastro-intes nal  tract . The duodenum  is 
the most  a ected primary  tumour site  in SBA,  followed by  the  jejunum and  ileum2-5. As 
early diagnosis is challenging, almost 40% of the pa ents are diagnosed with synchronous 
metasta c disease       . Overall survival of these pa ents is poor with a one-year survival rate 
of approximately 25% .
Despite the lack of randomised controlled trials in pa ents with metasta c SBA, pallia ve 
chemotherapy is widely used in daily clinical prac ce to improve quality of life and prolong 
survival. The most prescribed chemotherapy regimen in  rst-line treatment consists of an 
oxalipla n-based doublet regimen with  uoropyrimidines6-10.
In the Netherlands, no guidelines exist for the pallia ve systemic treatment of metasta c 
SBA.  As  SBA  and  colorectal  cancer  (CRC)  share mul ple  genomic  altera ons,  treatment 
regimens for SBA are tradi onally extrapolated from CRC  . In metasta c CRC, the targeted 
agents  bevacizumab,  an  an -VEGF-A  (vascular  endothelial  growth  factor-A)  monoclonal 
an body,  and  panitumumab  and  cetuximab,  both  an -EGFR  (epidermal  growth  factor 
receptor)  monoclonal  an bodies,  have  demonstrated  improvement  in  progression-free 
survival  (PFS)12-18. By  analogy,  a  few reports  have  recently  described  the use  of  targeted 
             19-24. Popula on-based data on the use and e ec veness of targeted therapy 
in metasta c SBA are currently lacking. Therefore, a popula on-based study was performed 
to provide  insight  into the popula on-based use and e ec veness of  targeted  therapy in 
synchronous metastases of SBA in a na onwide cohort.
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Data collec on
Data were retrieved  from the Netherlands Cancer Registry  (NCR). The NCR covers nearly 
17 million inhabitants of the Netherlands and collects popula on-based data on all newly 
diagnosed malignancies. The primary source of no  ca on of  the NCR is the automated 
na onwide  pathological  archive  (PALGA),  supplemented  with  data  from  the  Na onal 
Registry  of  Hospital  Discharge  Diagnoses.  Specially  trained  registry  clerks  of  the  NCR 
rou nely collect data  from medical  records, which  comprises  informa on on pa ent and 
tumour characteris cs, diagnosis and treatment. In the databases of the NCR, the primary 
tumour stage is determined according to the tumour-node-metastasis (TNM) classi ca on. 
In case of missing pathological data, the clinical TNM stage is used. The anatomical site of 
the primary tumour and its metastases are registered according to the third version of the 
Interna onal Classi ca on of Disease for Oncology (ICD-O).
For  this  study,  some  addi onal  data  were  retrospec vely  collected  by  registry  clerks  of 
the NCR on used  systemic  treatment  regimens  for  pa ents  diagnosed with  synchronous 
metastases  of  small  bowel  adenocarcinoma  (ICD-O  code  C17)  between  2007  and  2016. 
Synchronous metastases were de ned as metastases diagnosed within 3 months a er the 
ini al SBA diagnosis. The addi onal collected data  included detailed informa on on used 
 rst-, second- and third-line systemic treatment regimens of both chemotherapeu cal and 
targeted agents. First-line systemic treatment was de ned as the ini al started therapy with 
chemotherapy and/or targeted agents. In case one of the agents of the ini al therapy was 
discon nued, while other(s) con nued, it was s ll regarded as  rst-line treatment. Second- 
and third-line systemic treatment was de ned as the adop on of a new treatment regimen, 
mostly due to  rst-line therapy failure or unacceptable toxici es. In case of a rechallenge 
of  a  chemotherapeu cal  and/or  targeted  agent  within  3  months  or  a er  maintenance 
therapy, the therapy was de ned to be a next line treatment. If the rechallenge occurred 
a er 3 months, without maintenance therapy, the therapy was classi ed as the same line 
treatment. Pa ents with unknown systemic treatment regimen were excluded from further 
analyses.
Vital  status of  the pa ents was assessed on 31  January 2019 through linkage of  the NCR 
with civil municipal registries and the central bureau for genealogy, which collects data on 
all deceased Dutch inhabitants.
Sta s cal analysis
First, pa ent and  tumour characteris cs and treatment modali es were described. Apart 
from the administra on of targeted agents, the use of chemotherapy was taken into account. 
  
Addi on of bevacizumab to  rst-line pallia ve chemotherapy in metasta c small bowel adenocarcinoma
First-,  second- and third-line systemic  treatment  regimens were categorized according  to 
the  administered  number  of chemotherapeu cal  agents  into  single-agent  chemotherapy 
and  combina on  chemotherapy.  Di erences  in  pa ent  and  tumour  characteris cs  were 
analysed with a two-sided chi-squared test or Fisher’s exact test in case of small samples. 
Trends  in   me were  evaluated  by means  of  a  Cochran-Armitage  trend  test.  Univariable 
logis c regression, including the 95% con dence interval (CI), was used to determine the 
in uence  of  pa ents  and  clinical  characteris cs  on  the  probability  of  receiving  targeted 
therapy  in   rst-line  treatment.  As  the  number  of  pa ents  were  limited,  mul variable 
regression analyses were not performed.
A propensity score matched sample was generated as the use of popula on-based data could 
cause  poten al  endogeneity  bias  when  comparing  pa ents with  and without  addi onal 
treatment with bevacizumab in  rst-line treatment. Propensity scores were determined by 
means of a logis c regression model in which the administra on of bevacizumab in  rst-line 
treatment was the variable of interest, and the independent variables were those factors 
that were signi cant in univariable logis c regression, in combina on with relevant clinical 
features,  including age and type of chemotherapy (single-agent or combina on). Pa ents 
were matched with  ght bounds of the propensity scores, in which the predicted probability 
could not vary more than 1%.
Overall survival (OS)  me was de ned as the  me from diagnosis to death or date of last 
follow-up. Pa ents who were lost to follow-up, emigrated or s ll alive at 31 January 2019 
were censored. Survival was computed on all-cause mortality. The log-rank test and Kaplan-
Meier analyses were used  to es mate OS. Median OS was presented  in months, with  its 
corresponding 95% CIs. Univariable and mul variable cox propor onal hazards regression 
analyses were run to iden fy prognos c factors for overall survival. Hazard ra os (HRs) were 
presented with 95% CIs.
Sta s cal  analyses  were  carried  out  by  the  sta s cal  package  SAS  Sta s cal  So ware 
(version 9.4, SAS Ins tute, Cary, NC, USA). For all analyses, a two-sided p-value of p < 0.05 
was considered as sta s cally signi cant.
 
  
         
       
In the period 2007-2016, 522 pa ents were diagnosed with synchronous metastases of small 
bowel adenocarcinoma. Pallia ve systemic treatment was ini ated in 199 pa ents (38%). In 
12 pa ents the treatment regimen was unknown, and these pa ents were excluded from 
further analyses.
In the total study popula on, gender was almost equally distributed and a median age of 
63 years was found. Most primary tumours were located in the duodenum (60%). Liver and 
peritoneal metastases were present in 63% and 36% of the pa ents respec vely. In  rst-line 
treatment, combina on chemotherapy was administered to 80% of the pa ents and single-
agent chemotherapy to 20% of the pa ents. Combina on chemotherapy mainly consisted 
of a doublet regimen of CAPOX/FOLFOX (95%). Single-agent chemotherapy consisted largely 
of  capecitabine monotherapy  (89%). Of  the  187  pa ents  treated with   rst-line  systemic 
treatment, 25 pa ents (13%) received targeted therapy, which was exclusively bevacizumab. 
Pa ent and tumour characteris cs did not signi cantly di er between the group of pa ents 
treated with and without targeted therapy, as shown in table 1. Although not sta s cally 
signi cant, rela vely more pa ents with a primary distal tumour received bevacizumab in 
addi on to  rst-line treatment than pa ents with a primary duodenal tumour (p = 0.13). 
Bevacizumab  was  more  o en  prescribed  to  combina on  chemotherapy  with  CAPOX/
FOLFOX (n = 24), than to capecitabine monotherapy (n = 1) (p = 0.03). Over  me, there was 
a slight decrease in prescrip on of bevacizumab, mainly a er 2014 (p = 0.28). Moreover, the 
prescrip on of bevacizumab was not a ected by the hospital of treatment (p = 0.30).
Logis c regression analysis modelling  the  probability  to  receive  bevacizumab  in   rst-line 
treatment revealed only a primary ileal tumour (OR 3.24, 95% CI 1.06-9.93) as compared to 
a primary duodenal tumour as a posi ve predic ve factor in univariable analyses (table 2).
In  second-  or  third-line  treatment,  several  targeted  agents  were  prescribed.  In  the  50 
pa ents  receiving  second-line  systemic  therapy,  10  pa ents  (20%)  received  targeted 
therapy. Bevacizumab was administered to 8 pa ents, whereas an -EGFR monotherapy was 
prescribed to 2 pa ents. In the group of pa ents treated with bevacizumab, it was prescribed 
in  addi on  to  an  oxalipla n-based  doublet  regimen  (n  =  4),  capecitabine  monotherapy 
(n = 3) or irinotecan monotherapy (n = 1). In 5 of these 8 pa ents, it was a re-introduc on 
a er use of bevacizumab in  rst-line treatment. In third-line treatment, 4 out of 11 (36%) 
pa ents received targeted therapy, solely panitumumab. Panitumumab was prescribed as 
monotherapy in 2 pa ents, and in combina on with irinotecan in the other 2 pa ents.
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d        General characteris cs of pa ents treated with pallia ve chemotherapy with and without addi onal 
use of bevacizumab in  rst-line treatment in synchronous metasta c small bowel adenocarcinoma between 
2007 and 2016 (n = 187).
d     Bevacizumab in  rst-line treatment
(n = 187)
   
(n = 25)
E 
(n = 162)
  (%)   (%)   (%)  -value
      
 D   
 Female
  
  
(52.4)
(47.6)
  
  
(56.0)
(44.0)
  
  
(51.9)
(48.2)
0.70
Age (years)
 <60
 60-69
 ≥70
  
  
  
(36.4)
(35.8)
(27.8)
  
 
 
(40.0)
(28.0)
(32.0)
  
  
  
(35.8)
(37.0)
(27.2)
0.68
      
 2007-2010
 2011-2013
 2014-2016
  
  
  
(31.0)
(33.7)
(35.3)
 
  
 
(36.0)
(40.0)
(24.0)
  
  
  
(30.3)
(32.7)
(37.0)
0.28
Loca on primary tumour
 Duodenum
 Jejunum
 Ileum
 NOS
   
  
  
  
(59.9)
(20.3)
(12.3)
(7.5)
  
 
 
 
(44.0)
(20.0)
(24.0)
(12.0)
   
  
  
  
(62.4)
(20.4)
(10.5)
(6.8)
0.13
Number of a ected metasta c sites
  
  
 ≥ 3
   
  
  
(59.9)
(24.1)
(16.0)
  
 
 
(60.0)
(24.0)
(16.0)
  
  
  
(59.9)
(24.1)
(16.1)
1.00
NOS = not otherwise speci ed
 
The OS was calculated for pa ents with and without bevacizumab in  rst-line treatment (table 
3). The median OS for pa ents in whom bevacizumab was added to  rst-line chemotherapy 
was 9.3 months,  compared to 9.1 months  in pa ents without addi onal bevacizumab  in 
 rst-line treatment (p = 0.85) ( gure 1). To eliminate the in uence of second- and third-line 
prescrip on, the OS was also calculated for pa ents who only received  rst-line treatment 
(table 3). The median OS of all pa ents treated with  rst-line treatment only was 6.8 months. 
In the group of pa ents  in whom bevacizumab was added to  rst-line chemotherapy, the 
median OS was 8.5 months, compared to 6.4 months  in pa ents exclusively  treated with 
 rst-line  chemotherapy  (p  =  0.54).  In  the  propensity  score  matched  sample  (table  4), 
iden cal results were found for the median OS.
In mul variable survival analyses, which were run for the total study popula on, including 
use of targeted therapy in  rst-line therapy, a primary jejunal tumour (HR 0.55, 95% CI 0.36-
 
  
         
0.84) as compared to a primary duodenal tumour was iden  ed as posi ve prognos c factor 
for survival in  rst-line treatment. The use of  rst-line bevacizumab was no prognos c factor 
(HR 1.01, 95% CI 0.65-1.59). Also in the propensity score matched sample, the addi onal 
use  of  rst-line bevacizumab was no prognos c  factor  for  survival  in univariable survival 
analysis (HR 1.09, 95% CI 0.53-2.26).
 
 
d        Univariable logis c regression modelling the odds of addi onal treatment of bevacizumab in  rst-
line treatment  in pa ents treated with pallia ve chemotherapy in synchronous metasta c small bowel 
adenocarcinoma (n = 187).
Univariable logis c regression
OR (95% CI)
      
 D   
 Female
1.00
0.85
(reference)
(0.36-1.98)
Age (years)
 <60
 60-69
 ≥70
1.00
0.68
1.06
(reference)
(0.24-1.90)
(0.39-2.89)
      
 2007-2010
 2011-2013
 2014-2016
1.00
1.03
0.54
(reference)
(0.39-2.74)
(0.18-1.64)
Loca on primary tumour
 Duodenum
 Jejunum
 Ileum
 NOS
1.00
1.39
3.24
2.50
(reference)
(0.45-4.30)
(1.06-9.93)
(0.61-10.36)
Number of a ected metasta c sites
  
  
 ≥ 3
1.00
1.00
1.00
(reference)
(0.36-2.75)
(0.30-3.25)
&                      
 Single-agent
 Combina on
1.00
6.86
(reference)
(0.90-52.42)
NOS = not otherwise speci ed, OR = Odds ra o, CI = con dence interval
  
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d        Overall survival of pa ents with small bowel adenocarcinoma treated with and without addi onal 
bevacizumab in  rst-line treatment.
K               
  3 months 
(%)
6 months 
(%)
9 months 
(%)
      
(%)
Median OS 
(months)
         
 -value
d    
 First-line chemo
 First-line chemo + bevacizumab
   
  
87.0
84.0
66.1
76.0
50.0
52.0
38.9
36.0
9.1
9.3
0.85
A er  rst-line treatment only
 First-line chemo
 First-line chemo + bevacizumab
   
  
82.5
75.0
55.0
68.8
37.5
31.3
27.5
25.0
6.4
8.5
0.54
Chemo = chemotherapy, OS = overall survival
 
&         Survival curve of pa ents with metasta c disease of small bowel adenocarcinoma, treated with 
pallia ve systemic therapy, according to type of prescrip on in  rst-line treatment.
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Pa ents at risk (n)                                   
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 
  
         
d        General characteris cs of the propensity score matched sample (n = 50).
Use of bevacizumab in  rst-line treatment 
                                      
   
(n = 25)
E 
(n = 25)
  (%)   (%)  -value
      
 D   
 Female
  
  
(56.0)
(44.0)
  
  
(56.0)
(44.0)
1.00
Age (years)
 <60
 60-69
 ≥70
  
 
 
(40.0)
(28.0)
(32.0)
  
 
 
(40.0)
(32.0)
(28.0)
0.94
      
 2007-2010
 2011-2013
 2014-2016
 
  
 
(36.0)
(40.0)
(24.0)
 
  
 
(24.0)
(40.0)
(36.0)
0.55
Loca on primary tumour
 Duodenum
 Jejunum
 Ileum
 NOS
  
 
 
 
(44.0)
(20.0)
(24.0)
(12.0)
  
 
 
 
(44.0)
(16.0)
(28.0)
(12.0)
0.98
Number of a ected metasta c sites
  
  
 ≥ 3
  
 
 
(60.0)
(24.0)
(16.0)
  
  
 
(48.0)
(44.0)
(8.0)
0.37
First-line combina on chemotherapy
 Yes
   
  
 
(96.0)
(4.0)
  
 
(96.0)
(4.0)
1.00
NOS = not otherwise speci ed
  
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Discussion
The present popula on-based study is the  rst to report on the community-based use of 
targeted therapy in addi on to pallia ve chemotherapy in synchronous metastases of SBA. 
In 13% of the pa ents, addi onal bevacizumab was used to pallia ve chemotherapy in  rst-
line  treatment.  Pa ents with  a  primary  ileal  tumour were  treated more  frequently with 
bevacizumab in  rst-line therapy as compared to pa ents with more proximal tumours. No 
sta s cally signi cant di erences in OS were observed a er the addi on of bevacizumab to 
pallia ve chemotherapy a er  rst-line treatment.
The  poten al  bene cial  e ect  of  bevacizumab  to   rst-line  pallia ve  chemotherapy  in 
synchronous  metasta c  SBA  has  only  been  described  in  a  few  reports,  including  three 
retrospec ve studies and one phase II-study. The mul centre, retrospec ve study of Aydin 
et al.  included 28 pa ents with advanced SBA, who were treated with FOLFOX or FOLFIRI 
 rst-line chemotherapy with (n = 12) and without (n = 25) addi onal bevacizumab  . Toxicity 
in pa ents treated with bevacizumab was limited to hypertension (n = 1) and nasal bleeding 
(n = 1). The reported improvement of median PFS (9.6 vs 7.7 months) and median OS (18.5 
vs 14.8 months) a er the addi on of bevacizumab to  rst-line combina on chemotherapy 
was not sta s cally signi cant.
Two Japanese retrospec ve studies, conducted by Hirao et al. and Takayoshi et al., included 
a  heterogenous  group  of  pa ents with  advanced  SBA,  including  ampullary  tumours  and 
recurrent,  non-cura vely  resected,  unresectable  or metasta c  SBA       .  In  both  reports, 
mul ple chemotherapy  regimens  in  rst- and  second-line  therapy were  used. Moreover, 
bevacizumab was prescribed in  rst-line and for a substan al part beyond  rst-line therapy. 
The  addi onal  administra on  of  bevacizumab  resulted  in  a median  OS  of  21.9 months, 
compared  to  11.4  months  in  the  bevacizumab-untreated  group  of  pa ents.  As  in  both 
studies  all  pa ents  treated  with  bevacizumab  in   rst-  and  second-line  treatment  were 
merged,  immortal  me biases played a major  role  in  these  results and  the  true value of 
bevacizumab in  rst-line treatment could not be established.
The only phase  II-study conducted by Gulha  et al.  inves gated  the bene t of addi onal 
bevacizumab to combina on chemotherapy with CAPOX in 30 pa ents with advanced SBA 
(n  =  23)  and  ampullary  tumours  (n  =  7)  .  Toxicity  in  pa ents  treated with  bevacizumab 
was limited and included hypertension, fa gue and anorexia. No treatment-related deaths 
were reported. The median PFS was 8.7 months and the median OS was 12.9 months. The 
obtained PFS was compared  to  the PFS of  25  pa ents with metasta c  SBA or ampullary 
tumours  from  the prior  phase  II-study  on  CAPOX of  the same  ins tu on, which showed 
no signi cant di erences . No comparison was made regarding the median OS, although a 
 
  
         
higher median OS was described in the prior phase-II study .
In the present study, bevacizumab was prescribed in only a limited number of pa ents  in 
addi on to  rst-line pallia ve chemotherapy. Probably the rarity of the tumour, the absence 
of  a  guideline  to  treat  SBA  and  the  lack  of  reimbursement  of  costly  targeted  therapy 
for metasta c SBA were  all  accountable  for  the  low percentage  of pa ents  treated with 
bevacizumab. Bevacizumab was more frequently prescribed to pa ents with a primary ileal 
tumour than to pa ents with more proximal small bowel tumours, which was not observed 
in the previous men oned studies. Hypothe cally, the historical perspec ve that distal small 
bowel tumours behave more like CRC could have in uenced clinicians  to treat metasta c 
ileal tumours and metasta c CRC in a similar fashion, with combina on chemotherapy and 
addi onal bevacizumab  .
Similar  to  the  treatment  of  wild  RAS-type  metasta c  CRC,  an -EGFR  therapy  with 
panitumumab  and  cetuximab  were  increasingly  prescribed  in  second-  and  third-line 
treatment in  the present study. However, as only 6 pa ents were treated with an -EGFR 
therapy, no conclusions can be drawn on its e cacy. Recently, a small phase-II study assessed 
the value of an -EGFR treatment in  rst-line therapy in metasta c SBA, which showed that 
panitumumab monotherapy had no clinically bene cial e ect in 9 pa ents with metasta c 
RAS wild-type SBA  .
The OS rates for pa ents receiving pallia ve chemotherapy with and without bevacizumab 
in   rst-line  treatment  were  not  sta s cally  signi cantly  di erent  in  the  present  study. 
However, as the number of pa ents treated with targeted therapy was low, an obvious non-
signi cant di erence in OS could have been clinically relevant, but such a striking di erence 
was  not  noted.  Although  study  designs  di ered,  the  presented  results  are  in  line  with 
the study of Aydin et al., who  showed non-signi cant di erences  in median OS between 
the  groups  of pa ents  treated with and without  addi onally bevacizumab  a er  rst-line 
treatment only  . Unfortunately, data on PFS were missing in the current study. However, 
in the studies of Aydin et al. and Gulha  et al., no signi cant di erences in PFS were found 
between  the  groups  of  pa ents  treated  with  combina on  chemotherapy  only  or  with 
addi onal bevacizumab      . Moreover, as genomic pro ling of pa ents with SBA showed 
a lower expression of VEGF-A in metasta c disease than  in locoregional disease, it seems 
crucial to iden fy the subgroup of pa ents poten al bene  ng from an -VEGF therapy  .
The popula on-based nature of our data is associated with several risks of poten al biases. 
Data  on  mul ple  prognos c  factors  are  lacking,  including  informa on  on,  for  instance, 
extent of  disease, disease  related symptoms, performance status,  comorbidi es  and  the 
  
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presence  of  RAS  or  BRAF  muta ons.  Moreover,  reasons  to  prescribe  chemotherapy  or 
targeted therapy were unknown, dura on of systemic therapy was not well documented for 
all pa ents, and selec on bias could have played a large role. However, as large prospec ve 
studies are hard  to conduct  in  the  eld of  this  rare disease,  the current data are of high 
value into providing insights into the use and e ects of targeted therapy in pa ents with 
metasta c SBA in daily prac ce.
In  conclusion,  taking  into  account  the  limited  number  of  pa ents  receiving   rst-line 
bevacizumab  and  the  unknown  reasons  to  prescribe  addi onal  targeted  therapy,  the 
corresponding survival rates of pa ents treated with and without addi onal bevacizumab 
in  rst-line treatment, might suggest a limited clinical e ect of bevacizumab in addi on to 
 rst-line  pallia ve chemotherapy on OS. Future  research should  focus on  iden fying  the 
subgroup of pa ents bene  ng from an -VEGF therapy in metasta c SBA.
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Un l  recently,  many  classi ca ons  existed  for  the  terminology  and  histopathological 
classi ca on of appendiceal mucinous neoplasms, mucinous appendiceal adenocarcinomas 
and pseudomyxoma peritonei (PMP). A major accomplishment was achieved by consensus-
based histopathologic classi ca ons on behalf of  the Peritoneal Surface Oncology Group 
Interna onal regarding mucinous appendiceal tumors and PMP. As di erent classi ca on 
were  used  over  the  years  and  also  owing  to  the  rare  nature  of  these  tumors,  many 
clinicians are not  familiar with  the  terminology and  the  impact  on  pa ent management. 
Hence, an overview concerning mucinous appendiceal neoplasms, mucinous appendiceal 
adenocarcinomas and PMP is provided to serve as an introduc on into the basic morphology 
of these tumors with tenta ve recommenda ons for management.
  
Review: Pathology and its clinical relevance of mucinous appendiceal neoplasms and PMP
Introduc on
Appendiceal epithelial tumors are scarce. In comparison, the incidence of colorectal cancer 
is approximately 100-fold higher . As appendiceal neoplasms and colorectal cancer exhibit 
a dis nctly di erent clinical and tumor behavior, these tumors are classi ed separately in 
the various tumor classi ca ons . Most appendiceal neoplasms are found during surgery 
or postopera vely in appendectomy specimens. However, the percentage of appendiceal 
tumors that  is  incidentally discovered preopera vely by  imaging is  increasing over years   
 . A clinical diagnosis  is challenging due to a variable symptomatology in pa ents, ranging 
from an asymptoma c course to vague acute or chronic abdominal complaints, even with 
symptoms mimicking acute appendici s4-6.
Pathology is of prognos c signi cance in pa ents with appendiceal cancer . Adenocarcinoma 
is  the most common histologic malignant subtype, accoun ng  for more  than half of  the 
     6-8. Other malignant  subtypes of  appendiceal  cancer  include  lymphomas,  sarcomas, 
grade 1 and 2 neuroendocrine tumors (NETs) and goblet cell tumors/carcinomas (previously 
called  goblet  cell  carcinoids)     .  Goblet  cell  tumors  are  a  remarkable  group  of  tumors, 
occurring almost exclusively in  the appendix. Recent  insights have shown that goblet cell 
tumors are lesions composed of several cell types, including neuroendocrine cells, Paneth 
cells  and  goblet  cells.  These  tumors  show  a  con nuum with  adenocarcinomas,  and  the 
prognosis is dependent of the dominant morphologic component of the goblet cell tumor   
  .
A  subgroup  of epithelial  tumors,  including  those with uncertain malignant poten al and 
adenocarcinomas, are known for their extensive mucus produc on and therefore, belong to 
the group of mucinous appendiceal neoplasms. Mucinous appendiceal neoplasms are the 
leading cause of pseudomyxoma peritonei (PMP), a unique clinical condi on characterized 
by  progressive  accumula on  of  mucinous  ascites  and  peritoneal  implants  with  fatal 
outcome1, 11-13. The terminology and histopathological classi ca on of mucinous appendiceal 
neoplasms, appendiceal adenocarcinomas and PMP has been subject to diverse consensus-
based changes over  me. The aim of this general overview is to provide an introduc on into 
the basic morphology of these tumors with tenta ve recommenda ons for management of 
these various neoplasms.
 
  
         
         
Mucinous  appendiceal  neoplasms  are  a  frequently  discussed  item  within  the  group  of 
appendiceal  tumors,  but  the  classi ca on  might  s ll  be  experienced  as  confusing  by 
          9-11, 13-18. Mucinous appendiceal neoplasms are dis nguished in 3 di erent categories 
according to the latest consensus-based classi ca on by  the Peritoneal Surface Oncology 
Group Interna onal (PSOGI), consis ng of true premalignant  lesions, tumors of uncertain 
malignant  poten al,  and malignant  lesions       .  Serrated  polyps  and  tubular,  villous,  and 
tubulovillous  adenomas  all  belong  to  the  group  of  premalignant  lesions.  Meanwhile, 
tumors of uncertain malignant poten al, also known as low-grade appendiceal mucinous 
neoplasms  (LAMNs)  and  high-grade  appendiceal  mucinous  neoplasms  (HAMNs),  share 
some histologic features with adenomas, but these lesions have the capacity to proliferate 
out of the appendix in a malignant fashion. Finally, the malignant lesions can be subdivided 
into mucinous adenocarcinomas, with or without a signet ring cell component, and signet 
ring  cell  carcinomas.  The  premalignant  lesions  do  not  have  the  poten al  to  cause  PMP, 
which is not the case for the other 2 categories      .
  D 
A  subgroup  of  mucinous  appendiceal  lesions  can  be  classi ed  as  LAMNs.  Historically, 
cystadenoma  and  mucocele  were  used  as  synonyms  for  LAMN,  but  these  terms  were 
abandoned based on consensus, owing  to  their  incomplete and misleading nature            
  .  The  histologic  criteria  for  LAMN are  summarized  in  table  1.  The most  important  and 
dis nc ve  feature  of  LAMN  is  the  low-grade  cytologic  atypia  without  signs  of  invasive 
in ltra on in the appendiceal wall. In almost all cases of LAMN, there is loss of the normal 
mucosal  architecture  of  the  appendix,  at  least  focally,  with  loss  of  the  lamina  propria 
and  muscularis  mucosa  with  lymphoid  follicle  atrophy  associated  with   brosis  of  the 
submucosa  . LAMNs are the main cause of PMP. These lesions generally do not cause nodal 
or distant extraperitoneal metastases  .
In  case  of  a  suspected  LAMN,  accurate  pathologic  examina on  of  the  total  appendix  is 
essen al, as  some  features are associated with poten al  intraperitoneal  tumour spread, 
which worsens  the  natural  disease  course  and  the  prognosis  of  the  pa ent. Worrisome 
features of LAMN include appendiceal rupture (including micro-perfora on), a background 
of  appendiceal  in amma on,  the  presence  of  extra-appendiceal  mucin,  or  extensive 
dissec ng mucin pools within the appendiceal wall. LAMNs with  these ominous  features 
                           D              . A LAMN in an intact appendix and without other risk 
factors is considered as benign with only very small risk to evolve to PMP.
Pa ents with LAMN show di erent characteris cs, clinical course, and survival than pa ents 
  
Review: Pathology and its clinical relevance of mucinous appendiceal neoplasms and PMP
with  a  mucinous  adenocarcinoma.  Pa ents  are  generally  young,  with  a  median  age  of 
approximately  53  years,  and  with  a  slightly  female  predominance  (~60%)            .  Among 
all mucinous appendiceal neoplasms without peritoneal spread, it has the most favorable 
prognosis.  In  pa ents  with  completely  resected  LAMNs  or  with  low-volume  peritoneal 
disease, a 5-year recurrence-free survival and overall survival rate of 95.2% and 100% were 
observed  .
 
d        Classi ca on and grading of mucinous epithelial lesions of the appendix Adapted from Carr et al.  
d                   ,                  
                                  Lesion with serrated featured, con ned to the mucosa and 
intact muscularis mucosae. In case of dysplasia, it can be 
classi ed as low or high grade.
        Low/high grade 
         
Adenoma with tubular, tubulovillous of villous features, 
resembling usual colorectal type. Con ned to mucosa and 
intact muscularis mucosae.
   E Low Mucinous neoplasm with low-grade cytologic atypia and 
without invasive in ltra on but with any of the following 
         
   loss of muscularis mucosae
    brosis of submucosa
   ‘pushing invasion’ (expansile or diver culum-like growth)
   dissec on of acellular mucin in the appendiceal wall
   undula ng or  a ened epithelial growth
                          
   mucin and/or cells outside the appendix
,  E High Mucinous neoplasm with the architectural features of LAMN 
but with high-grade cytologic atypia.
         
              
Well/ moderately/
poorly di eren ated
Mucinous neoplasm, comprising of >50% extracellular mucin, 
with in ltra ve invasion.
         
                    
                 
Poorly di eren ated Mucinous adenocarcinoma, comprising up to 50% signet ring 
     
                 
              
Poorly di eren ated Adenocarcinoma, comprising of >50% signet ring cells
LAMN = low-grade appendiceal mucinous neoplasm, HAMN = high-grade appendiceal mucinous neoplasm.
 
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The term HAMN was added in the latest classi ca on for mucinous neoplasms, but these 
tumors are extremely rare and therefore s ll poorly understood  . These lesions display the 
same architectural features of a LAMN but with high-grade cytology (table 1)      . It might 
be hypothesized that HAMNs form an intermediate group between LAMNs and mucinous 
adenocarcinomas. In a small study by Misdraji et al HAMNs had a more aggressive clinical 
              D    . Informa on on prognosis is lacking for pa ents with HAMNs.
 
  
         
D                                                                  
Appendiceal mucinous  adenocarcinomas  are  de ned  as mucinous  neoplasms  comprised 
of >50% extracellular mucin, with  the presence of  in ltra ve  invasion of  the appendix.    
   According to the PSOGI classi ca on, mucinous adenocarcinomas are classi ed as well, 
moderately,  and  poorly  di eren ated,  although  the  histologic  criteria  for  the  di erent 
grading systems are not well-established  . The presence of  signet ring cells  in  the lesion 
to whatever extent,  indicates a poorly di eren ated carcinoma.  If more than 50% of the 
tumor consists of signet ring cells, the term signet ring cell carcinoma is used. Otherwise, if 
less than 50% of the cells have signet ring cell morphology, the tumor is classi ed as poorly 
di eren ated adenocarcinoma with signet ring cells  .
Mucinous  adenocarcinomas  develop  mainly  from  precursor  lesions       .  Pa ents  are 
generally young, with a median age of 50 to 60 years, and many pa ents already present with 
synchronous metasta c disease, especially in the case of signet ring cell adenocarcinomas   
      . Nodal metastases are commonly seen, in contrast to pa ents with LAMNs. Mucinous 
and signet ring cell adenocarcinomas metastasize  intra- and extraperitoneally, but usually 
intra-abdominal  dissemina on  occurs   rst.  Survival  is  strongly  dependent  of  histological 
                    . Among appendiceal  adenocarcinomas, mucinous  adenocarcinoma has  the 
most favorable prognosis, with a median overall survival of over 60 months. Like colorectal 
cancer, pa ents with signet  ring cell  appendiceal adenocarcinoma have  the worst overall 
survival among all morphologies, with a reported median overall survival of approximately 
20 to 25 months and a 5-year survival rate of 22% to 38%            .
  
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                  
PMP is a heterogeneous clinical disease, for which a uniform and comprehensive de ni on 
is s ll lacking. It is dis nguished from usual peritoneal metastases of other gastrointes nal 
cancers by the presence of excessive amounts of mucin in the peritoneal cavity  . However, 
as the extent of mucinous ascites to be classi ed as PMP is not clari ed, the exact cuto  
point between (mucinous) peritoneal metastases and PMP is unclear. As already stated by 
Carr et al, PMP should only be used for the macroscopic appearance of mucinous ascites, 
                                     . Mucinous appendiceal neoplasms are the leading cause 
    D   .
PMP can be divided into several categories based on histologic features of the peritoneal 
disease with  its clinical consequences and prognos c value, including acellular PMP, low-
grade PMP, high-grade PMP and high-grade PMP with signet ring cells. It is of importance 
to describe and subdivide the histologic grade of both peritoneal disease and the primary 
tumor, as morphology can be discordant  in  rare cases. For  instance, pa ents with  LAMN 
may  present  with  high-grade  PMP,  whereas  invasive  adenocarcinomas  could  cause  low-
grade PMP. This discordance may in some cases be explained by sampling error or incorrect 
diagnosis.  However,  the histologic grade  of  the peritoneal disease outweighs  its primary 
appendiceal lesion in terms of prognosis          .
           D 
The separated en ty of acellular mucin in the overarching group of PMP is characterized by 
the absence of epithelial cells in the mucin within the peritoneal cavity. In case of appendiceal 
origin, this acellular mucin usually results from LAMNs with low-volume peritoneal disease, 
mostly located in the right lower quadrant of the abdomen  . Pa ents with acellular mucin 
comprise a small group within the spectrum of PMP and have the most favorable clinical 
outcome, owing to the rela vely indolent course of disease      .
           D 
Low-grade PMP is the most common variant of PMP. Other terms used for low-grade PMP 
are low grade mucinous carcinoma peritonei and disseminated peritoneal adenomucinosis 
(DPAM)  . All histologic  features associated with low-grade PMP are described  in  table 2. 
The main cause of low-grade PMP are LAMNs  .
 
   
         
d        Classi ca on of pseudomyxoma peritonei. Adapted from Carr et al.      
d           ,                  
           D  Mucin within the peritoneal cavity without neoplas c epithelial cells
Low-grade PMP    Low-grade or minimal cytologic atypia
   Epithelial component typically scanty
   Strips, gland-like structures or small clusters of cells
   Not more than occasional (sporadic) mitoses
   ‘Pushing’ invasion into underlying organs
High-grade PMP    High-grade cytologic atypia
   High cellularity
   Cribiform growth
   Numerous mitoses
   Destruc ve in ltra ve invasion of underlying organs
High-grade PMP with signet ring cells Any lesion with a component of signet ring cells
PMP = pseudomyxoma peritonei
            D 
Peritoneal disease with high-grade cytologic atypia is also known in literature as high-grade 
mucinous carcinoma peritonei, peritoneal mucinous carcinomatosis (PMCA) and high-grade 
PMP. High-grade PMP is in the majority of cases caused by mucinous adenocarcinomas      . 
Further details are listed in table 2. It remains to be seen whether HAMNs will cause high or 
low-grade PMP or even an intermediate form. A con nuum is present between high-grade 
PMP and non-mucinous peritoneal metastases in which the presence of a large amount of 
mucin points to PMP instead of non-mucinous peritoneal metastases  .
            D                        
High-grade PMP with signet ring cells is classi ed separately from high-grade PMP without 
signet ring cells, as the presence of signet ring cells is a powerful nega ve prognos c factor 
for survival in pa ents with PMP      . All further criteria for high-grade PMP also apply for 
high-grade PMP with signet ring cells.
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  D 
For  pa ents  without  extra-appendiceal  disease,  appendectomy  and  follow-up  is 
recommended.  Right  hemicolectomy  should  not  be  performed,  because  it  provides 
no  survival  bene t  for  pa ents with  LAMNs,  as  these  lesion  usually  do  not  cause  nodal 
metastases      .  In pa ents with  posi ve margins, addi onal surgery  like cecectomy may 
be considered, although several data suggest no survival bene t a er further resec on     . 
Although the exact dura on and prognos c value of follow-up is unknown, long-term follow-
up of 5 to 10 years is recommended, because peritoneal dissemina on can occur lately a er 
the primary lesion      . Currently, follow-up is recommended to start annually, including an 
abdominal computed tomography (CT) scan and determina on of serum tumour markers 
(carcinoembryonic  an gen,  cancer  an gen  19.9,  and  cancer  an gen-125)  .  Especially 
in  pa ents with  worrisome  prognos c  signs,  such  as  elevated  tumour markers,  posi ve 
resec on margins  or  the  presence  of  mucin  beyond  the  appendix,  close  and  extended 
follow-up  is  advised       . Whether  pa ents with  a  radically  resected  and  intact  appendix 
with LAMN without worrisome features need close and frequent follow-up is debatable, as 
it is considered as a lesion with an indolent behaviour and a low poten al to develop PMP . 
In the study of Guaglio et al, a 5-year recurrence-free rate of 95.2% and no pa ent deaths 
were found in pa ents with radically resected LAMNs or low-volume peritoneal disease  .
  D 
As the term HAMN was introduced recently, limited literature regarding the management of 
this lesions is present. Moreover, the diagnosis HAMN is exclusively made a er surgery by 
pathological examina on of the appendix, in which the surgeon has already performed an 
appendectomy, cecectomy or right hemicolectomy. Due to the rareness of the tumour, it is 
s ll unknown whether local removal of the tumour is su cient or a more extended tumour 
resec on is needed. Long-term follow-up is advised, since pa ents with HAMNs might have 
                                                 .
D                                  
In  pa ents  with  mucinous  adenocarcinomas,  a  right  hemicolectomy  with  lymph  node 
dissec on should be performed in locoregional disease, due to an increased risk of lymph 
node  invasion and improved survival rates compared with appendectomy only          . The 
value of adjuvant chemotherapy is unknown, as no randomized controlled trials have been 
conducted due to the rarity of the appendiceal adenocarcinomas. In a retrospec ve cohort 
study of Asare et al, the role of adjuvant systemic therapy on overall survival was evaluated 
and  showed  a  survival  bene t  for  treated  pa ents  with  mucinous  and  non-mucinous 
morphology  . However, in this study, informa on about the systemic regimens used were 
 
   
         
lacking, and adjuvant chemotherapy was administrated in all locoregional stages (I-III). In all 
pa ents with appendiceal mucinous adenocarcinomas, follow-up is recommended according 
to  the  guidelines  of  colorectal  cancer,  because  recurrence  and  distant  metastases  are 
frequently observed, comparable with other gastrointes nal mucinous adenocarcinomas  .
                  
Cytoreduc ve surgery with hyperthermic intraperitoneal chemotherapy (CRS+HIPEC)
In  peritoneal  dissemina on,  CRS+HIPEC  is  recommended  for  all  types  of  PMP,  although 
di erent  criteria  apply  for  low- and  high-grade PMP.  For  all  peritoneal malignancies,  the 
extent of the peritoneal disease is assessed by the peritoneal cancer  index (PCI). The PCI 
comprises a score between 1 to 39, composed of a scoring system in which the peritoneal 
cavity and small bowel are divided in 13 regions, in which the tumour burden is assessed 
                                 .  For  example,  in  peritoneal metastases  of  colorectal  origin, 
CRS+HIPEC is usually not performed if PCI ≥20, as radical resec on of the peritoneal tumour 
is  nearly  impossible  and  the  morbidity  caused  by  CRS+HIPEC  outweighs  the  poten al 
minimal bene cial e ect on survival  .
In pa ents with low-grade PMP, CRS+HIPEC should always be considered irrespec ve of the 
PCI.  If  complete  cytoreduc on  could  be achieved,  CRS+HIPEC  is  s ll  a  cura ve op on  in 
pa ents with high peritoneal tumour load         . The great impact of CRS+HIPEC on survival 
in  low-grade PMP  is  re ected  in a  reported median overall  survival of 7.7  to 12.3 years, 
and a 5-year and 10-year survival rate of 84% and 48%, respec vely,  in case of complete 
cytoreduc on             . In case of incomplete cytoreduc on, the 5-year survival rate decreased 
to 63%  . Even in pa ents with very extensive disease with a PCI ranging from 31 to 39, long 
term survival was achieved with 5- and 10-year survival rates of 73% and 68%, respec vely, 
                           . These results might indicate an increased survival for a selected 
group of pa ents, if referred to a specialized center .
In  contrast,  the  PCI  may  be  considered  to  select  pa ents  with  high-grade  PMP  for 
CRS+HIPEC,  as  a  high  PCI  is  associated  with  signi cant  poorer  survival.  A er  achieving 
complete  cytoreduc on,  a median  overall  survival  of  2.8  to  5.3  years,  and  a  5-year  and 
10-year survival rate of, respec vely, 48% and 40% are reported                 . However, a er 
incomplete cytoreduc on the 5-year overall survival decreases to only 23%  .
CRS+HIPEC  can  be  considered  in  pa ents  with  high-grade  PMP  with  signet  ring  cells, 
although a posi ve  impact of CRS+HIPEC on survival  is  less clear. Several  studies showed 
a poor prognosis a er CRS+HIPEC for pa ents with high-grade PMP with signet ring cells, 
with a median overall survival of only 9 to 31 months and a 5-year survival rate varying from 
   
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0 to 22%          . As pa ent selec on by clinicians already occurred in these studies, the use 
of CRS+HIPEC for high-grade PMP with signet ring cells might be  limited in daily prac ce, 
especially given  the  small gain  in survival and  the major morbidity up  to 50%  in  treated 
pa ents caused by CRS+HIPEC      .
Systemic therapy
Neo-adjuvant se ng
Several studies inves gated the e ect of neo-adjuvant chemotherapy prior to CRS+HIPEC. 
Only in the study of Milovanov et al, in a small group of 18 pa ents with high-grade PMP with 
signet  ring cells, a bene t  in progression-free survival and overall survival were observed 
with  preopera ve  systemic  therapy,  followed  by  complete  cytoreduc on  .  However,  it 
should be no ced that many di erent chemotherapeu c regimens and targeted therapies 
were used  . No other studies found a survival gain for pa ents treated with neo-adjuvant 
or periopera ve chemotherapy in low- or high-grade PMP1, 38-43.
Adjuvant se ng
No evidence exists for a bene cial e ect of the subsequent use of adjuvant systemic therapy 
a er CRS+HIPEC in pa ents with PMP of any type      .
Pallia ve se ng
Pallia ve  systemic  therapy  can  be  considered  in  pa ents  with  irresectable  or  recurrent 
(high-grade)  PMP,  who  are  not  suitable  for  CRS+HIPEC.  Generally  accepted  reasons 
for  surgical  ineligibility  include  short  progression-free  survival  (o en  <1  year  to  prior 
CRS+HIPEC),  residual  disease  a er  prior  CRS+HIPEC,  and  extensive  comorbidi es       . No 
randomized controlled trials have been performed for pallia ve systemic therapy in pa ents 
with PMP. Commonly, chemotherapy regimens by analogy of colorectal cancers are used, 
like   uoropyrimidine-based  regimens,  either   uorouracil/  capecitabine monotherapy,  or 
oxalipla n- or irinotecan-based combina on therapy      . In the series of Choe et al., addi on 
of targeted therapy to pallia ve chemotherapy was used in 50% of the cases, mainly with 
a doublet chemotherapeu cal regimen  . Owing to  the  rarity of  the  tumour, most of  the 
performed studies were of retrospec ve design and conducted in the same single ter ary 
ins tu on. Besides, di erent pa ent  inclusion criteria and  chemotherapy regimens were 
used in most studies.
Despite di erent regimens used in diverse studies, it was suggested that pallia ve systemic 
therapy  could provide a  survival bene t  in  selected  pa ents not suitable  for CRS+HIPEC. 
In the treated group of pa ents, the median progression-free survival and median overall 
survival was around 8 months and 26 to 56 months, respec vely41, 46-48. Overall response rate 
 
   
         
(ORR) varied between 20% and 60%, depending on the de ni on of ORR and the regimens 
    41, 46-48. The use of the biologic agent bevacizumab, an an -vascular endothelial growth 
factor (an -VEGF) an body, in 95% of the cases in addi on to combina on chemotherapy, 
was associated with an ORR of 87% and a gain in progression-free and overall survival in a 
selected group of pa ents of 5 months and 34 months, respec vely  .
Among pa ents treated with pallia ve chemotherapy, a moderately to poorly di eren ated 
tumour,  including signet ring histology, was associated with poorer survival than pa ents 
with a well-di eren ated tumour, which re ects the more aggressive biological behaviour 
of  the  higher  grade  tumors  .  However,  the  administra on  of  pallia ve  chemotherapy 
provides  a  bene t  in  progression-free  survival  and  overall  survival  for  selected  pa ents 
with high-grade PMP.  In these pa ents, with primary moderately or poorly di eren ated 
tumours (including signet ring cells), the overall survival improved for moderate and poor 
di eren a on from 20 to 36 months and 12 to 19 months, respec vely  . The use of an -
VEGF therapy was associated with prolonged progression-free survival and overall survival in 
all histologic subtypes, but especially in high-grade PMP  . Although the number of pa ents 
included  in  the  studies were  small  and  selec on  bias  probably  played  a  signi cant  role, 
these  results  favour  the use of pallia ve chemotherapy and targeted  therapy in selected 
pa ents with irresectable or recurrent high-grade PMP.
Pa ents  with  low-grade  PMP  derive  less  to  no  bene t  from  pallia ve  chemotherapy 
compared  to higher grade  tumors      . Asare et al. even showed a worse overall  survival 
for pa ents treated with pallia ve chemotherapy compared with non-treated pa ents  . A 
clinical relevant gain of 7 months in progression-free survival was observed in pa ents with 
low-grade PMP a er the administra on of an -VEGF therapy  . Perhaps this might indicate 
a role for this targeted agent in symptoma c pa ents with low-grade PMP not suitable for 
CRS+HIPEC. However,  the  generally  indolent  behaviour  of  irresectable  or  recurrent  low-
grade PMP challenges both clinicians and pa ents to decide between an ac ve management 
or observa on.
   
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Discussion
The  classi ca on and  nomenclature  of mucinous  appendiceal neoplasms and  PMP have 
been adapted several  mes over the years      . However, these classi ca ons are based on 
experiences and theore c assump ons of experts in the  eld, and are not totally evidence-
based. Future research is needed to determine the accuracy and clinical relevance of the 
most recent consensus-based classi ca on.
Despite the increased knowledge and insights concerning appendiceal mucinous neoplasms 
in  recent  years,  there  is  s ll  much  to  be  inves gated  and  clari ed.  For  instance,  exact 
informa on on the incidence and natural course of LAMNs and HAMNs is lacking. Besides, 
it is di cult to dis nguish between the true benign and the premalignant lesions with its 
poten al to cause PMP within the subgroup of LAMNs, which might a ect management and 
surveillance decisions. Especially the subgroup of HAMNs is currently poorly understood, as 
this subgroup is extremely rare, and it is unknown whether the biological behaviour di ers 
signi cantly from other subgroups, also in their poten al to cause peritoneal disease      .
No strict guidelines exist for the management of mucinous appendiceal neoplasms, especially 
LAMNs and HAMNs, and PMP.  In pa ents with PMP, CRS+HIPEC should be  considered  in 
all  types of  PMP,  taking  the poten al bene ts and  harms  into account  for  the histologic 
subtypes1, 26, 27, 33-36. For instance, in pa ents with the aggressive high-grade PMP with signet 
ring cells, the value of CRS+HIPEC is  limited. However, selected pa ents could s ll have a 
clinical bene t from CRS+HIPEC in high-grade PMP with signet ring cells, but this has to be 
studied in a larger subset of pa ents.
There seems to be no  indica on  for  standard neo-adjuvant or adjuvant systemic therapy 
in  PMP. However,  it  is  theore cally  possible  that  selected  high-grade  PMP pa ents with 
irresectable disease due to a high degree of tumour burden could bene t from neo-adjuvant 
chemotherapy1, 38-44. On an individual level, the administra on of neo-adjuvant chemotherapy 
could  result  in a  situa on of  resectable peritoneal  disease, a er which CRS+HIPEC could 
be performed. Pallia ve systemic  therapy can be considered  in pa ents with irresectable 
or  recurrent PMP,  especially  in  high-grade  PMP pa ents.  The administra on of pallia ve 
chemotherapy could result in a prolonged survival in high-grade PMP pa ents, but probably 
not in pa ents with low-grade PMP25, 41, 46-48. There are indica ons that both low- and high-
grade PMP pa ents could possibly bene t from the use of targeted therapy  . However, it 
should be noted that the obtained evidence on pa ent management is mainly based on the 
experience of a few ter ary centres.
Moreover,  the  present  insights  into  appendiceal  mucinous  neoplasms  including  LAMNs 
 
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are  largely  derived  of  collected  samples  by  hospitals  and  pathology  archives  .  Data  on 
lesions that were previously assumed to be non-malignant lesions are usually not recorded 
by  cancer  registries.  For  example,  in  the  Netherlands  Cancer  Registry  only  in  case  of 
PMP,  data  on  the  primary  appendiceal  lesions  as  LAMNs  and HAMNs  are  registered.  In 
addi on, due to the new classi ca on of mucinous appendiceal neoplasms, the available 
data of  these  tumours might be contaminated, as  some LAMNs were probably classi ed 
as well-di eren ated mucinous  adenocarcinomas,  resul ng  in  incorrect  survival  rates  in 
retrospec ve or popula on-based studies. However, if collected properly, popula on-based 
data could be of value for future research in re ec ng the clinical course of the disease and 
the use and e ect of treatments in daily prac ce.
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            The aim of this popula on-based study was to determine the prognos c value 
of the histologic subtypes mucinous (MAC), non-mucinous (AC) and signet ring cell (SRCC) 
adenocarcinoma among pa ents with appendiceal cancer.
                          Data  from  the  Netherlands  Cancer  Registry  (NCR)  of  pa ents 
with  primary  appendiceal  adenocarcinomas  with MAC,  AC  and  SRCC  histologic  subtype, 
diagnosed between  2001-2015 were used  (n  =  675).  To  categorize  pa ents  according  to 
the  recent histopathological  classi ca on,  the NCR was  linked with  the Dutch  Pathology 
Registry  (PALGA).  Log-rank  tests  and Kaplan-Meier  analyses were  performed  to es mate 
overall survival (OS), and the cox propor onal hazards model was run to iden fy prognos c 
factors.
          AC  was  the  most  frequently  encountered  histologic  subtype  (50.9%),  followed 
by MAC  (35.8%) and SRCC  (13.3%).  In  locoregional disease, histologic  subtype was not a 
prognos c factor for OS with 5-year survival rates for pa ents with AC, MAC and SRCC of 
60.0%, 60.5% and 69.6% respec vely (p = 0.68). Metasta c disease was more common in 
SRCC (53.8%) than in MAC (38.8%) and AC (23.4%) (p < 0.0001). Median OS for pa ents with 
metasta c disease was 12.6, 27.7 and 18.2 months in AC, MAC and SRCC respec vely (p < 
0.005). MAC was associated with higher survival  compared  to AC  (HR 0.48, 95% CI 0.34-
0.69). In subanalyses, MAC was only a posi ve prognos c factor compared to AC in pa ents 
with peritoneal metastases (HR 0.42, 95% CI 0.28-0.62).
             Histologic  subtype  had  no  prognos c  relevance  in  locoregional  or  systemic 
metasta c  disease  in  appendiceal  adenocarcinoma.  In  peritoneal  metastases,  mucinous 
histologic  subtype  was  a  favourable  prognos c  factor,  compared  to  non-mucinous  and 
signet ring cell subtype.
   
The prognos c relevance of histologic subtype in appendiceal adenocarcinoma 
Introduc on
Appendiceal epithelial tumours are rare, and are mostly incidentally found in appendectomy 
specimens .  The  most  frequently  encountered  malignant  subtype  within  the  group  of 
appendiceal  neoplasms  is  the  adenocarcinoma2-4.  Appendiceal  adenocarcinomas  are 
subdivided into the mucinous, non-mucinous and signet ring cell subtype    . The histologic 
subtype is thought to be of signi cant relevance in appendiceal adenocarcinomas, as earlier 
research revealed that pa ents with a mucinous appendiceal adenocarcinoma have a be er 
or comparable outcome, compared to non-mucinous adenocarcinomas, depending on the 
                1-3, 5.
However, up un l recently the de ni on of a mucinous appendiceal adenocarcinoma has 
not been universal, as di erent histopathological criteria and classi ca ons for mucinous 
appendiceal  neoplasms  existed6-10.  Recently,  a  consensus-based  histopathological 
classi ca on  regarding  mucinous  appendiceal  neoplasms  and  pseudomyxoma  peritonei 
(PMP)  was  published  on  behalf  of  the  Peritoneal  Surface  Oncology  Group  Interna onal 
(PSOGI)  . With this classi ca on, appendiceal mucinous neoplasms, including the low-grade 
appendiceal  mucinous  neoplasm  (LAMN),  high-grade  appendiceal  mucinous  neoplasms 
(HAMN) and mucinous appendiceal adenocarcinoma, can be classi ed with interna onally 
corresponding de ni ons, based on well-de ned criteria.
As  universal  and  clear  de ni ons  for mucinous  appendiceal  neoplasms  were  previously 
lacking,  it  could  be  possible  that  prognos cally  favourable  LAMNs  and  HAMNs  were 
incorrectly  classi ed  as  mucinous  appendiceal  adenocarcinomas.  Therefore,  it  was  the 
aim of the present popula on-based study to determine the prognos c value of histologic 
subtype more accurately, by using the new consensus-based histopathological classi ca on, 
in a subset of pa ents with mucinous, non-mucinous and signet ring cell adenocarcinomas 
in The Netherlands between 2001 and 2015.
 
   
         
                    
Data collec on
Data were drawn from the Netherlands Cancer Registry (NCR). The NCR collects popula on-
based data on all newly diagnosed malignancies of all Dutch ci zens and covers an area 
of  approximately 17 million  inhabitants.  Primary source of  no  ca on of  the NCR  is  the 
automated na onwide network and registry of histo- and cytopathology in the Netherlands 
(PALGA),  supplemented  with  data  from  the  Na onal  Registry  of  Hospital  Discharge 
           .  Specially  trained administrators of  the NCR rou nely  extract  informa on on 
pa ent and tumour characteris cs, diagnosis and treatment from the medical records.  In 
the NCR, all primary tumours are staged according to the Tumour Node Metastasis (TNM) 
classi ca on.  In case the pathological data is missing, the clinical TNM stage is used. The 
topographical site of the primary tumour and systemic metastases are registered according 
to  the  third  version  of  the  Interna onal  Classi ca on  of  Disease  for  Oncology  (ICD-O). 
Unfortunately, the exact topographical metasta c site was not collected un l 2008 in some 
regions of the NCR.
All consecu ve pa ents diagnosed with primary appendiceal adenocarcinomas (ICD-O code 
C18.1) between 2001 and 2015 were included in this study. Appendiceal adenocarcinomas 
were  classi ed  into mucinous  (morphology  codes  8470,  8480  and  8481),  non-mucinous 
(morphology  codes  8140,  8141, 8144,  8145,  8210, 8211,  8255, 8260,  8261,  8262, 8263, 
8440, 8460, 8560, 8570 and 8574) and signet ring cell adenocarcinomas (morphology code 
8490).
As  mul ple  tumour  classi ca ons  of  appendiceal  mucinous  neoplasms  existed  over 
 me,  the  group  of  formerly  classi ed mucinous  appendiceal  adenocarcinomas  could  be 
contaminated. Therefore, the pathological reports,  including macroscopy and microscopy 
reports, of pa ents with appendiceal mucinous adenocarcinomas with morphology codes 
8470 and 8480, in which cystadenomas and LAMNs, HAMNs or PMP may have been included, 
were retrospec vely revised through linkage with PALGA (n = 424). The  rst revision of the 
pathological reports was performed by LL, and a erwards checked and revised by CH. The 
histologic subtype was retrospec vely adjusted for the pa ents concerned, according to the 
most recent histopathological classi ca on for mucinous appendiceal neoplasms   .
For the present study, pa ents with LAMNs, HAMNs, clinical or pathological con rmed PMP 
without  con rmed  appendiceal  mucinous  adenocarcinomas  as  origin  and  pa ents with 
an  unknown  tumour  stage, were  excluded  from  further  analyses.  A  dis nc on  between 
locoregional  (T
1-4
 
0-2
D
 
)  and  metasta c  disease  (T
1-4
 
0-2
D
 
)  was  made  to  evaluate  the 
prognos c relevance of histologic subtype according to primary stage. In metasta c disease, 
   
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the  metasta c  sites  retroperitoneum  and  peritoneum  (C48),  connec ve,  subcutaneous 
and other so   ssues of abdomen  (C49.4) and ovaries  (C56) were de ned as peritoneal 
metastases. All other metasta c sites were coded as systemic metastases.
Vital status of pa ents at 31 January 2019 was assessed through linkage of the NCR with 
civil municipal  registries and  the central bureau for genealogy, which collects data on all 
deceased inhabitants of the Netherlands. Survival was calculated on all-cause mortality.
Sta s cal analysis
Descrip ve  sta s cs  were  used  to  provide  an  overview  of  the  pa ent  and  tumour 
characteris cs.  Di erences  in  pa ent  and  tumour  characteris cs  were  analysed  with  a 
two-sided chi-square test. Survival  me was de ned as the  me from the date of diagnosis 
to death or last follow-up date for pa ents who were lost to follow-up or s ll  alive at 31 
January  2019.  Survival was  es mated with  the  log-rank  test and  Kaplan-Meier  analyses. 
Mul variable  survival  analyses,  using  the  Cox  propor onal  hazards model,  were  run  to 
iden fy  independent  prognos c  factors  of  overall  survival.  To  evaluate  the  prognos c 
impact of metasta c site, the subgroups peritoneal and systemic metastases were created. 
Pa ents with both peritoneal and systemic metastases, were analysed in both subgroups, 
corrected for several clinical prognos c factors. Poten al clinical prognos c factors for which 
was corrected, included gender, age, period of diagnosis and treatment. The tumour related 
treatment strategies for which was corrected, included surgery for both the primary tumour 
and metasta c sites, cytoreduc ve surgery and hyperthermic intraperitoneal chemotherapy 
(CRS+HIPEC), systemic therapy (chemotherapy + targeted therapy), radiotherapy and other 
pallia ve interven ons. Hazard ra os (HRs) were presented with 95% con dence intervals 
(CIs).
The sta s cal package SAS Sta s cal So ware (version 9.4, SAS Ins tute, Cary, NC, USA) was 
used for the analyses. For all sta s cal tests, a two-sided p-value of p < 0.05 was considered 
as sta s cally signi cant.
 
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The current study included 986 pa ents diagnosed with an appendiceal adenocarcinoma 
between  2001  and  2015.  A er  revision  of  the  pathological  reports  of  pa ents  ini ally 
diagnosed or  classi ed with mucinous  appendiceal  adenocarcinomas, 264  pa ents were 
excluded  due  to  failure  of  primary  linkage  (n  =  29),  incorrect  linkage  (n  =  4),  missing 
informa on (n = 9), incorrect primary tumours or no primary appendiceal tumour, (n = 32), 
contamina on of the results due to appendici s (n = 1), and a primary LAMN (n = 187) or 
HAMN (n = 4). Therea er, pa ents with an unknown tumour stage were excluded (n = 22), 
remaining 698 pa ents, including 355 pa ents with (non-mucinous) adenocarcinoma, 250 
with mucinous appendiceal adenocarcinoma and 93 with the signet ring cell subtype ( gure 
1).
&         An overview of the included pa ents with primary appendiceal adenocarcinoma diagnosed be-
tween 2001 and 2015 in the Netherlands.
 
Adenocarcinoma, 
n = 355 
Mucinous adenocarcinoma, 
n = 250 
Signet ring cell 
adenocarcinoma, n = 93 
Excluding: 
Failure of primary linkage, n = 29 
Incorrect linkage, n = 4 
Missing informa on, n = 9 
Incorrect or no primary appendiceal 
tumour, n = 32 
Contamina on (appendici s), n = 1 
LAMN, n = 187 
HAMN, n = 4 
Unknown tumour stage, n = 22 
Pa ents with primary appendiceal 
adenocarcinoma, included in the NCR from 
2001-2015 (n = 978) 
Study popula on
Among  the  histologic  subtypes,  signi cant  di erences  were  noted  according  to  stage 
of disease at  the  me of diagnosis. Pa ents with signet  ring cell adenocarcinoma  (SRCC) 
presented with metasta c disease in 53.8% of the cases, compared to 38.8% and 23.4% in 
pa ents with primary mucinous adenocarcinoma (MAC) and non-mucinous adenocarcinoma 
   
The prognos c relevance of histologic subtype in appendiceal adenocarcinoma 
(AC) respec vely (p < 0.0001).
In locoregional disease, pa ents with a primary MAC were more frequently female (56%), 
whereas in SRCC a male preference (65%) was noted (p < 0.05). Median age was comparable 
for the histologic subtypes in locoregional disease, and was between 67 and 70 years old. 
Further  details  of pa ents with  locoregional  disease  are shown  in  table 1.  In metasta c 
disease, there was a signi cantly female predominance in all histologic subtypes (66-76%). 
Median age in metasta c disease was between 62 and 64 years old. Details on other pa ent- 
and tumour characteris cs for metasta c disease are listed in table 2.
 
d        General characteris cs of pa ents with non-mucinous, mucinous and signet ring cell appendiceal 
adenocarcinoma in locoregional disease (n = 468).
E            
              
(n = 272)
         
              
(n = 153)
                 
              
(n = 43)
  (%)   (%)   (%)  -value
      
 D   
 Female
   
   
(51.1)
(48.9)
  
  
(43.8)
(56.2)
  
  
(65.1)
(34.9)
< 0.05
Age (years)
 < 60
 60-69
 ≥ 70
  
  
   
(28.7)
(28.3)
(43.0)
  
  
  
(26.8)
(24.8)
(48.4)
  
 
  
(34.9)
(14.0)
(51.2)
0.31
     
  
  
  
  
   
  
(28.3)
(51.5)
(20.2)
  
  
  
(17.0)
(59.5)
(23.5)
 
  
 
(18.6)
(60.5)
(20.9)
0.10
      
 2001-2005
 2006-2010
 2011-2015
  
  
   
(34.6)
(28.3)
(37.1)
  
  
  
(34.0)
(30.1)
(36.0)
  
  
  
(23.3)
(39.5)
(37.2)
0.54
In metasta c  disease,  the most  commonly  a ected metasta c  site was  the  peritoneum 
(89%), including ovarian involvement, followed by the liver (16%). Peritoneal dissemina on 
was signi cantly more common in MAC (97%) and SRCC (94%) than in AC (77%) (p < 0.0005). 
Ovarian metastases as a part of peritoneal dissemina on, were more frequent in MAC (36%) 
and SRCC (35%) than in AC (16%) (p = 0.01). Metastases con ned to the peritoneal cavity, 
which may include the ovaries, but without other systemic metastases, were present in 64% 
of pa ents with AC, and  in 81% and 85% of the pa ents with MAC and SRCC respec vely 
(p = 0.01). Liver metastases were more frequently encountered  in AC (29%) than  in MAC 
(13%) or SRCC (2%) (p < 0.0005).
 
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d        General characteris cs of pa ents with non-mucinous, mucinous and signet ring cell appendiceal 
adenocarcinoma in metasta c disease (n = 230).
E            
              
(n = 83)
         
              
(n = 97)
                 
              
(n = 50)
  (%)   (%)   (%)  -value
      
 D   
 Female
  
  
(33.7)
(66.3)
  
  
(24.7)
(75.3)
  
  
(24.0)
(76.0)
0.32
Age (years)
 < 60
 60-69
 ≥ 70
  
  
  
(41.0)
(27.7)
(31.3)
  
  
  
(43.3)
(27.8)
(28.9)
  
  
  
(42.0)
(38.0)
(20.0)
0.57
      
 2001-2005
 2006-2010
 2011-2015
  
  
  
(25.3)
(32.5)
(42.2)
  
  
  
(24.7)
(38.1)
(37.1)
 
  
  
(14.0)
(34.0)
(52.0)
0.37
Number of a ected metasta c 
      
  
  
 ≥ 3
  
  
 
(65.8)
(21.9)
(12.3)
  
  
  
(47.7)
(31.4)
(20.9)
  
  
 
(47.9)
(35.4)
(16.7)
0.15
                      
(including ovarian)*
 Yes
   
  
  
(76.7)
(23.3)
  
 
(96.5)
(3.5)
  
 
(93.8)
(6.3)
< 0.0005
K                  
 Yes
   
  
  
(16.4)
(83.6)
  
  
(36.1)
(64.0)
  
  
(35.4)
(64.6)
0.01
                    
 Yes
   
  
  
(35.6)
(64.4)
  
  
(18.6)
(81.4)
 
  
(14.6)
(85.4)
0.01
* Calculated for the pa ents with known metasta c sites only (n = 207)
Survival and prognos c factors
In locoregional disease, median overall survival was reached in none of the histologic subtypes, 
as more than 50% of the pa ents were alive at the end of the study period. The 5-year survival 
rates for pa ents with AC, MAC and SRCC were 60.0%, 60.5% and 69.6% respec vely (p = 0.68). 
Histologic  subtype  was  not  a  prognos c  factor  for  overall  survival.  Mul variable  survival 
analyses run for locoregional disease, showed that pa ents over 60 years old, compared to 
age <60 years had a  lower overall survival (60-69 years vs <60 years; HR 1.91, 95% CI 1.24-
2.94 and ≥70 years vs <60 years; HR 4.25, 95% CI 2.95-6.13). Crude 5-year survival rates were 
80.9%, 67.1% and 43.4% for pa ents <60 years, 60-69 years and ≥70 years respec vely.
   
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In metasta c  disease, median  overall  survival  di ered  signi cantly  among  the  histologic 
subtypes, being 12.6 months, 27.7 months  and 18.1 months  in metasta c AC, MAC and 
SRCC  respec vely  (p  <  0.005)  ( gure  2). One-year  survival  rates were  53.0%,  69.1%  and 
58.0%  in  AC,  MAC  and  SRCC  respec vely.  Mul variable  survival  analyses  also  revealed 
histologic  subtype  to  be  a  relevant  prognos c  factor  for  overall  survival  in  metasta c 
disease. Pa ents with metasta c MAC had a higher overall survival compared to those with 
AC (HR 0.48, 95%CI 0.34-0.69). The subtype SRCC was no prognos c factor compared to AC. 
In subanalyses, taking metasta c site into account, the histologic subtype MAC was only a 
posi ve prognos c factor compared to AC in pa ents with peritoneal metastases and not in 
other systemic metastases, as shown in table 3. Moreover, elderly over 70 years, compared 
to age <60 years (≥70 years vs <60 years; HR 1.99, 95%CI 1.38-2.88), had a  lower overall 
survival, re ected in crude 5-year survival rates of 31.6% and 14.1% for pa ents aged <60 
years and ≥70 years respec vely.
&         Survival curve of pa ents with metasta c disease of appendiceal adenocarcinoma, mucinous 
adenocarcinoma and signet ring cell adenocarcinoma.
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d        Median overall survival and mul variable survival analyses for pa ents with primary appendiceal 
adenocarcinoma according to extent of metasta c disease.
E                
survival (months)
        
       
,   (95% CI)
              
   
 D  
 SRCC
  
  
  
12.6
27.7
18.1
< 0.005
1.00
0.48
0.89
(reference)
(0.34-0.69)
(0.60-1.31)
                     
   
 D  
 SRCC
  
  
  
13.3
31.2
16.2
< 0.0005
1.00
0.42
0.80
(reference)
(0.28-0.62)
(0.52-1.23)
                   
   
 D  
 SRCC
  
  
 
10.4
10.7
28.4
0.53
1.00
1.07
0.63
(reference)
(0.49-2.31)
(0.24-1.63)
AC = (non-mucinous) adenocarcinoma, MAC = mucinous adenocarcinoma, SRCC = signet ring cell adenocarcinoma, 
HR = hazard ra o, CI = con dence interval, * adjusted for age, gender, period of diagnosis and treatment
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Discussion
The  current  study  evaluated  the  prognos c  value  of  histologic  subtype  in  pa ents  with 
appendiceal adenocarcinomas in a veri ed popula on-based cohort. The histologic subtype, 
with special regard  to mucinous histology, was shown to be only a favourable prognos c 
factor for overall survival in peritoneal metasta c disease, but not in locoregional disease or 
in systemic metastases.
In  locoregional disease,  the histologic  subtype was not of prognos c relevance  in overall 
survival. This  nding  is in line with  the  results of Widmann et al., which also showed no 
impact of histologic subtype in survival . However, in metasta c disease, mucinous histologic 
subtype  was  a  prognos c  factor  for  higher  overall  survival,  which was  also  observed  in 
                      . Although  it  should  be  taken  into  considera on  that  the  presence of 
peritoneal dissemina on was the only factor of in uence in metasta c disease, as pa ents 
with a mucinous tumour did not have a signi cant higher overall survival than pa ents with 
a non-mucinous  tumour or SRCC  in  systemic metastases.  These  results are most  likely  a 
re ec on of the biological behaviour of these tumours in peritoneal dissemina on. MAC 
and  SRCC  both  belong  to  the  subgroup  of mucinous  appendiceal  neoplasms, which  are 
                        D       . PMP is a rare clinical disease characterized by progressive 
accumula on of mucinous tumour deposi on and mucinous ascites, which can be classi ed 
based  on  histologic  features  and  its  prognosis  into  four  histologic  subtypes,  including 
acellular PMP, low-grade PMP, high-grade PMP and high-grade PMP with signet ring cells. 
MACs are  the main cause of high-grade PMP, whereas SRCCs can give  rise  to high-grade 
PMP with signet ring cells      . In contrast, non-mucinous tumours cause more frequently 
systemic  metastases  and  classical  non-mucinous  peritoneal  metastases,  which  harbour 
di erent clinical and prognos c features than PMP      .
In  the  di erent  histologic  subtypes,  gender  was  not  distributed  equally  among  the 
subgroups in locoregional disease with a male predominance in SRCC. In metasta c disease, 
a signi cant female predominance was observed in all histologic subtypes. This observa on 
is  in contrast with colorectal cancer, where a male predominance is present in all disease 
            . In mucinous peritoneal disease, it is known that the dis nc on between mucinous 
appendiceal neoplasms and ovarian  cancer can be  challenging,  as mucinous appendiceal 
neoplasms  can mimic  ovarian mucinous  tumors  .  However,  the  observed  rela vely  low 
percentage of ovarian metastases in all histologic subtypes in metasta c disease does not 
explain the female predominance.
Although  the  presented  results were already adjusted  for all available  clinical prognos c 
factors,  including  treatment,  the  in uence  of  the  di erent  applied  treatment  strategies 
 
   
         
should be considered. Pa ents with peritoneal metastases may be treated with cura ve intent 
by cytoreduc ve surgery and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC). In 
pa ents with systemic metastases,  currently only systemic pallia ve therapy  is  available. 
Moreover,  pa ents  with  primary  appendiceal  mucinous  tumours,  including  SRCC,  are 
more  likely  to  receive  CRS+HIPEC  in  peritoneal  dissemina on  than  pa ents with  a  non-
mucinous appendiceal tumour, probably because non-mucinous tumours more frequently 
simultaneously cause systemic metastases      . However, the posi ve impact of CRS+HIPEC 
in pa ents with high-grade PMP with signet ring cells is not well determined13, 20-22.
Strikingly, more than half of the pa ents ini ally diagnosed with a MAC were excluded from 
the  present  study.  These  tumours  are  now  recognized  as  a LAMN or HAMN.  Previously, 
these rare tumour types were not clearly de ned, were unknown to some pathologists and 
could not be  registered accurately  in  interna onal cancer  registries, due  to one  iden cal 
morphology code for PMP and mucinous adenocarcinomas. This  nding underlines the urge 
of reassessment of pathologic reports of pa ents according to the newest consensus-based 
histopathological classi ca on with a diagnosis or classi ca on of an appendiceal MAC, as 
pa ents with a LAMN have a far be er prognosis than pa ents with MAC, and may bene t 
from other treatment modali es          .
Addi onally, the popula on-based nature of the presented data is inherently associated with 
risks of several poten al biases. In the NCR, data on numerous prognos c factors are not 
provided, including informa on on performance status, comorbidi es, extent of the disease 
and disease related symptoms. Furthermore, only the primary treatment a er diagnosis is 
registered, and therefore, data on for instance repeated CRS+HIPEC procedures are lacking. 
However, by crea ng a reliable study popula on through linkage of the NCR with PALGA, the 
present study could determine the true prognos c value of histologic subtype in pa ents 
with primary appendiceal adenocarcinomas.
In conclusion, mucinous histologic subtype is only a favourable prognos c factor compared 
to AC  and  SRCC  in  pa ents with  peritoneal metastases  of  appendiceal  adenocarcinoma, 
which might be a re ec on of the biological behaviour of PMP compared to classic peritoneal 
metastases  of  non-mucinous  origin.  In  locoregional  disease  and  in  systemic  metasta c 
disease, histologic subtype has no prognos c impact in appendiceal adenocarcinoma. These 
results  con rm  that mucinous  appendiceal  adenocarcinomas,  including  SRCC,  should  be 
considered as a di erent en ty, with respect to prognosis and possible treatment modali es.
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In this  nal chapter, the main  ndings of the studies performed in this thesis are summarized 
and  subsequently  discussed  in  a  broader  context.  A erwards,  several  methodological 
considera ons  are  discussed  that  should  be  taken  into  account  when  interpre ng  the 
results  of  the  studies  presented  in  this  thesis.  Also  implica ons  for  clinical  prac ce  and 
future research are discussed.
Summary of the main  ndings
This thesis aimed to provide insight into clinical and pathological aspects of small bowel and 
appendiceal cancer, by examining the epidemiology, clinical disease course, treatment and 
prognos c factors of these rare gastrointes nal cancers.
          of this thesis, insight into the epidemiology of small bowel cancer was provided, by 
studying the incidence, trends in treatment and overall survival. In                           
treatment and overall survival over  me of pa ents with small bowel adenocarcinoma (SBA) 
in both locoregional and metasta c disease was established by conduc ng one of the largest 
popula on-based  studies  in  SBAs  to  date.  The  study  revealed an  increasing  incidence of 
SBAs, which was mainly caused by an absolute twofold increase of duodenal tumours in the 
latest years, from 233 pa ents in the study period 1999-2003 to 478 pa ents in 2009-2013. 
Moreover,  the percentage of pa ents presen ng with  synchronous metastases  increased 
over  me as well,  from 27%  in 1999-2003  to almost 40% of  the pa ents a decade  later. 
The most common metasta c sites were  the liver  (46%) and  the peritoneal cavity (29%), 
although di erences in metasta c pa ern were recognizable between the primary tumour 
loca ons. Pa ents with a primary duodenal tumour more frequently presented with liver 
metastases (54%), whereas pa ents with a more distal tumour more o en had peritoneal 
metastases (44%). In locoregional disease, the prescrip on of adjuvant chemotherapy was 
associated with higher survival rates. In metasta c disease, the administra on of pallia ve 
chemotherapy increased over  me, but median overall survival remained stable around 4-5 
months.
The  incidence,  risk  factors  and  treatment-related  survival  of  pa ents  with  peritoneal 
metastases of SBA, one of the most frequent encountered metasta c sites, was studied in 
         . Synchronous peritoneal metastases were found in 13% of all pa ents with SBA, of 
which the incidence increased over  me, especially in pa ents with a non-duodenal tumour 
(22% of the pa ents in 2010-2014). In comparison to all pa ents with a SBA, pa ents with 
peritoneal  metastases  were  younger,  more  o en  had  a  primary  non-duodenal  tumour 
and more  o en  had  an  advanced  T-  and  N-stage. Median  survival  with  suppor ve  care 
only was very poor, and was found to be only 2.5 months. Pa ents treated with pallia ve 
chemotherapy, surgery of the primary tumour or cytoreduc ve surgery with hyperthermic 
   
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intraperitoneal chemotherapy (CRS+HIPEC) showed a median overall survival of 11, 11 and 
32 months respec vely.
        of this thesis evaluated the use and e ects of pallia ve systemic treatment in pa ents 
with  metasta c  small  bowel  cancer.  As  details  on  systemic  treatment  are  not  rou nely 
collected in  the Netherlands Cancer Registry, addi onal data on  rst-,  second- and  third-
line systemic treatment regimens, including details and dura on of the chemotherapeu cal 
and targeted agents, of pa ents diagnosed with metasta c SBA between 2007 and 2016 
were  na onwide  retrospec vely  assembled  in March  of  2018.                             
use and e ects of pallia ve chemotherapy. Pallia ve chemotherapy was  received by 199 
pa ents (38%) with metasta c disease. Pa ents who received pallia ve chemotherapy were 
younger than non-treated pa ents (63 vs. 72 years). The  rst-line chemotherapy regimens 
were mainly based on  uoropyrimidines (5- uorouracil and capecitabine) and oxalipla n. 
First-line combina on chemotherapy was prescribed to 80% of the pa ents, of which 97% 
received an oxalipla n-based doublet or triplet  regimen,  including capecitabine (CAPOX), 
5- uorouracil (FOLFOX) or epirubicin with capecitabine (EOX). Single-agent chemotherapy 
in   rst-line  treatment  mostly  consisted  of  capecitabine  (86%).  Mul variable  logis c 
regression showed that elderly pa ents (≥70 years) had a lower chance to receive  rst-line 
combina on chemotherapy and second-line treatment as well (65% and 12%, respec vely). 
Second-line systemic therapy was received by only 27% of the pa ents, mostly consis ng 
of  single-agent chemotherapy (58%) with a preference for  irinotecan. Third-line systemic 
therapy was administered in only 6% of the pa ents. The median overall survival for pa ents 
treated with pallia ve chemotherapy was 9.3 months, compared to 3.0 months for pa ents 
only receiving best suppor ve care. A er  rst-line therapy only, median overall survival of 
pa ents  receiving single-agent  chemotherapy was  5.6 months, compared  to 7.0 months 
with combina on chemotherapy.
            , insight  into the use and e ec veness of the addi on of targeted therapy to 
pallia ve chemotherapy in pa ents with synchronous metastases of SBA was provided. It 
was  shown  that  only  25  pa ents  (13%)  received  addi onal  targeted  therapy  in   rst-line 
treatment, exclusively bevacizumab. In almost all cases (96%), bevacizumab was added to 
combina on chemotherapy with CAPOX or FOLFOX. Pa ents with a primary  ileal  tumour 
were more likely to receive bevacizumab than pa ents with more proximal tumours. Median 
overall  survival  was  9.3 months  for  pa ents  treated  with  chemotherapy  and  addi onal 
bevacizumab, and 9.1 months for pa ents treated with chemotherapy only. For comparing 
survival outcomes of pa ents treated with and without addi onal targeted therapy in  rst-
line treatment, a propensity  score matched sample was generated  to eliminate poten al 
endogeneity bias.  In  the group of pa ents  in whom bevacizumab was added  to  rst-line 
 
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chemotherapy,  the median  overall  survival was  8.5 months,  compared  to 6.4 months  in 
pa ents exclusively  treated with  rst-line chemotherapy, with equal 1-year survival  rates 
of  25%.  In  mul variable  regression  analyses,  the  use  of   rst-line  bevacizumab  was  no 
prognos c factor (HR 1.25, 95% CI 0.70-2.24). Also in the propensity score matched sample, 
the addi onal use of  rst-line bevacizumab was no prognos c factor for survival (HR 1.09, 
95% CI 0.53-2.26).
            of  this thesis, the prognos c value of histologic subtype in appendiceal cancer 
was studied, with special a en on to mucinous appendiceal neoplasms. In the past years, 
new insights were gathered with regard to mucinous appendiceal neoplasms and its rela on 
to  pseudomyxoma peritonei  (PMP). More  speci cally,  clear  and  universal  de ni ons  for 
mucinous appendiceal neoplasms were established by the development of an interna onal 
consensus-based  histopathological  classi ca on  regarding  mucinous  appendiceal 
neoplasms. In           an overview of the basic terminology of the histologic subtypes in 
mucinous appendiceal neoplasms was provided, with tenta ve  recommenda ons for the 
management of these neoplasms for clinicians encountering pa ents with these diseases. 
Mucinous  appendiceal  neoplasms  can  be  dis nguished  into  3  subgroups,  including  true 
premalignant  lesions  or  adenomas,  tumours of  uncertain malignant  poten al,  known  as 
low-grade mucinous appendiceal neoplasms (LAMNs) and high-grade mucinous appendiceal 
neoplasms  (HAMNs),  and  malignant  lesions,  including  mucinous  and  signet  ring  cell 
adenocarcinomas. PMP is the clinical term for peritoneal disease of mucinous appendiceal 
neoplasms.  It  is  dis nguished  from  usual  non-mucinous  peritoneal  metastases  by  the 
presence of excessive amounts of mucin in the peritoneal cavity. Analogous to the primary 
lesions, PMP  is subdivided into several  categories, based on histologic subtype,  including 
acellular PMP, low-grade PMP, high-grade PMP and high-grade PMP with signet ring cells. 
Poten al  treatment op ons  for the primary lesions, as well as  for  the peritoneal disease 
of mucinous  appendiceal  neoplasms  were  summarized.  In  locoregional  disease,  surgical 
resec on should be performed.  In PMP, CRS+HIPEC should be considered  for all types of 
PMP, taking the poten al bene ts and harms for the pa ents with the speci c subtype into 
account. Pallia ve chemotherapy can be considered  in pa ents with high-grade PMP and 
high-grade PMP with signet ring cells, but not in the other two subcategories. The role of 
targeted therapy should be be er determined.
                  of this  thesis, addi onal data of  the Dutch Pathology Registry  (PALGA) 
was linked with the NCR to create a uniform group of pa ents with mucinous appendiceal 
neoplasms,  according  to  the  newest  histopathological  classi ca on.  In                      
thesis, the true prognos c value of histologic subtype, with use of this new consensus-based 
histopathological classi ca on, in a subset of pa ents with mucinous, non-mucinous and 
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signet  ring cell adenocarcinomas was determined. The study showed that in  locoregional 
disease,  histologic  subtype  was  not  a  prognos c  factor  for  overall  survival,  with  5-year 
survival rates for pa ents with non-mucinous adenocarcinoma, mucinous adenocarcinoma 
and  signet  ring  cell  adenocarcinoma  of  60.0%,  60.5%  and  69.6%  respec vely.  However, 
in  metasta c  disease,  mucinous  adenocarcinoma  was  associated  with  higher  survival 
compared to non-mucinous adenocarcinoma (median overall survival 27.7 vs. 12.6 months, 
HR  0.48,  95%CI  0.34-0.69).  Signet  ring  cell  adenocarcinoma  was  no  prognos c  factor 
compared to non-mucinous or mucinous histology. In sub analyses, taking metasta c site 
into account, mucinous histology was only a posi ve prognos c factor compared to non-
mucinous histology in peritoneal metastases (median overall survival 31.2 vs. 13.3 months, 
HR 0.42, 95%CI 0.28-0.62) and not in systemic metastases (median overall survival 10.7 vs. 
10.4 months, HR 1.07, 95%CI 0.49-2.31).
            described  and  evaluated  the  clinical  disease  course  of  metasta c  mucinous 
appendiceal  neoplasms,  including  LAMNs,  HAMNs  and  mucinous  adenocarcinomas  as 
classi ed  according  to  the  latest  consensus-based  histopathological  classi ca on,  in  a 
veri ed  popula on-based  cohort.  It  was  shown  that  of  the  235  pa ents  registered  as 
metasta c  mucinous  appendiceal  adenocarcinoma  or  PMP,  136  pa ents  (57.9%)  had 
a  LAMN,  2  pa ents  (0.9%)  a  HAMN  and  97  pa ents  (41.1%)  a  mucinous  appendiceal 
adenocarcinoma a er pathological reassessment of pathologic reports and in some cases of 
 ssue sec ons. Survival rates were dependent on histologic subtype, as the 5-year survival 
rate amounted to 78.9% in pa ents with metasta c LAMN, compared to 33.2% in metasta c 
mucinous adenocarcinoma. Also mul variable survival analyses revealed histologic subtype 
to be of prognos c relevance in metasta c disease (mucinous adenocarcinoma vs. LAMN; 
HR 3.90, 95%CI 2.64-5.76).
 
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Due to the rarity of small bowel and appendiceal cancer, it is di cult to conduct prospec ve 
cohort  studies  or  randomized  controlled  trials.  However,  clinicians  are  confronted  with 
pa ents  with  these  diseases  in  clinical  prac ce.  Therefore,  this  thesis  aimed  to  obtain 
insights into the clinical and pathological aspects of these two rare gastrointes nal cancers.
                                                          
The absolute number of pa ents newly diagnosed with small bowel and appendiceal cancer 
has increased over the years, which is mainly caused by the improvement of imaging and 
endoscopical techniques. In par cular, with the ongoing development of the quality of cross-
sec onal  imaging,  such  as  computed  tomography  (CT)  and magne c  resonance  imaging 
(MRI), tumours in both the small bowel and appendix could be detected more easily, at an 
earlier  stage  and more  frequently preopera vely1-3.  In  small  bowel cancer, especially  the 
development of CT and magne c resonance (MR) enterography improved the detec on of 
the neoplas c  lesions. In studies comparing these techniques with  ssue and endoscopic 
 ndings, an accuracy of 97% was found in MR enterography4-6. Other new diagnos c tools 
to enhance preopera ve explora on of the small bowel include video capsule endoscopy 
(VCE) and double-balloon enteroscopy (DBE), in which small bowel abnormali es could be 
detected  in  the majority of cases . This enhanced detec on could also partly explain  the 
increased incidence of SBA in the study presented in this thesis.
As presented in this thesis, the increasing incidence rates in SBAs were mainly accountable 
to  the  signi cant  twofold  rise  of  duodenal  adenocarcinomas.  The  increase  in  duodenal 
adenocarcinomas was also observed  in other popula on-based studies, with even an six 
fold  increase  in  both  sexes  in  Sweden  in  the  period  1960-20098-11.  Several  hypotheses 
have been  formulated  for  the di ering  cancer  incidence  rates  in  the duodenum and  the 
more  distal  small  bowel.  First,  the  improved  quality  of  imaging  techniques  could  have 
caused  a  decline  in misclassi ca on  of  duodenal  adenocarcinomas  as  pancrea c  cancer 
or  adenocarcinoma  of  unknown  primary  in  metasta c  disease       .  Secondly,  lifestyle 
associated risk factors could play a role as well, as it is known that a high sugar and re ned 
carbohydrate intake predisposes for small bowel cancer. Since the duodenum is the  rst part 
of the gastrointes nal tract responsible for the absorp on of nutri onal elements, ingested 
carcinogens reach the highest concentra on in the duodenum         .
The improved diagnos c accuracy may have led to an increase in the propor on of pa ents 
diagnosed with metasta c disease as well    . In the present thesis, the propor on of pa ents 
diagnosed with synchronous metasta c disease increased from 27% in 1999-2003 to even 
38% of  the pa ents  in 2009-2013. The propor on of pa ents diagnosed with peritoneal 
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dissemina on also  increased over  me, especially  in pa ents with a primary  jejunal and 
ileal tumour, in which 22% of the pa ents was found to have peritoneal metastases in the 
period 2010-2014. It is thought that peritoneal metastases of a primary duodenal tumour 
are less common due to its retroperitoneal loca on, which makes direct con guous tumour 
                                                 .
Pallia ve systemic therapy in metasta c small bowel cancer
Although metasta c disease  is  frequently encountered  in SBA,  limited data exists on  the 
role  of  pallia ve  systemic  therapy.  Moreover,  no  standard  frontline  regimen  has  been 
de ned due to the lack of randomized trials16-18. In this thesis, only 38% of the pa ents with 
metasta c  disease was  treated with pallia ve systemic  therapy,  even  in  the most  recent 
years. The percentage of treated pa ents is low, compared to colorectal cancer      .
As several molecular altera ons between small bowel cancer and both gastric and colorectal 
cancer  overlap,  pa ents  with metasta c  SBA  are  o en  treated  with  the  same  systemic 
regimens  as  pa ents with metasta c  gastric  or  colorectal  cancers16-18,  21.  These  regimens 
have been studied in a subset of retrospec ve and phase II studies, and mainly include the 
cytotoxic agents 5- uorouracil, capecitabine, oxalipla n and cispla n16-18, 22-29.
Early retrospec ve studies reported on pa ents treated with the single-agent 5- uorouracil, 
showed low response rates ranging from 7% to 36%      . The Eastern Coopera ve Oncology 
Group (ECOG) performed between 1983 and 1985 a phase II study with the FAM regimen, 
a combina on of 5- ourouracil, doxorubicin and mitomycin C, as this regimen had shown 
promising  results  in  gastric  cancer.  However,  the  response  rate  of  the  treated  pa ents 
with metasta c SBA was only 18%  . Subsequently conducted research mainly studied the 
combina on of a  uoropyrimidine and a pla num compound, as cispla n and oxalipla n. 
In 2008, a retrospec ve study by Overman et al. showed that 5- ourouracil and a pla num 
agent signi cantly improved response rates from 16% to 46% and progression-free survival 
from 3.9 months  to  8.7 months,  in  a  subset  of 80  pa ents,  compared  to  all  other  used 
systemic  regimens  .  In  2010,  Zaanan  et  al.  revealed  a  superiority  of  oxalipla n-based 
combina on  chemotherapy  over  cispla n-based  therapy  in  terms  of  both  progression 
free  survival  (6.9  vs  4.8 months,  p  ≤  0.0001)  and  overall  survival  (17.8  vs  9.3  months, 
p = 0.02)  . Addi onal small phase II studies using doublet oxalipla n-containing pallia ve 
chemotherapy  regimens  showed  promising  results with  response  rates  around  50%  and 
a median  overall  survival of  approximately  15  to  17 months            . As  phase  II  trials  are 
associated  with  several  major  limita ons,  the  implica ons  of  these  kind  of  studies  for 
daily  clinical  prac ce  are  o en  limited.  In  the  present  thesis,  it was  shown  that  in  daily 
prac ce only  a minority  of  the  pa ents  with metasta c  SBA was  treated with  pallia ve 
 
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chemotherapy. This thesis con rmed the use of oxalipla n-based chemotherapy in  rst-line 
treatment, which also  impacted  the median overall survival on a popula on-based  level, 
sugges ng CAPOX/FOLFOX could be a reasonable op on for  rst-line treatment in pa ents 
with metasta c SBA in clinical prac ce.
In the subset of pa ents with peritoneal metastases, it was shown in this thesis that the use 
of pallia ve chemotherapy in peritoneal metastases of SBA resulted in a popula on-based 
improvement of median overall survival, which contrast the general opinion of peritoneal 
metastases as a virtually untreatable disease  . For these pa ents, the suggested frontline 
regimen could also serve as a poten al treatment op on.
In addi on to pallia ve chemotherapy, the role of several targeted agents in SBA has been 
studied, as several molecular altera ons in SBA could serve as a poten al target for targeted 
                                      . Genomic pro ling of pa ents with SBA has  shown a high 
expression of vascular endothelial growth factor-A (VEGF-A) in 92% of the pa ents, sugges ng 
a poten al role  for the  targeted agent bevacizumab     . However,  it should be  taken into 
account  that  in metasta c  disease  a  higher  percentage  of  pa ents  has  a  lower  VEGF-A 
            . Only one phase-II study addressed the bene t of addi onal bevacizumab to 
pallia ve combina on chemotherapy with CAPOX, which showed no signi cant di erences 
in progression-free or overall survival compared to combina on chemotherapy with CAPOX 
      . Moreover a retrospec ve study by Aydin et al. also showed no sta s cally signi cant 
improvement  in progression-free or overall  survival with  the addi on of bevacizumab  to 
pallia ve chemotherapy, compared to combina on chemotherapy with FOLFOX or FOLFIRI 
      . In daily prac ce, this thesis showed that only 13% of the pa ents received addi onal 
bevacizumab to pallia ve chemotherapy, which  resulted  in equal median overall survival 
and  one-year  survival  rates  compared  to  pa ents  treated  with  pallia ve  chemotherapy 
only. All these results might indicate a limited clinical e ect of bevacizumab in addi on to 
pallia ve chemotherapy in daily prac ce on overall survival. However, as 91% of the SBAs 
harboured a poten ally  targetable  genomic  altera on,  the  role  of other  targeted  agents 
should be further inves gated  . The high incidence up to 35% of microsatellite instability 
(MSI) in SBA could suggest a poten al role for checkpoint immunotherapy                 .
Prognos c value of histologic subtype in appendiceal cancer
Historically, appendiceal cancer was classi ed according to colorectal cancer up to the 6   
edi on of the TNM (TNM-6) classi ca on of malignant tumours  . In the past years, several 
new  insights  were  gathered  in  appendiceal  cancer,  including  neuroendocrine  tumours, 
goblet  cell  tumours,  mucinous  appendiceal  neoplasms  and  carcinomas40-43.  As  a  result 
of  these  advancing  insights,  appendiceal  cancer  and  colorectal  cancer  were  classi ed 
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separately since the establishment of the TNM-7 in 2010  .
Mucinous histologic subtype is thought to be of prognos c relevance in pa ents with mucinous 
appendiceal neoplasms and adenocarcinomas45-48. However, a lot of research was conducted 
in the  me period before the development of the recent consensus-based histopathological 
classi ca on  for mucinous neoplasms,  including mucinous adenocarcinomas,  resul ng  in 
poten ally incorrect results. Data on the accuracy and clinical relevance of this most recent 
consensus-based  classi ca on  is  largely  lacking.  Studies  included  in  this  thesis  tried  to 
answer  these relevant  research ques ons, and  showed  that in pa ents with appendiceal 
adenocarcinoma, mucinous  histologic  subtype was s ll of prognos c relevance, but  only 
in  pa ents with  peritoneal  dissemina on  (median  overall  survival  31.2  vs.  13.3 months, 
HR  0.42,  95%CI  0.28-0.62).  Histologic  subtype was  no  prognos c  factor  in  pa ents with 
systemic metastases, de ned as metastases outside the peritoneal cavity, or in pa ents with 
locoregional disease. Probably, the prognos c relevance of histologic subtype in peritoneal 
disease is a re ec on of the di erences in natural disease course, as mucinous and signet 
ring cell adenocarcinomas could cause PMP, whereas non-mucinous adenocarcinomas more 
frequently  cause  usual  peritoneal metastases       .  As  already  stated  in  TNM-8,  in  which 
mucinous and non-mucinous appendiceal adenocarcinoma should be classi ed separately, 
it is of importance to subdivide these pa ents with an appendiceal adenocarcinoma, as it 
has prognos c implica ons  .
Addi onally,  this  thesis  showed  that  each  subtype  of  mucinous  appendiceal  neoplasm 
has a dis nct clinical disease course  in  the metasta c se ng. The 5-year survival  rate of 
pa ents with low-grade PMP of a disseminated LAMN was more than twice as high as it was 
for pa ents with high-grade PMP of a mucinous adenocarcinoma. Also previous research 
showed evident di erences  in survival in pa ents with low-grade PMP, previously known 
as di use  peritoneal  adenomucinosis  (DPAM) and  high-grade PMP  (peritoneal mucinous 
carcinomatosis; PMCA), in which higher survival rates were achieved in pa ents with low-
grade PMP, even a er correc on for intensive treatment with CRS+HIPEC52-55. The obtained 
results show the need to subdivide pa ents with low- and high-grade PMP according to the 
latest proposed consensus-based histopathological classi ca on. However, as all  types of 
PMP are classi ed with one corresponding morphologic code (8480/6), research could be 
             . Therefore,  it could be suggested for the ICD-O-4 to separately classify PMP 
with either a di ering morphologic code, or, a more realis c op on, to be er subdivide the 
tumour behaviour of the PMP into low-grade (8480/5) and high-grade (8480/6).
 
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Methodological considera ons
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The studies included in this thesis are based on data of the Netherlands Cancer Registry, in 
which data of all newly diagnosed malignancies in the Netherlands  is collected. Although 
much  informa on  regarding  pa ent  and  tumour  characteris cs,  diagnosis  and  ini al 
treatment are recorded, several important details are lacking due to its popula on-based 
nature, especially in rare tumours. For instance, in pa ents with metasta c SBA, extensive 
data on the type and dura on of systemic treatment regimen are not rou nely collected. 
Therefore,  for  chapter  3&4  in  this  thesis,  addi onal  data  was  retrospec vely  collected 
on  systemic  treatment  regimen  for  pa ents  treated with  pallia ve  systemic  therapy  for 
synchronous metastases of  SBA diagnosed between  2007  and 2016  by  registry clerks  of 
the Netherlands Cancer Registry. Moreover, data on several prognos c factors are lacking, 
including  clinical  performance  status,  comorbidi es,  extent  of  the  metasta c  disease, 
disease related symptoms, the serum levels of tumour markers and the muta onal status 
of  the primary tumour such as RAS/BRAF/MSI. Also  informa on regarding metachronous 
disease,  second-line  treatment,  repeated  treatment procedures and  the  reasons  to  (not) 
administer pa ents a speci c therapy is missing, which is a poten al pi all.
            
All studies in this thesis had an observa onal design and were based on every day clinical 
data.  Although  randomised  controlled  trials  (RCTs)  are  considered  as  the  gold  standard 
for determining the precise e ect of new treatments, biomarkers or other prognos c and 
predic ve factors, by minimising the risk of bias by confounding through randomisa on, the 
external validity might be limited  . Popula on-based observa onal studies have a superior 
external validity, as  it provides  insights  into  the outcomes of unselected pa ents  in daily 
clinical  prac ce.  Popula on-based  research  is  especially  highly  valuable  in  the  subset  of 
pa ents who do not meet the eligibility criteria for RCTs or pa ents with rare diseases, in 
which RCTs are hard to conduct.  In this thesis,  insights were derived into both prognos c 
factors and the use and e ects of treatments in pa ents with small bowel and appendiceal 
cancer, by  combining  the na onwide clinical data of pa ents with  these  rare diseases  in 
consecu ve  years.  Nevertheless,  popula on-based  research  is  prone  to  several  biases, 
which should be considered when interpre ng the results in this thesis.
Selec on bias
Selec on bias was present in many studies included in this thesis, par cularly in the studies 
in which the role of therapy was addressed. For instance, baseline characteris cs between 
the  treated  and  non-treated  di ered  (chapter  4),  and  even  the  pa ent  characteris cs 
between  the di erent  treatment strategies  varied  (chapter  3&4). One should  take  these 
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pretreatment di erences into account, as in clinical prac ce the trea ng physician already 
decided how to treat a pa ent, in which the decision could be partly based on the pa ent’s 
prognos c pro le. Consequently, it could be hard to establish the true e ect of a treatment 
in popula on-based research, as the di erences in outcomes may not re ect the e ect of 
the  treatment, but  rather  the di erences  in pa ent- and  tumour characteris cs. For  this 
reason,  mul variable  regression  models  were  performed  to  determine  the  e ect  of  a 
dependent prognos c  factor,  such as  histologic subtype  (chapter  7), adjusted  for  several 
pa ent  and  tumour  characteris cs.  In  order  to  eliminate  poten al  endogeneity  bias, 
propensity score matching was also used in chapter 5 to compare pa ents with and without 
addi onal  bevacizumab beside  pallia ve  chemotherapy  in metasta c  SBA.  In  this  study, 
propensity scores were determined by means of a  logis c regression model  in which the 
administra on  of  bevacizumab  in   rst-line  treatment  was  the  variable  of  interest,  and 
the  independent variables were  those  factors  that were signi cant  in univariable  logis c 
regression,  in  combina on with  relevant  clinical  features.  Pa ents were matched within 
 ght  bounds  of  the propensity  scores,  in which  the  predicted probability could  not vary 
more than 1%. However, even a er propensity score matching, it is s ll possible that pa ent 
groups are not totally comparable, due to the impossibility of gathering informa on on all 
prognos c factors.
Immortal  me bias
Several  studies  in  this  thesis may  have  been  exposed  to  immortal  me bias,  as  pa ents 
should  be  alive  to  receive  treatment.  A er  ini al  diagnosis,  a  period  of  immortal   me 
arises un l a  pa ent  receives a  type of  treatment, either surgical or  systemic. Especially 
in  the  studies on pallia ve systemic  treatment  (chapter 4&5),  immortal  me bias should 
be considered, in par cular for the pa ents treated with second- or third-line treatment. 
Unfortunately,  it was not possible for all included pa ents to determine the exact  me of 
ini al start of therapy. Otherwise, survival  me could have been de ned from the date of 
treatment, instead of date of diagnosis.
Stage migra on
Stage migra on  should  be  considered when  interpre ng  trends  in  treatment  and  (stage 
speci c)  survival.  Improved diagnos c techniques, especially  in  the area of diseases with 
non-speci c  symptoms  as  small  bowel  and  appendiceal  cancer,  could  have  led  to  an 
earlier  detec on  of  both  the  primary  and  metasta c  disease.  Small  metastases,  which 
were previously invisible on historic imaging techniques, could nowadays be visualized at 
an earlier  stage  than  in a previous  me period,  causing  the sugges on of an  increase  in 
metasta c rate (chapter 2&3).  In chapter 2,  it was shown that the propor on of pa ents 
presen ng with metasta c disease of SBA increased over  me, and, par cularly, an increase 
 
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in pa ents diagnosed with mul ple metasta c sites were seen, which can be a ributed to 
stage migra on.
                    
As  the  studies  included  in  this  thesis covered  rare gastrointes nal  cancers,  by de ni on 
only rela vely small numbers of pa ents are  included. Consequently, it is possible that  in 
several grouped pa ent and tumour characteris cs over-aggrega on occurred, as control 
of confounding might have not been  ght enough. For example, in chapter 3 it was shown 
that  elderly  pa ents  (≥70  years)  had  a  lower  chance  to  receive   rst-line  combina on 
chemotherapy and second-line  treatment. Poten ally,  if the number of included pa ents 
was higher,  it  could be hypothe cally possible  that only elderly pa ents ≥75 or 80 years 
were at risk for receiving less  rst-line combina on chemotherapy, and not those pa ents 
with an age of 70-75 years, which might have caused residual confounding. Moreover, as 
not  all prognos c  factors  could be  collected,  due  to  the  popula on-based nature  of  the 
Netherlands Cancer Registry, is it possible that addi onal confounders were not considered, 
also resul ng in residual confounding.
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Implica ons for clinical prac ce
As shown in this thesis, rare cancers, to which small bowel and appendiceal cancer belong, 
are  associated  with  worse  survival  rates  compared  to  more  frequently  encountered 
tumours, which is mainly caused by the combina on of a diagnos c delay and the ignorance 
and unfamiliarity of physicians with poten al treatment op ons, in partly due to the lack of 
                 .
In  pa ents  with  synchronous  metastases  of  SBA,  pallia ve  chemotherapy  without  the 
addi on  of  the  targeted  agent  bevacizumab  should  be  considered  in  daily  prac ce.  An 
oxalipla n-based combina on regimen of CAPOX or FOLFOX could be suggested as frontline 
regimen in metasta c SBA. The prescrip on of irinotecan-containing chemotherapy could 
be  a  reasonable  op on  for  second-line  treatment. However, pa ent and  tumour  related 
prognos c factors should be taken into account to determine the best suitable treatment 
for each individual pa ent.
In  pa ents with  appendiceal  cancer,  histologic  subtype  is  a  highly  important  prognos c 
factor, which should be taken into considera on for poten al treatment purposes. Especially 
in pa ents with  isolated peritoneal dissemina on of appendiceal  adenocarcinomas, who 
are poten al candidates for extensive treatment with CRS+HIPEC, histologic subtype should 
be considered. In the subgroup of pa ents with mucinous appendiceal neoplasms, it  is of 
utmost importance to subdivide pa ents with low- and high-grade lesions according to the 
latest  proposed  consensus-based  histopathological  classi ca on  for  both  treatment  and 
prognos c purposes.
Centralisa on of pathologic diagnosis and treatment
In recent years, centralisa on of care has signi cantly improved overall survival in pa ents 
with upper gastrointes nal cancers and rare cancers as head or neck cancer and sarcomas59-63. 
By  centralising  surgical  treatment  in  oesophageal,  gastric  and  pancrea c  cancer,  several 
improvements  in pa ent  related outcomes were seen,  including an  increase  in  resec on 
rates, decline  in postopera ve mortality and a major  increase  in overall  survival61-65. Also 
in pa ents treated with pallia ve systemic therapy in metasta c disease for oesophageal, 
gastric and pancrea c  cancer, a higher survival was observed  in pa ents  treated  in high-
volume  centers66-68.  These  improvements  were  caused  by  the  enhanced  experience  of 
medical  specialists  and  an  improved  infrastructure  for  pa ent  management,  which  are 
various posi ve aspects of centralisa on of care      .
Given  the  improvement  of  pa ent  outcomes  in  other  rare  and  upper  gastrointes nal 
cancers by the centralisa on of care, a empts should be made to centralise pa ent care 
 
   
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for  small  bowel  and  appendiceal  cancer  to  obtain  equivalent  results  in  these  pa ents. 
However, in pa ents with appendiceal cancer, centralisa on of care should not only focus 
on oncologic treatment, but also on pathologic diagnosis. Previous research has shown that 
second review of pathologic  ssue sec ons by a subspecialist pathologist improves pa ent 
outcome, by a spectacular decrease in diagnos c errors equal to 30-50%  . By centralising 
the  pathologic  assessment of  rare  appendiceal  tumours, a  decrease  in misdiagnosis  and 
misclassi ca on is expected, leading to an enhanced pa ent management and poten ally 
improved survival rates.
Notably,  already a part of  the  surgical  treatment  procedures are  centralised  for  pa ents 
with  small  bowel  and  appendiceal  cancer.  For  instance,  for  pa ents  with  locoregional 
duodenal  cancer  in  the upper part of  the duodenum and PMP of appendiceal mucinous 
neoplasms, the  surgical procedures pylorus preserving pancrea coduodenectomy (PPPD) 
and CRS+HIPEC are concentrated in some high-volume centres nowadays  . As these high-
volume centres for PPPDs and CRS+HIPEC already gained experience over  the years with 
pa ents  with  small  bowel  and  appendiceal  cancer  across  the  total  treatment  pathway, 
including all  coopera ng  specialisms of pathologists,  radiologists and medical oncologists 
in mul disciplinary teams, further centralisa on of care for pa ents with small bowel and 
appendiceal cancers would be easy to establish. Hopefully, the further enhanced experience 
of medical  specialists and  the be er  infrastructure  for pa ents with  these  rare diseases, 
leads to an improved iden  ca on of pa ents pro  ng from several treatment op ons and 
increased survival rates.
   
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Implica ons for future research
As  small  bowel  and  appendiceal  cancer  are  rare,  it  seems  very  hard  to  conduct  large 
prospec ve  observa onal  or  randomized  trials  in  the  future.  E orts  should  be made  to 
improve pa ent care  in pa ents with  these rare diseases by  interna onal coopera on of 
specialised  ter ary medical  centres  through  exchange of  their  exper se  and  knowledge, 
and the crea on of a  large interna onal prospec ve database,  in which extensive pa ent 
baseline  characteris cs,  tumour  characteris cs,  and  details  on  prognos c  factors  and 
treatment would  be  collected. Consequently, pretreatment di erences  between  pa ents 
and the  impact of prognos c  factors  could be be er established,  serving as an entry for 
improved pa ent management,  for both cura ve and pallia ve  treatment,  as well as  for 
best suppor ve care.
If centralisa on of care for pa ents with small bowel and appendiceal cancer is realized, its 
e ects on pa ent outcomes should be studied to determine its superiority to present clinical 
prac ce. Moreover,  by concentra ng  care  for pa ents with  rare  tumours, pa ents could 
more easily be enrolled in future clinical studies, which could be designed and performed 
for inves ga ng several poten al treatment op ons. For instance, as 91% of the pa ents 
with SBA has a poten ally targetable genomic altera on, the role of other targeted agents 
should be further inves gated by the development of n-of-1 clinical trials, also in order to 
personalize pa ent care  .
 
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In  daily  prac ce,  pa ents  with  small  bowel  and  appendiceal  cancers  have  historically 
been  treated  in  a  similar  fashion  as  frequently  encountered  gastrointes nal  cancers, 
mainly  as  colorectal  or  gastric  cancer.  However,  the  ra onale  for  this  extrapola on  is 
not  evidence-based  and  therefore,  this  thesis  aimed  to  provide  insights  into  clinical  and 
pathological  aspects  of  these  two  rare  gastrointes nal  cancers.  It was  shown  that  small 
bowel  and appendiceal  cancer both  have  a  dis nct  clinical  disease course,  compared  to 
other gastrointes nal cancers. Metasta c disease was common in pa ents with SBA, and 
only  a minority was  treated with  pallia ve  systemic  treatment.  An oxalipla n-containing 
regimen  could  be  a  suggested  frontline  regimen,  without  the  addi on  of  the  targeted 
agent bevacizumab. In appendiceal cancer, histologic subtype is of prognos c relevance in 
mainly peritoneal disease, and it is of utmost importance to classify pa ents with mucinous 
appendiceal neoplasms according to the latest proposed consensus-based classi ca on for 
prognos c and treatment purposes.
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Wereldwijd komt kanker in het maag-darmkanaal veelvuldig voor, waarvan dikkedarmkanker 
het  meest  voorkomend  is.  Andere  veelvoorkomende  vormen  van  kanker  in  het  maag-
darmkanaal  zijn  lever-,  maag-  en  slokdarmkanker.  In  2018  had  wereldwijd  28%  van  de 
pa ënten  die  gediagnos ceerd  werd  met  kanker,  een  tumor  in  het  maag-darmkanaal. 
Alleen al in Nederland werden in 2018 maar liefst 13.900 pa ënten gediagnos ceerd met 
dikkedarmkanker.
Dunne  darm-  en  appendixkanker  zijn  daarentegen  zeldzame  vormen  van  kanker  in 
het  maag-darmkanaal,  waarmee  jaarlijks  slechts  enkele  honderden  pa ënten  worden 
gediagnos ceerd. Zo werden in Nederland in 2018 slechts 300 pa ënten gediagnos ceerd 
met  dunnedarmkanker  en  200  met  appendixkanker.  Door  het  zeldzame  karakter  van 
deze  tumoren,  is  er weinig onderzoek  verricht  naar deze  tumorsoorten.  In  de dagelijkse 
prak jk worden pa ënten met dunne darm- en appendixkanker daarom vaak beschouwd 
en behandeld als maag- of dikkedarmkanker. Echter is het onduidelijk of dunne darm- en 
appendixkanker  zich  op  eenzelfde  manier  gedragen  als  maag-  en/of  dikkedarmkanker, 
waardoor het onbekend is of de gangbare behandelingen voor maag- en dikkedarmkanker 
ook een soortgelijk posi ef e ect hebben op de overleving van pa ënten met dunne darm- 
en appendixkanker.
Daarbij zijn door het zeldzame karakter van dunne darm- en appendixkanker grote klinische 
studies vaak niet mogelijk of las g uit te voeren, omdat er niet genoeg pa ënten geïncludeerd 
kunnen  worden.  Hierdoor  is  het  bestaande  en  uitgevoerde  onderzoek  vaak  gebaseerd 
op  pa ënten  en  resultaten  uit  het  verleden  en  veelal  a oms g  van  gespecialiseerde 
behandelcentra, waardoor dit geen goede afspiegeling is van de dagelijkse klinische prak jk.
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Doel van dit proefschri 
Het doel  van  dit  proefschri   is  om  inzicht  te  verkrijgen  in  de klinische  en  pathologische 
aspecten van dunne darm- en appendixkanker, door het bestuderen van de epidemiologie 
(de leer van het optreden en de verspreiding van ziekten in de bevolking en de kennis van 
factoren die hierop van  invloed  zijn), het  ziektebeloop, de behandeling en prognos sche 
factoren  van  deze  twee  zeldzame  tumoren  in  het  maag-darmkanaal.  De  belangrijkste 
doelstellingen van dit proefschri  zijn:
   Inzicht geven in de epidemiologie van locoregionale (niet uitgezaaide) en gemetastaseerde 
(uitgezaaide)  dunnedarmkanker,  door  het  bestuderen  van  de  inciden e  (het  aantal 
nieuwe pa ënten met  een  ziekte  per  jaar),  behandeling  en  overleving  van  pa ënten 
over de  jd (deel I).
   Evalueren  van  het  gebruik  en  de  e ecten  van  pallia eve  systemische  therapie 
(behandeling met chemotherapie of doelgerichte therapie, die niet meer gericht is op 
genezing) bij pa ënten met uitgezaaide dunnedarmkanker (deel II).
   Onderzoeken  van  de  prognos sche  waarde  van  histologisch  subtype  (verschillende 
type weefsels) en de impact hiervan op de behandeling en overleving bij pa ënten met 
appendixkanker (deel III).
                         
In deel I van dit proefschri  wordt inzicht gegeven in de epidemiologie van dunnedarmkanker. 
                  wordt  de  inciden e,  behandeling  en  overleving  van  pa ënten  over   jd 
met  locoregionale  en  gemetastaseerde  dunnedarmkanker  (subtype:  adenocarcinoom) 
weergegeven.  In  deze  studie  werd  gevonden  dat  de  inciden e  van  dunnedarmkanker 
toenam over de  jd, wat voornamelijk kwam door een toename van het aantal pa ënten 
met een  tumor  in de twaalfvingerige darm. Ook presenteerden zich meer pa ënten met 
uitgezaaide ziekte in verloop van de  jd. Zo steeg dit percentage van 27% van de pa ënten 
in de periode 1999-2003 tot bijna 40% in 2009-2013. In het geval van uitzaaiingen, hadden 
de meeste  pa ënten  uitzaaiingen  in  de  lever  (46%)  en  het  peritoneum  (buikvlies,  29%), 
al was dit a ankelijk van de  primaire  loca e van de  tumor. Pa ënten met een  tumor  in 
de twaalfvingerige darm hadden vaker leveruitzaaiingen (54%), terwijl pa ënten met een 
tumor verderop in de dunne darm vaker buikvliesuitzaaiingen (44%) hadden. Ondanks het 
toenemende  gebruik  van  pallia eve  chemotherapie,  hadden  pa ënten  met  uitgezaaide 
ziekte een overleving van ongeveer 4-5 maanden.
                  worden  de  resultaten  van  de  studie  naar  de  inciden e,  risicofactoren, 
behandeling en overleving van pa ënten met buikvliesuitzaaiingen van dunnedarmkanker 
(subtype: adenocarcinoom) getoond. In 13% van alle pa ënten met dunnedarmkanker was 
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er sprake van buikvliesuitzaaiingen. In vergelijking met alle pa ënten met dunnedarmkanker, 
waren  pa ënten  met  buikvliesuitzaaiingen  vaak  jonger  en  hadden  ze  vaker  een  tumor 
verderop in de dunne darm (na de twaalfvingerige darm). De overleving van pa ënten die 
geen tumorgerichte behandeling kregen, was slechts 2.5 maand. Pa ënten die behandeld 
werden  met  pallia eve  chemotherapie  leefden  ongeveer  11  maanden,  tegenover  32 
maanden  in een strikt geselecteerde groep pa ënten die CRS+HIPEC hadden ontvangen. 
CRS+HIPEC is een combina e van een opera e waarbij alle zichtbare tumorresten worden 
verwijderd (cytoreduc eve chirurgie; CRS), waarna de buik gespoeld wordt met verwarmde 
chemotherapie (HIPEC).
           van dit proefschri  worden het gebruik en de e ecten van pallia eve systemische 
therapie  bij  pa ënten  met  gemetastaseerde  dunnedarmkanker  (type:  adenocarcinoom) 
geëvalueerd, waarbij in             wordt ingegaan op pallia eve chemotherapie. In deze 
studie werd gevonden dat slechts 38% van de pa ënten met uitgezaaide ziekte pallia eve 
chemotherapie had ontvangen in de periode 2007-2016. Pa ënten die behandeld werden 
met pallia eve chemotherapie waren een stuk jonger dan onbehandelde pa ënten (63 vs. 
72  jaar).  Als  aanvangstherapie  ontving  80%  van  de  pa ënten  combina echemotherapie 
(meer dan 1 middel), voornamelijk CAPOX of FOLFOX. Pa ënten die behandeld werden met 
monotherapie  (1 middel)  kregen  in 86% van de gevallen capecitabine. Oudere pa ënten 
(70+)  werden  vaker  behandeld  met  monotherapie  dan  met  combina echemotherapie. 
Tweedelijnsbehandeling  (de  opvolgende  behandeling  na  aanvangstherapie) werd  slechts 
voorgeschreven  aan  27%  van  de  behandelde  pa ënten,  waarbij  irinotecan  het  meest 
voorgeschreven middel was. De overleving van pa ënten behandeld met chemotherapie 
bedroeg 9.3 maanden, vergeleken met 3.0 maanden bij pa ënten die niet behandeld waren 
met pallia eve chemotherapie. Pa ënten die alleen behandeld waren met aanvangstherapie, 
en  geen  opvolgende  lijn  behandeling  hadden  gekregen,  hadden  een  overleving  van  7.0 
maanden na combina echemotherapie en 5.6 maanden na monotherapie.
                 wordt  vervolgens  het  gebruik  en  e ect  van  doelgerichte  therapie,  naast 
het  gebruik  van  pallia eve  chemotherapie,  geëvalueerd  bij  pa ënten  met  uitgezaaide 
dunnedarmkanker. Hierbij werd  gevonden  dat  slechts  13%  van  de pa ënten  bij aanvang 
behandeld  werd  met  aanvullende  doelgerichte  therapie,  naast  chemotherapie.  Hierbij 
werd alleen het doelgerichte middel bevacizumab voorgeschreven. In 96% van de gevallen 
was  dit  in  combina e met  combina echemotherapie met  CAPOX  of  FOLFOX.  Pa ënten 
met een ileumtumor (laatste stuk dunne darm grenzend aan de dikke darm) kregen vaker 
bevacizumab voorgeschreven dan pa ënten met dunnedarmkanker in een ander deel van 
de  dunne  darm.  De  overleving  van  pa ënten  die  behandeld  waren met  chemotherapie 
zonder bevacizumab was 9.3 maanden, tegenover 9.1 maanden in de groep pa ënten die 
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wel  behandeld  was  met  bevacizumab  in  combina e  met  chemotherapie.  Als  wederom 
weer  gekeken werd  naar  pa ënten  die  alleen  behandeld  waren  met  aanvangstherapie, 
zonder  opvolgende  lijn  behandeling,  was  de  overleving  6.8 maanden  voor  pa ënten  na 
chemotherapie,  vergeleken  met  8.5  maanden  bij  pa ënten  die  behandeld  waren  met 
chemotherapie en bevacizumab.
Deel III van dit proefschri  beschrij  de prognos sche waarde van histologisch subtype bij 
pa ënten met appendixkanker, waarbij vooral gekeken is naar mucineuze (slijmvormende) 
tumoren. De afgelopen jaren werden wereldwijd verschillende classi ca es gehanteerd voor 
mucineuze appendixtumoren. Door voortschrijdende inzichten is in 2017 een op consensus 
gebaseerde interna onale classi ca e opgesteld door experts om zo eenduidig mucineuze 
appendixtumoren  te  kunnen  classi ceren.  In                worden  de  verschillende 
histologische subtypes bij pa ënten met mucineuze appendixtumoren uitgediept aan de 
hand  van  deze  nieuwe  classi ca e. Mucineuze  appendixtumoren  kunnen  onderverdeeld 
worden in 3 subgroepen, namelijk in 1. premaligne (voorstadia van kanker) laesies, ook wel 
adenomen genoemd, 2. tumoren die mogelijk kwaadaardig kunnen worden, onderverdeeld 
in laaggradige en hooggradige laesies, die bekend staan als LAMN (laaggradige mucineuze 
appendixtumoren) en HAMN (hooggradige mucineuze appendixtumoren) en 3. de maligne 
(kwaadaardige)  laesies,  waaronder  de  mucineuze  adenocarcinomen  en  zegelringcel 
adenocarcinomen. Verder wordt ingegaan op pseudomyxoma peritonei (PMP), de term die 
gebruikt wordt voor naar het buikvlies uitgezaaide ziekte door mucineuze appendixtumoren. 
PMP onderscheidt zich van klassieke buikvliesuitzaaiingen door de aanwezigheid van grote 
hoeveelheden slijm in de buikholte. Net als bij mucineuze appendixtumoren, kan PMP ook 
onderverdeeld worden  in verschillende categorieën, namelijk in 1. acellulair (geen cellen 
aanwezig in het slijm) PMP, 2.  laaggradig PMP, 3. hooggradig PMP en 4. hooggradig PMP 
met  zegelringcellen.  Laaggradig PMP wordt  in  de meeste gevallen  veroorzaakt  door een 
primaire LAMN, hooggradig PMP door een mucineus adenocarcinoom en hooggradig PMP 
met zegelringcellen door een zegelringcel adenocarcinoom.
                         wordt  verder  ingegaan  op  mucineuze  appendixtumoren,  waarbij 
gebruik  gemaakt  is  van  aanvullende  data  van  het  Pathologisch-Anatomisch  Landelijk 
Geautoma seerd  Archief  (PALGA;  de  landelijke  Nederlandse  pathologiedatabase).  In 
             wordt  de  prognos sche waarde  van  histologisch  subtype  bij  pa ënten met 
appendixtumoren  beschreven,  waarbij  gekeken  is  naar  pa ënten  met  mucineuze,  niet-
mucineuze (niet slijmvormende) en zegelringcel adenocarcinomen in de periode 2001 tot 
2015. Hierbij werd gevonden dat bij niet uitgezaaide ziekte, histologisch subtype niet van 
prognos sche waarde was  op  de  overleving  van  pa ënten.  In  het  geval  van  uitgezaaide 
ziekte,  hadden  pa ënten  met  mucineuze  adenocarcinomen  een  betere  overleving  dan 
   
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pa ënten met niet-mucineuze adenocarcinomen, namelijk 27.7 maanden  tegenover 12.6 
maanden. Echter,  indien gekeken werd naar de  loca e van uitzaaiingen, werd gezien dat 
pa ënten met mucineuze tumoren alleen een betere overleving hadden  in het geval van 
buikvliesuitzaaiingen, maar niet in het geval van uitzaaiingen elders in het lichaam.
Door de verschillende histopathologische classi ca es voor mucineuze appendixtumoren 
in de afgelopen 20 jaar en de toenmalige onbekendheid van de subtypen LAMN en HAMN 
bij clinici en pathologen, is het mogelijk dat uit vroeger onderzoek conclusies zijn getrokken, 
die  hedendaags  niet meer  kloppen met  de  voortschrijdende  inzichten. Daarom werd  in 
            het ziektebeloop van bepaalde typen uitgezaaide mucineuze appendixtumoren, 
namelijk LAMN, HAMN en mucineuze adenocarcinomen beschreven en geëvalueerd. In de 
periode 2001 tot 2015 waren er 235 pa ënten in Nederland geregistreerd als hebbende een 
uitgezaaid mucineus adenocarcinoom of PMP. Na herbeoordeling van de pathologieverslagen 
en enkele pathologische preparaten van deze pa ënten, bleek dat 136  (57.8%) pa ënten 
een uitgezaaid LAMN hadden, 2 (0.9%) een uitgezaaid HAMN en 97 (41.3%) een uitgezaaid 
mucineus adenocarcinoom. Er werd gevonden dat de overleving van pa ënten a ankelijk 
was van het histologisch subtype, gezien na 5 jaar 78.9% van de pa ënten nog in leven was 
met een uitgezaaid LAMN, tegenover 33.2% van de pa ënten met een uitgezaaid mucineus 
adenocarcinoom.
   
Nederlandse samenva ng
                         
In de dagelijkse prak jk worden pa ënten met zeldzame dunne darm- en appendixkanker 
vaak  behandeld  op  eenzelfde manier  als  andere  veelvoorkomende maag-darmtumoren, 
zoals  maag-  en  dikkedarmkanker.  De  onderbouwing  hiervoor  ontbreekt  echter 
grotendeels.  Dit  proefschri   verscha   inzicht  in  de  klinische  en  pathologische  aspecten 
van  dunne  darm-  en  appendixkanker,  door  het  bestuderen  van  de  epidemiologie,  het 
ziektebeloop, de behandeling en prognos sche factoren bij deze twee zeldzame tumoren 
in  het maag-darmkanaal.  Dit  proefschri   laat  zien  dat  dunne  darm-  en  appendixkanker 
unieke  kankersoorten  zijn,  met  ieder  een  zeer  verschillend  ziektebeloop.  Pa ënten met 
dunnedarmkanker werden  vaak al bij diagnose gediagnos ceerd met uitgezaaide  kanker, 
en  slechts  een  kleine minderheid  werd  hiervoor  behandeld met  pallia eve  systemische 
therapie. Combina e-chemotherapie met oxalipla n (CAPOX/FOLFOX) zou op basis van de 
resultaten in dit proefschri  gesuggereerd kunnen worden als aanvangsbehandeling voor 
pa ënten met uitgezaaide dunnedarmkanker,  zonder de toevoeging van het doelgerichte 
middel  bevacizumab.  Bij  pa ënten  met  appendixkanker  is  histologisch  subtype  van 
prognos sche waarde, voornamelijk in het geval van naar het buikvlies uitgezaaide ziekte. 
Derhalve is het van belang om de weefsels van pa ënten met mucineuze appendixtumoren 
te  classi ceren  aan  de  hand  van  de  nieuwste  op  consensus  gebaseerde  richtlijn  voor 
mucineuze appendixtumoren, voor zowel therapeu sche als prognos sche doeleinden.

List of publica ons
List of publica ons
   
Published ar cles
         ,  Bernards  N,  Gerritse  SL,  van  Oudheusden  TR,  de  Hingh  IHJT,  Creemers  GJ, 
Ten  Tije  AJ,  Lemmens VEPP.  Trends  in  incidence,  treatment  and  survival  of  small  bowel 
adenocarcinomas between 1999 and 2013: A popula on-based study in The Netherlands. 
Acta Oncol. 2016;55:1183-1189.
        , Simkens GA, Creemers GJ, Lemmens VEPP, de Hingh IHJT. Synchronous peritoneal 
metastases  of  small  bowel  adenocarcinoma:  Insights  into  an  underexposed  clinical 
phenomenon. Eur J Cancer. 2017;87:84-91.
        , Bernards N, Lemmens VEPP, de Hingh IHJT, Creemers GJ, van Erning FN. Pallia ve 
chemotherapy for pa ents with synchronous metastases of small-bowel adenocarcinoma: A 
re ec on of daily prac ce. United European Gastroenterol J. 2019;7:1380-1388.
        , van Erning FN, Bernards N, Lemmens VEPP, de Hingh IHJT, Creemers GJ. Addi on 
of bevacizumab to  rst-line pallia ve chemotherapy in pa ents with metasta c small bowel 
adenocarcinoma: A popula on-based study. Target Oncol. 2019;14:699-705.
        , Creemers GJ, de Hingh IHJT, Lemmens VEPP, Huysentruyt CJ. Review: Pathology 
and  Its  Clinical  Relevance  of  Mucinous  Appendiceal  Neoplasms  and  Pseudomyxoma 
Peritonei. Clin Colorectal Cancer. 2019;18:1-7.
        , van Erning FN, Creemers GJ, Lemmens VEPP, de Hingh IHJT, Huysentruyt CJ. The 
prognos c relevance of histologic subtype in appendiceal adenocarcinoma. Eur J Surg Oncol. 
[Epub ahead of print].
Submi ed
        , van Erning FN, Creemers GJ, Lemmens VEPP, de Hingh IHJT, Huysentruyt CJ. The 
clinical relevance of the histopathological classi ca on for metasta c mucinous appendiceal 
neoplasms in a veri ed popula on-based cohort.
List of publica ons

Dankwoord
Acknowledgements

                
Curriculum vitae
   
Curriculum vitae
                
 
Laura M.  Legué was  born  on  the  20    of October  1993  in Houten,  the Netherlands.  She 
 nished secondary educa on at the Utrechts Stedelijk Gymnasium in 2011. Subsequently, 
she  started medical  school  at Maastricht University.  In  2014 she  received her Bachelor’s 
degree in Medicine cum laude. A er her  rst regular internship, she conducted her scien  c 
internship with  data  of  the Netherlands  Cancer  Registry.  This  internship  focused  on  the 
incidence, treatment and survival of small bowel adenocarcinoma, under supervision of dr. 
G.J. Creemers and prof.dr. V.E.P.P. Lemmens. During her following regular internships, she 
con nued doing  research.  In  2017, a er  receiving  her Master’s degree  in Medicine cum 
laude, she started her PhD project at the Netherlands Comprehensive Cancer Organisa on, 
on providing insight into the clinical and pathological aspects of small bowel and appendiceal 
cancer.  At  the  same   me,  she  started  working  as  a  resident  not  in  training  (ANIOS)  in 
internal medicine, at the department of medical oncology of the Catharina Hospital for 3 
days a week, under supervision of dr. G.J. Creemers. A er comple ng her PhD, she started in 
September 2019 as a resident not in training (ANIOS) in internal medicine in the St. Antonius 
Hospital in Nieuwegein (head: dr. P.Chr. de Jong).

PhD Por olio
   
PhD Por olio
PhD por olio
Name PhD student:    Laura M. Legué
Erasmus MC Department:    Public Health/Netherlands Comprehensive Cancer
        Organisa on (IKNL)
PhD period:      September 2017 – July 2019
Promotor:      Prof.dr. V.E.P.P. Lemmens
Copromotors:      Dr. G.J. Creemers
        Dr. F.N. van Erning
Year Workload 
Hours/
ECTS
       
Wetenschappelijke Integriteit, Erasmus MC       
D                                                   
                      
    Gastrointes nale symposium, IKNL       
Wetenschapsavond, Catharina ziekenhuis       
                                           
Regionaal Upper GI MDO Symposium, Catharina ziekenhuis       
Wetenschapsavond, Catharina ziekenhuis       
Wetenschapsavond, Catharina ziekenhuis       
Presenta ons
Oral presenta on, 10  Gastrointes nale symposium        
Poster presenta on, 10   Interna onal Congress on Peritoneal Surface 
Malignancies (PSOGI)
       
Oral presenta on, 10   Interna onal Congress on Peritoneal Surface 
Malignancies (PSOGI)
       
Oral presenta on, Oncologieweek 2018        
Oral presenta on, Nascholing oncologie voor fysiotherapeuten        
Oral presenta on, Wetenschapsavond 2019        
Poster presenta on, European Mul disciplinary Colorectal Cancer 
Congress (EMCCC)
       
   
PhD Por olio
           
     Interna onal Congress on Peritoneal Surface Malignancies (PSOGI)        
European Mul disciplinary Colorectal Cancer Congress (EMCCC)        
                           
Fa ma Jid, ‘An overview and outcomes of systemic therapy in pa ents 
with colorectal cancer in the Catharina Hospital’
2018-2019   
K    
Actualisa e Dunnedarmkanker, kanker.nl 2018-2019   
Actualisa e Pseudomyxoma peritonei, kanker.nl        
ANIOS medische oncologie, Catharina ziekenhuis 2017-2019     
Total     

